Cover Page for Prot ocol and SAP 
Sponsor name: Novo Nordisk A/S 
NCT number [STUDY_ID_REMOVED]
Sponsor trial ID: NN7088-3908
Official title of study: Safety and Efficacy of turoctocog alfa pegol (N8-GP) in
Previously Untreated Patients with Haemophilia A
Document date:* 15 June 2020
aa* Document date refers to the date on which the document was most recently upd ted.
Note: The date in the header of Page 2 is the date of compilation of the documents, and not of an update to content.
Link
Link
Link
Link
Link
Link
Link
Link
Link
Link
LinkList of contents
Protocol ...............................................................................................................................................
Attachment I and II ............................................................................................................................
Amendment  log ..................................................................................................................................
Amendment  1 -PT............................................................................................................................
Amendment 2 -Global .......................................................................................................................
Amendment 3 -Global .......................................................................................................................
Amendment  4 -IL.............................................................................................................................
Amendment 5 -Global .......................................................................................................................
Amendment  6 -IL.............................................................................................................................
Amendment  7 -JP.............................................................................................................................
Amendment 8 -Global .......................................................................................................................CONFIDENTIALDate: Novo Nordisk
Version:
Status:turoctocog alfa pegol
Trial ID: NN7088-3908
Clinical Trial Report
Appendix 16.1.124 February 2022
1.0
Final
16.1.1 Protocol and protocol amendments
Redacted protocol  
Includes redaction of personal identifiable information only.  
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 1of 114
Protocol
Trial ID:NN7 088-3908
Safety and Efficacy of turoctocog alfa pegol (N8-GP) in 
Previously Untreated Patients with Haemophilia A
An open -label single -arm multicentre non-controlled phase 3a trial investigating safet y and efficacy 
of N8 -GP in prophy laxis and treatment of bleed ing episodes in previously  untreated paediatric 
patients with severe haemophilia A 
Trial phase: 3a
Protocol originator: 
, International Trial Manager
Haemophilia, Clinical Operations 2
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 1 . -  | 1
 |
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.

Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 2of 114
Table of contents    
Page
Table of contents ...............................................................................................................................................2
Table of figures .................................................................................................................................................6
Table of tables ...................................................................................................................................................6
List of abbreviations .........................................................................................................................................7
1Summary ..................................................................................................................................................11
2Flow chart ................................................................................................................................................14
3Background information and rationale for the trial ............................................................................18
3.1 Background information ..............................................................................................................18
3.1.1 Haemophilia A ...........................................................................................................18
3.1.2 N8-GP........................................................................................................................18
3.1.3 N8-GP clinical data ....................................................................................................19
3.2 Rationale for the trial ...................................................................................................................20
3.3 Risk and benefits ..........................................................................................................................21
4Objective(s) and endpoint(s) ..................................................................................................................24
4.1 Objective(s) ..................................................................................................................................24
4.2 Endpoint(s) ...................................................................................................................................24
4.2.1 Primary En dpoint .......................................................................................................24
4.2.2 Secondary Endpoint ...................................................................................................24
5Trial design ..............................................................................................................................................25
5.1 Type of trial .................................................................................................................................25
5.2 Rationale for trial design ..............................................................................................................26
5.3 Treatment of patients ...................................................................................................................27
5.3.1 Pre-prophylaxis treatment ..........................................................................................28
5.3.2 Prophylaxis treatment ................................................................................................28
5.3.3 Treatment of bleeding episodes .................................................................................29
5.3.4 Treatment of suspected bleeding episodes .................................................................30
5.3.5 Surgery .......................................................................................................................31
5.3.6 Treatment of patients with FVIII inhibitors ...............................................................32
5.3.7 Vaccinations ...............................................................................................................34
5.4 Treatment after end of trial ..........................................................................................................34
5.5 Rationale for treatment ................................................................................................................35
6Trial population .......................................................................................................................................36
6.1 Number of patients .......................................................................................................................36
6.2 Inclusion criteria ..........................................................................................................................36
6.3 Exclusion criteria .........................................................................................................................36
6.4 Withdr awal criteria ......................................................................................................................36
6.5 Patient replacement ......................................................................................................................37
6.6 Rationale for trial population .......................................................................................................37
6.6.1 Rationale for inclusion criteria ...................................................................................38
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 2 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 3of 114
  6.6.2 Rationale for exclusion criteria ..................................................................................38
6.6.3 Rationale for withdrawal criteria ...............................................................................38
7Milestones .................................................................................................................................................39
8Methods and assess ments .......................................................................................................................41
8.1 Visit procedures ...........................................................................................................................41
8.1.1 Visit 0 – screening visit .............................................................................................43
8.1.1.1 Pre-prophylaxis treatment ...................................................................44
8.1.1.2 Prophylaxis treatment ..........................................................................44
8.1.2 Visit 1 – first dosing with N8 -GP..............................................................................45
8.1.3 Visit 2, 3, 4-6 – main phase .......................................................................................45
8.1.4 Visit 7-8 – main phase ...............................................................................................46
8.1.5 Visit 9 – end of main phase ........................................................................................47
8.1.6 Visit 10-13 – extension phase ....................................................................................47
8.1.7 Visit 14 - end of extension phase ...............................................................................48
8.1.8 Visit 15- X until end of trial ........................................................................................48
8.1.9 End of trial visit .........................................................................................................49
8.1.10 Unscheduled visit .......................................................................................................49
8.1.11 I TI Visit ......................................................................................................................49
8.1.12 Home treatment ..........................................................................................................50
8.1.12.1 Prophylactic home treatment ...............................................................50
8.1.12.2 Home treatment of bleeding episodes .................................................50
8.2 Patient related information ...........................................................................................................51
8.2.1 Concomitant illness and medical history ...................................................................51
8.2.1.1 Details on haemophilia ........................................................................51
8.2.1.2 Allergies ..............................................................................................51
8.2.2 Concomitant medication ............................................................................................51
8.2.3 Treatment of bleeding episodes in inhibitor patients .................................................52
8.2.4 Prohibited medication ................................................................................................52
8.2.5 Demography ...............................................................................................................52
8.3 Clinical assessments ....................................................................................................................52
8.3.1 Body measurements ...................................................................................................52
8.3.2 Physical examination .................................................................................................52
8.3.3 Vital signs ..................................................................................................................53
8.4 Laboratory assessments ...............................................................................................................53
8.4.1 Local laboratory assessments .....................................................................................54
8.4.1.1 FVIII activity .......................................................................................54
8.4.2 Central laboratory assessments ..................................................................................54
8.4.2.1 FVIII activity .......................................................................................55
8.4.2.2 Antibody assessments .........................................................................55
8.4.2.3 HIV testing and CD4+ lymphocyte count ...........................................58
8.4.2.4 Haematology .......................................................................................58
8.4.2.5 Biochemistry .......................................................................................58
8.4.2.6 F8and HLA genotype testing ..............................................................59
8.4.2.7 Allergic reaction testing ......................................................................59
8.4.3 Blood sampling in infants and children .....................................................................60
8.4.4 Storage of samples .....................................................................................................60
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 3 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 4of 114
  8.5 N8-GP administration ..................................................................................................................61
8.6 Bleeding episodes ........................................................................................................................61
8.6.1 Asse ssments of bleeding episodes and treatment response .......................................62
8.7 Surgery .........................................................................................................................................63
8.7.1 Minor surgery ............................................................................................................63
8.7.2 Major surgery .............................................................................................................63
8.8 Training and reminders ................................................................................................................64
8.8.1 Trial card dispensing ..................................................................................................64
8.8.2 Home treatment training ............................................................................................64
8.8.3 Electronic diary (eDiary) ...........................................................................................65
8.8.3.1 eDiary dispensing and collection ........................................................65
8.8.4 Contact between the investigator/medically qualified person and the patient ...........65
8.8.5 Interactive voice/web response system ......................................................................66
8.9 Patient compliance .......................................................................................................................66
9Trial supplies ...........................................................................................................................................68
9.1 Trial product ................................................................................................................................68
9.2 Packing, l abelling and dispensing ................................................................................................69
9.3 Storage .........................................................................................................................................69
9.4 Drug accountability and destruction ............................................................................................70
9.5 Auxiliary supply ..........................................................................................................................71
10Interactive voice/web response system (IV/WRS) ................................................................................72
11Adverse events and technical complaints ..............................................................................................73
11.1 Definitions ...................................................................................................................................73
11.2 Reporting of adverse events .........................................................................................................78
11.3 Follow -up of adverse events ........................................................................................................81
11.4 Technical complaints and technical complaint samples ..............................................................82
11.4.1 Reporting of technical complaints .............................................................................82
11.4.2 Collection, storage and shipment of technical complaint samples ............................82
11.5 Precautions and/or overdose ........................................................................................................83
11.6 Committees related to safety ........................................................................................................83
11.6.1 Novo Nordisk safety committee ................................................................................83
11.6.2 Rules for putting the enrolment on hold ....................................................................83
12Case report forms ....................................................................................................................................85
12.1 Corrections to case report forms ..................................................................................................85
12.2 Case report form flow ..................................................................................................................86
12.3 E lectronic diary ............................................................................................................................86
13Monitoring procedures ...........................................................................................................................88
14Data management ....................................................................................................................................90
15Computerise d systems .............................................................................................................................91
16Statistical considerations ........................................................................................................................92
16.1 Sample size calculation ................................................................................................................93
16.2 Definition of analysis sets ............................................................................................................93
16.3 Primary endpoint ..........................................................................................................................93
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 4 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 5of 114
  16.4 Secondary endpoints ....................................................................................................................93
16.4.1 Confirmatory secondary endpoints ............................................................................93
16.4.2 Supportive secondary endpoints ................................................................................94
16.4.2.1 Number of bleeding episodes during prophylaxis ...............................94
16.4.2.2 Haemostatic effect ...............................................................................94
16.4.2.3 Incidence of high titre inhibitors .........................................................95
16.4.2.4 FVIII consumption ..............................................................................95
16.4.2.5 Safety endpoints ..................................................................................95
16.4.2.6 Other assessments ...............................................................................95
16.5 Interim reporting ..........................................................................................................................96
16.6 Sequential safety analysis and safety monitoring ........................................................................96
16.7 Reporting of F8 and HLA genotype .............................................................................................96
17Ethics ........................................................................................................................................................97
17.1 Informed consent .........................................................................................................................97
17.2 Data handling ...............................................................................................................................98
17.3 Information to patient, parent(s)/LAR(s) during the trial ............................................................99
17.4 Premature termination of the trial and/or trial site .......................................................................99
18Protocol compliance ..............................................................................................................................100
19Audits and inspections ..........................................................................................................................101
20Critical documents ................................................................................................................................102
21Respons ibilities ......................................................................................................................................104
22Reports and publications ......................................................................................................................105
22.1 Communication of results ..........................................................................................................105
22.1.1 Authorship ...............................................................................................................106
22.1.2 Trial site -specific publication(s) by investigator(s) .................................................106
22.2 Investigator access to data and review of results .......................................................................106
23Retention of clinical trial documentation and human biospecimens ................................................
107
23.1 Retention of clinical trial documentation ...................................................................................107
23.2 Retention of human biospecimens .............................................................................................107
24Institutional Review Boards/Independent Ethics Committees and regulatory authorities ............109
25Indemnity statement .............................................................................................................................110
26 .References .............................................................................................................................................112
Approval of Final Protocol
Agreement on Final Protocol
Attachment I – Global List of key staff and relevant departments and CRO(s)
Attachment II – Country List of key staff and relevant departments
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 5 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 6of 114
  Table of f igures  
Page
Figure 5–1 Patient flow chart ....................................................................................................................27
Figure 8–1 Visit flow diagram ..................................................................................................................41
Figure 11–1 Initial reporting of AEs ...........................................................................................................80
Figure 16–1 Individual patient flow and time periods for trial reporting ...................................................92
Table of t ables   
Page
Table 2–1 Flow chart visits and assessments ...........................................................................................14
Table 2–2 Flow chart explanatory descriptions .......................................................................................17
Table 5–1 Intravenous N8 -GP treatment .................................................................................................34
Table 8–1 4- point scale ............................................................................................................................62
Table 9–1 Trial Product ...........................................................................................................................68
Table 9–2 Storage ....................................................................................................................................69
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 6 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 7of 114
  List of abbr eviations
AE adverse event
APCC activated prothrombin complex concentrate 
BP blood pressure
BU Bethesda U nits
BW body  weight
CRF case report form
CFR code of federal regulations
CHMP Committee for Medical Products for Human Use
CHO chinese hamster ovary
CNS central nervous s ystem
CLAE clinical laboratory  adverse event
CRO contract research organisation
CTA clinical trial application
CTR clinical trial r eport
CV curriculum vitae
DU dispensing unit 
DUN dispensing unit number
eCRF electronic case report form
EDexposure day  (Definition: An exposure day  (ED) is any  day on 
which the patient has been exposed to trial product)
eDiary electronic diary
EMA European Medicines Agency
EOT end of trial
eSIF electronic safet y information form
F8 factor VIII gene
FAS full analy sis set
FDA Food and Drug Administration
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 7 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 8of 114
  FPFV first patient first visit
FVII coagulation factor VII
FVIII coagulation factor VIII
FVIIIa activated coagulation factor VIII
FX coagulation factor X
FU follow -up
GCP Good Clinical Practice
HCP host cell protein
HIV human immunodeficiency virus
HLA human l eucocy te antigen
HTC haemophilia treatment centre
IB investigator’s brochure
ICH International Conference on Harmonisation
ICMJE International Committee of Medical Journal Editors
IEC independent ethics committee
IgE immunoglobulin E
IMP investigational medicinal product
IND investigational new drug
IRB institutional review board
IR30min incremental recovery  30 min
ITI immune tolerance induction
IU international unit
I.V. intravenous
IV/WRS interactive voice/web response sy stem 
LAR legally  acceptable representative
LOCF last observed carried forward
M months
MedDRA medical 
dictionary  for regulatory  activities
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 8 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 9of 114
  MESI medical event of special interest
N8-GPturoctocog alfa pegol, gly copegy lated recombinant coagulation 
factor FVIII
NIMP non-investigational medicinal product
PDCO Paediatric Committee (EMA)
Pd-aPCC plasma -derived activated prothrombin complex concentrates 
PdFVIII plasma derived FVIII
Pd-PCC plasma -derived prothrombin complex concentrates
PEG polyethylene gly col
PI principal investigator
PIP paediatric investigation plan
PK pharmacokinetics
PPX prophy laxis
PT prothrombin time
PTP previously  treated patients
PUP previously  untreated patients
rFVIIa activated recombinant factor VII
rFVIII recombinant coagulation factor VIII
SAE serious adverse event
SAP statistical analy sis plan
SAS safet y analysis set
SIF safety information form
SDV source data verification
SUSAR suspected unexpected serious adverse reaction
TEAE treatment emergent adverse event
TESAE treatment emergent serious adverse event
TMM trial materials manual
UNS unscheduled visit
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 9 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 10of 114
  UTN universal t rial number
V visit
W weeks
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 10 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 11of 114
  1 Summary
Objective(s) and endpoint(s):
Primary Objective
To evaluate immunogenicity  of N8 -GP (turoctocog alfa pegol) in previously  untreated patients 
(PUPs) with severe haemophilia A
Primary Endpoint
Incidence of FVIII inhibitors 
Secondary Objectives
To evaluate safet y other than immunogenicit y of N8-GP (turoctocog alfa pegol) in PUPs with 
severe haemophilia A
To evaluate efficacy  of N8-GP (turoctocog alfa pegol) in PUPs with severe haemophilia A
oin long -term proph ylaxis treatment (bleeding preventive effect)
oin the treatment of bleeding episodes 
Key Secondary Endpoint
Frequency  of adverse events including serious adverse events and medical events of s pecial 
interes t.
Incidence of confirmed high titre inhibitors (define das inhibitor ti tre > 5BU ).
Number of breakthrough bleeding episodes during prophy laxis with N8 -GP (annualised 
bleeding rate).
Haemostatic effect of N8 -GP in treatment of bleeding episodes, assessed by a predefined 4-
point haemostatic response scale (“excellent”, “good”, “moderate” and “none”).
Time frames for evaluation of Objectives/E ndpoints
All objectives/endpoints will be evaluated when the first 50 PUP have reached at least 50 exposure 
dates , when the first 100 PUP have reached 100 exposure dates, and at end of trial. End of trial will 
be up to 4 y ears after the patient has reached 100 exposure dates.
Trial design:
This is a multi -national, non-randomised, open label phase 3 trial investigat ing the safet y (including 
immunogenicit y) and efficacy of N8 -GP in prophylaxis and treatment of bleeds in a paediatric 
population of PUPs (age below 6 y ears) with severe haemophilia A ( factor VIII baseline level < 
1%). There will only  be one treatment arm and no comparator.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 11 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 12of 114
  The European medical agency requires submission of safet y and efficacy data from minimum 50 
exposure day sin at least 50 patients for approval of the indication in PUPs, with a post -approval 
commitment to follow -at lea st 100 patients fo r a minimum of 100 exposure day s. When the first 50 
patients have reached a minimum of 50 exposure days , the anal ysis and evaluation for the main trial 
report will be performed. All patients continue in the extension phase for the purpose of collecting 
data for a minimum of 100 exposure day sin at least 100 patients. 
Trial population:
Inclusion criteria
Informed consent obtained before an y trial -related activities. Trial- related activities are an y 
procedures that are carried out as part of the trial, inclu ding activities to determine suitability
for the trial
Male, a ge <6 years at the time of signing inform edconsent
Diagnosis of 
severe haemophilia A ( factor VIII activity  level < 1%) based on medical records
or central laboratory  results
No prior use of purified clotting factor products ( 5 previous exposure to blood components is 
acceptable) 
Exclusion criteria
Any history  of FVIII inhibitor (defined by  medical records)
Known or suspected h ypersensitivity  to trial product or related products 
Previous participation in this trial. Participation is defined as administration of trial product
Receipt of an y investigational medicinal product within 30 day s before screening
Congenital or acquired coagulation disorder other than haemophilia A . Any  chronic disorder or 
severe disease which, in the opinion of the Investigator , might jeopardise patient’s safet y or 
compliance with the protocol.
Patient’s parent(s)/ legally  acceptable representative (s) m ental incapacit y, unwillingness to 
cooperate, or a language barrier precluding adequate understanding and cooperation 
Assessments:
Key Safety assessments
Antibody  assessment: binding antibodies towards trial product (N8 -GP)and inhibitory
antibodies (factor VIII inhibitors)
Other adverse events
Key Efficacy assessments
Breakthrough b leeding episodes (annualised bleeding rate)
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 12 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 13of 114
  Haemostatic effect in treatment of bleeds
Number of doses to treat a bleed
Trial product
The following trial product will be used in the trial:
N8-GP (500 U/vial and 2000 U /vial)
N8-GP is supplied as a sterile, freeze- dried pow derin a single use vial with a nominal content of 
500 U/vial or 2000 U/vial to be reconstituted with 4.3 mL  0.9% Sodium Chloride solution for 
intravenous 
injection
N8-GP is used for prevention and treatment of bleeding episodes.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 13 . -  | 1
 |
CONFIDENTIAL
Protocol UTN: U1111 -1148 -1897 Date: 04 November 2013 Status: Final Novo Nordisk
Trial ID: NN7088 -3908 EudraCT No.: 2013 -004025 -88 Version: 1.0 Page: 14of 114
  2Flow  chart
Table 2–1 Flow chart visits and assessments
Visit number 01112 3 4-6 7-8 9 10-13 141815-X19EOT
Visit purpose Screening Dosing Dosing Dosing Dosing DosingEnd of 
mainDosingEnd of 
extensionDosing
(until EOT)End of
Trial
Time of visit (ED (s))20 1 2 5 10, 15, 20330,40 5060, 70, 80, 
90100 NA
Visit interval (ED(s))20 0 3±1 5±2 10±2 10+2 10±2 10+2 24w±4w 
PATIENT RELATED 
INFORMATION
Informed consent X
Assent form , if applicab le4(X) (X) (X) (X) (X) (X) (X) (X) (X) (X)
Informed Consent for 
Genotyp ing(X)12(X)12(X)12(X)12(X)12(X)12
Inclusion / Exclusion 
criteriaX
Eligibility evaluation X
Withdrawal criteria X X X X X X X X X X
Demography X
Concomitant illness & 
Medical historyX
Concomitant medication X X X X X X X X X X X
ADVERSE EVENTS
Adverse events5X X X X X X X X X X X
CLINICAL 
ASSESSMENTS
Body measurements6X X X X X X X X X X X
Physical examination X X X X
Vital signs7X X7X X X
CENTRAL VV-TMF-1266622|1.0|NN7088 -3908
  Protocol  v 1|14 of 114
CONFIDENTIAL
CONFIDENTIAL
Protocol UTN: U1111 -1148 -1897 Date: 04 November 2013 Status: Final Novo Nordisk
Trial ID: NN7088 -3908 EudraCT No.: 2013 -004025 -88 Version: 1.0 Page: 15of 114
  Visit number 01112 3 4-6 7-8 9 10-13 141815-X19EOT
Visit purpose Screening Dosing Dosing Dosing Dosing DosingEnd of 
mainDosingEnd of 
extensionDosing
(until EOT)End of
Trial
Time of visit (ED (s))20 1 2 5 10, 15, 20330,40 5060, 70, 80, 
90100 NA
Visit interval (ED(s))20 0 3±1 5±2 10±2 10+2 10±2 10+2 24w±4w 
LABORATORY 
ASSESSMENTS
FVIII activity –trough9X8X X X X X X X X X
FVIII activity –recovery 
(30 post -dose)X X X X X X X X
N8-GP/FVIII binding 
antibodies9 X X X X X X X X X
PEG antibodies9X X X X
FVIII inhibitor test9X X X X X X X X X
HIV 1 and 2 antibodies (X)10
CD4+ lymphocyte count 
and HIV viral load(X)10
Haematology X X11X X X
Biochemistry X X11X X X
F8+ HLA genotype testing (X)12(X)12(X)12(X)12(X)12(X)12
Allergic reaction testing X
TRIAL PRODUCT 
ADMINISTRATION
N8-GP administration X X X X X X X X X
Change of regimen X X X X X X X X
N8-GP dispensing for 
home treatmentX13X X X X X X X17
N8-GP accountability X X X X X X X X X X
TRAINING AND 
REMINDERS
Trial card dispensing XVV-TMF-1266622|1.0|NN7088 -3908
  Protocol  v 1|15 of 114
CONFIDENTIAL
CONFIDENTIAL
Protocol UTN: U1111 -1148 -1897 Date: 04 November 2013 Status: Final Novo Nordisk
Trial ID: NN7088 -3908 EudraCT No.: 2013 -004025 -88 Version: 1.0 Page: 16of 114
  Visit number 01112 3 4-6 7-8 9 10-13 141815-X19EOT
Visit purpose Screening Dosing Dosing Dosing Dosing DosingEnd of 
mainDosingEnd of 
extensionDosing
(until EOT)End of
Trial
Time of visit (ED (s))20 1 2 5 10, 15, 20330,40 5060, 70, 80, 
90100 NA
Visit interval (ED(s))20 0 3±1 5±2 10±2 10+2 10±2 10+2 24w±4w 
Home treatment training X X X X X X X X X
eDiary training X14X14X14X14X14X14X14X14X14
Compliance check of
eDiary data ,protocol 
requirements and used 
drugX X X X X X X X X
Contact with patient ’s 
parent/LAR(X)16(X)16
IV/W RS15X X X X X X X X X X X
End of trial form XVV-TMF-1266622|1.0|NN7088 -3908
  Protocol  v 1|16 of 114
CONFIDENTIAL
CONFIDENTIAL
Protocol UTN: U1111 -1148 -1897 Date: 04 November 2013 Status: Final Novo Nordisk
Trial ID: NN7088 -3908 EudraCT No.: 2013 -004025 -88 Version: 1.0 Page: 17of 114
Table 2–2 F low chart explanatory descriptions 
Footer Description
1 V0 and V1 can be combined to one visit, if the patient fulfils the in- and exclusion criteria
2When the patient has commenced prophylaxis, visits can for practical purposes be planned according to the predicted number of EDs based on the patient’s prophylaxis regimen. 
A visit does not need to be re -scheduled even if the actual EDs between visits turn out higher or lower due to treatment of bleeding episodes during the home treatment period.
3If not already on prophylaxis, all patients must initiate prophylaxis treatment no later than at V6. Pre -prophylaxis is only allowed for children below the age of 24 months or up to 
V6, whatever comes first.
Visits at 10EDs±2EDs, 15EDs±2EDs , 20EDs±2EDs must be performed even the window allows 2 visits to be 2 EDs aside (eg ED12 and ED13)
4Any patient above the age of 3 years should sign a child assent form, if capable, and if required by local requirements. This can b e performed on a separate day. As this is a long 
term trial the investigator should check the progressing maturation of the child and hisability to assent throughout the trial.
5 After Informed consent has been obtained all Adverse Events must reported in the eCRF
6The frequency of body weight m easurements should follow local practice, but should at least be measured every 10 weeks in children ≥ 3 years of age and within a timeframe of 6 
weeks in children <3 years of age. Please refer to Section 8.3.1
7Vital signs should be measured prior to dosing at all screening, V1, V9, V14 and EOT . In addition vital sig ns should also be measured 30±10minutes after the first injection with 
N8-GP  at V 1.
8FVIII activity should only be measured at V0 if diagnosis of haemophilia A (FVIII<1%) has not been documented in the patients’ medi cal record. FVIII activity at V0 can either 
be measured at local or central laboratory depending on the urgency of rece iving the result i.e. in case V0 and V1 are combined 
9 Blood samples must be collected prior to dosing at dosing visits. Please check that the required washout period has been met for inhibitor testing, see section 8.1.1.3
10HIV 1 and 2 antibodies are only to be assed, if status is unknown (i.e. previous test older than 6 months). Tests for CD4+ lymphocyte count and HIV vira l load are only required 
for HIV positive patients . Sampling can be postponed to the earliest convenient visit to ensure that the a llowed blood volume is not exceeded
11 In case V1 is more than a month after V0, Haematology and Biochemistry need to be retaken at V1 prior to dosing, see Section  8.4.2.4 and 8.4.2.5
12F8and HLA genotype sample is only allowed upon patient’s parent(s)/LAR (s)signing the consent for genotyp ingand should only be done if not already documented in patient’s 
medical record. The sample can be collected at any visit between V0 and V9, taking the limitation of the allowed blood sampling volume into account
13 Home treatment can be postponed until the patient’s parent(s)/LAR(s) are comfortable with reconstitution procedure and administration of N 8-GP
14eDiary training prior to initiating home treatment to ensure that the patient’s parent (s)/LAR (s)are comfortable entering data in the eDiary. Retrain in the use of the eDiary as 
applicable at V2 -VX to ensure entry of correct eDiary data
15 IV/WRS to be used for screening, visit registration, trial drug dispensing, drug accountability and completion. Refer to Section 10for more informat ion
16When site visits are more than 3 months apart the Investigator must contact the patient’s parent (s)/LAR (s)at least every 12 weeks ± 1week to ensure patients well-being. For 
details please refer to Section 8.8.4 . Primarily expected to be applicable for patients treated according to pre -prophylaxis (V1-V6) and who mvisit the trial site less frequent than 
every 3 months. In addition all visits from V15 -VX will be scheduled every 24 weeks ±4 weeks
17 At every dosing visit from V15 -VX, drug will be dispensed to cover up to 3 months of treatment. Depending on patient’s treatment regimen, an additional dispensing visit might 
be needed to cover treatment in the entire period between visits.
18 In case V 14will be the EOT visit, the procedures for the EOT visit should be followed
19 V15 to VX will be performed every 24 E Ds ± 4EDs until the End of TrialVV-TMF-1266622|1.0|NN7088 -3908
  Protocol  v 1|17 of 114
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 18of 114
  3Backgr ound information and rationale for  the trial
The trial will be conducted in compliance with this protocol, I CH GCP1and applicable regulatory  
requirements, and in accordance with the Declaration of Helsinki.2
In this document, the term investigator refers to the individual responsible for the overall conduct of 
the clinical trial at a trial site.
3.1 Background information
3.1.1 Haemophilia A
Haemophilia A is a recessive X -linked congenital bleeding disorder, resulting from deficiency  of 
the essential blood coagulation factor VIII ( FVIII)and characterised b y increased bleeding 
tendency . Haemophilia is classified as “severe (<1%)”, “moderate (1- 5%)” or “mild (>5%)” 
according to the plasma activity  of the affected clotting factor. 
The primary  goals of haemophilia care are the prevention of bleeding episodes (prophy laxis), rapid 
and definitive treatment of bleeding episodes that do occur, and provision of adequate haemostasis 
during surgery  and other major challenges to haemostasis. Currently , these goals are essentiall y met 
for patients with haemophilia A by  intravenous ( i.v.)injections of the commerciall y available FVIII 
products approximately  3 times a week. However, with currentl y marketed FVIII products, the 
clinical practice for prophy laxis is associated with substantial unmet medical needs, primaril y 
linked to cumbersome, frequent and painful i.v. administration of the haemostatic agent. 
Consequently  adherence to prophy laxis is in general suboptimal, and non-
compliance with a 
frequent injection schedule is one of the most commonly  cited reasons for failure of proph ylaxis 
with FVIII products. 
The most serious complication of haemophilia treatment with current FVIII products is FVIII 
inhibitor development. These inhibitors are antibodies formed as an immune response to allogeneic 
FVIII, which reduce or eliminate the activity  of FVIII proteins. This condition develops in about 
30% of previousl y untreated patients ( PUPs) with severe haemophilia A following exposur e to 
FVIII products.3,4Availability  of a recombinant human FVIII ( rFVIII)product with reduced 
immunogenicit y has been the priority reques
t by the haemophilia community  for many  years. The 
immunogenicit y of N8 -GP will be monitored in the clinical setting and further investigated in 
nonclinical models to explore preliminary findings of reduced binding and uptake of N8 -GP in 
human antigen pres enting cells.
3.1.2 N8-GP
N8-GPis a g lycopegy lated recombinant coagulation FVIII hereafter referred to as N8- GPand
represents a new rFVIII with a longer terminal half -life (t½) than currently available rFVIII 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 18 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 19of 114
  products. Clinical areas of interest include preven tion (prophy laxis) and treatment of bleeding 
episodes in patients with haemophilia A without inhibitors, as well as the prevention of bleeding in 
surgery  undertaken in these patients.
The N8 -GP product is based on turoctocog alfa, which is a state of the a rt serum -free truncated 
rFVIII containing 21 amino acids of the wild t ype B -domain. N8 -GP is a rFVIII molecule where a 
single 40 -kDa pol yethylene gl ycol (PEG) is specifically  attached to a unique O -glycan in the 
truncated B-domain of turoctocog alfa, manuf actured using three enzy mes all produced b y 
recombinant technology . When activated by  thrombin, the B -domain containing the pegy lation is 
cleaved off, thus generating active FVIII (FVIII a)which is similar in structure to native activated 
FVIII -a key  feature of the compound. N8- GP is a recombinant product, not based on human blood 
components, and hence the risk of transmission of viral and other blood -borne diseases has been 
eliminated. No animal -derived components besides the cell line (Chinese Hamster O vary (CHO) 
cells) are used during the manufacturing process. 
For full information on medicinal aspects and qualities of the N8 -GP product please refer to the 
investigator brochure (IB).5
3.1.3 N8-GP clinical data
In accordance with the European Medicines Agency  (EMA) guidelines andother regulatory  advice 
the clinical programme for N8 -GP was initiated with a first -human- dose trial to document the 
essential PK characteristics of the product and to obta in initial safety information. 
In the first human dose trial (NN7088 -3776) , a sing le dose of N8- GP (25, 50 or 75 U/ Kg) was 
administered to 26 adult previously  treated patients (PTPs) with severe haemophilia A being in a 
non-bleeding state. N8 -GP was well -tolerated and the safet y profile of N8- GP appeared similar to 
that of marketed FVII I products. The mean half -life of N8- GP was shown to be 18.4 hours, 
corresponding to a 1.6 -fold prolongation compared to the half -life of commerciall y available FVIII 
products (patient’s previous product i ncluding rFVIII and plasma derived FVIII ( pdFVIII ))
.6
Three clinical trials investigating the safet y and efficacy of N8 -GP are on- going. The pivotal trial
(pathfinder ™2) in adolescents and adults aims to document the safety  and efficacy  of a prophy lactic 
regimen with 50 U/ Kg body  weight ( bw) of N8- GP given every  four day s. The surgery  trial
(pathfinder ™3) aims to document the safety  and efficacy  of N8 -GP during major surgery .The 
pathfinder ™5 trial evaluates PK, safet y and efficacy  of N8-GP in previously  treated children 
(below 12 y ears of age).
An internal review of safety  and efficacy  data for 52 bleedi ng episodes reported by  10 patients in 
the pivotal pathfinder™2 trial (including adolescent and adult PTPs) was performed in order to 
initiate N8- GP prophy laxis treatment in patients from the US participating in pathfinder™2, and to 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 19 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 20of 114
  allow the pathfinder™3 surgery  trial to open globally . The cut -off-date was 12 -Feb-2013. Among 
the patients included in the review N8 -GP was well tolerated and no safet y issues have been 
identified. In particular no FVIII inhibitors were detected and no treatment related serious adverse 
events (SAEs) were reported. The efficacy  data showed that N8 -GP effectively  arrests bleeding 
episodes (96% of bleeds treated successfull y) and thereby has the intended haemostatic potential. 
These results were confirmed in a subsequent review of safet y and efficacy data from 20 adults and 
adolescents having at least 50 N8
-GP exposure days (EDs)1in the pathfinder™2 trial, performed 
according to the EMA guideline7,in order to allow the pathfinder™5 trial in paediatric PTPs below 
12 years to be initiated ( first patient first visit (FPFV ) 20- Feb-2013). In conclusion, currentl y 
available clinical data indicate that N8 −GP effectively  arrests bleeds and has shown the intended 
haemostatic potential. In addition, no safet y issues have been reported. Recently  one case of low -
titre FVIII inhibitor formation after multiple exposure to N8-GP has been reported in the ongoing 
phase 3 trial NN7088 -
3859 in adolescent and adult PTPs (as per 28- Jul-2013 this trial included 182 
patients being treated with N8 -GP). The FVIII inhibitor formation was reported for an 18 -years-old 
patient receiving N8 -GP every  4th day  for prophy laxis. After 94 exposures to N8 -GP a FVIII 
inhibitor test was positive for the first time, with an observed titre of 1.3 BU. The result was 
confirmed in the follow -up test 14 day s later (1.9 BU). Hence, the protocol definition for the 
presence of a FVIII inhibitor was met.
In accordance with the EMA guideline7,N8-GP exposure of PUPs may  be initiated when treatment 
data from 20 paediatric PTPs with at least 50 N8- GP EDs are available from the pathfinder™5 trial, 
including data from a minimum of 10 patients below 6 y ears, and pharmacokinetic investigations in 
children (below 12 years) are completed.
For further information on medicinal aspects, non -clinical data and quality  of N8 -GP please refer to 
the IB.5
3.2 Rationale for the trial
N8-GP represents a new recombinant FVII I product with a prolonged half -life developed to 
decrease the burden of treatment and thereb y increase treatment compliance for patients with 
haemophilia A, potentially leading to better clinical outcomes.
The N8 -GP clinical programme is designed to generate data on the pharmacokinetic (PK), safet y 
and efficacy  profile of N8- GP in all age groups. 
Given the prolonged half -life of N8
-GP it is expected that bleeding prophy laxis, treatment of acute 
bleeding episodes, and control and prevention of bleeding in the surgical setting may  be achieved 
                                                
1An exposure day (ED) is any day on which the patient has been exposed to trial product. This will be used for 
reporting purposes.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 20 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 21of 114
  with a reduced frequency and number of injections as compared to current treatment options. This 
may increase treatment compliance, and thereby  potentially  leading to better clinical outcomes for 
patients with haemophil ia A.
The rationale for performing the pathfinder™6 trial is to evaluate the safety  (including 
immunogenicit y) and efficacy of N8 -GP in the treatment of PUPs with severe haemophilia A in 
accordance with EMA requirements.7For Europe, EMA requires a separate investigation in the 
PUP population as part of the development programme to be initiated before market authorisation.7
The approval of the indication in PUPs will be based on a clinical trial in a minimum o f 50 PUPs 
evaluated for efficacy  and safet y during at least 50 EDs connected with a post -approval 
commitment to follow up at least 100 PUPs for a minimum of 100 EDs. The 50 patients will 
continue to reach at least 100 EDs, and additional 50 patients will be included also to reach at least 
100 EDs.
Given the prolonged half -life of N8- GP it is expected that bleeding prophy laxis, treatment of acute 
bleeds, and control and prevention of bleeding in the surgical setting may be achieved with a 
reduced frequency  and number of injections as compared to current treatment options. This may  
increase treatment compliance, and thereb y potentially  leading to better clinical outcomes for 
patients with haemophilia A.
Finally , as the HIV and hepatitis C epidemics in patients with haemophilia have subsided, the most 
serious complication of haemophilia treatment with current FVIII products is FVIII inhibitor 
development. These inhibitors are antibodies formed as an immune response to allogeneic FVIII, 
which reduce or el iminate the activity  of FVIII proteins. This condition develops in about 30% of 
PUPs with severe haemophilia A following exposure to FVIII products.3,4
3.3 Risk and benefits
Children are among those who might benefit from prophy laxis with N8-GP. Current products 
available for the treatment of haemophilia A have short half- life of approximately 12 hours 
demanding frequent dosing for proph ylaxis of bleeding episodes , with 3 - 4weekl y injections. The 
prolonged half -life of N8-GPoffers an expected advantage of twice weekly  or potentially  even less 
frequent injections , which reduces the burden of treatment while maintaining effective haemostasis . 
Likewise 
it may  promote adherence to therapy  due to less frequent injection s.
The recombinant F VIII part of N8- GPhas an amino acid sequence almost identical to human F VIII
and to the currently  marketed r FVIII product sand is produced by the CHO cell -line AAMP5, a 
mammalian cell line shown to be free of known infectious agents. 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 21 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 22of 114
  There is a risk for development of antibodies against N8-GPand/or F VIIIthat could decrease the 
effectiveness of future treatment with F VIIIproducts. However, this ri sk is not expected to be 
higher than with other F VIII products.
The benefits of N8 -GP in PUPs include reduced frequency  of injections compared with existing 
FVIII treatments due to the long half- life of N8- GP. L ack of compliance with a frequent injection 
schedule i s one of the most commonly  cited reasons for failure of prophylaxis with factor 
treatments.8Less frequent dosing is anticipated to result in a higher compliance. Furthermore, less 
frequent dosing regimens are believed to cause less interruption of daily  life, which might improve 
the quality  of life of the patients and their families.
N8-GP is manufactured in a serum- free pr ocess and the risk of transmission of viruses, prions and 
other known blood- borne diseases ha vebeen eliminated. Monoclonal antibodies used for 
purification of the product further reduce the risk of allergic reactions .
The primary  concern in PUPs is the risk of development of inhibitory antibodies to FVIII 
(inhibitors). P otential development of inhibitors will be monitored by  a Nijmegen modified 
Bethesda assay  (which has a high sensitivity  for low concentrations of inhibitors), and testing for 
presence of N8 -GP binding antibodies will be performed shortly  after each visit. A patient is 
diagnosed with inhibitor formation if the patient has been tested positive for inhibitors at two 
consecutive tests from the central labora tory. If antibodies are identified, these will be further 
characterised on an exploratory  basis an
d there will be close follow -upand case -by-case 
evaluations.
As with other proteins, allergic ty pe hy persensitivity  reactions, including anaphy laxis/anaphy lactoid 
reactions, may  
occur . As the N8- GP product contain strace amount of hamster cell protein s
antibodies to these may  occur. P arent (
s)/legall y acceptable representatives ( LAR )(s)to patients 
enrolled in the present trial will be informed of the signs of immediate t ype hypersensitivity 
reactions including hives, pruritus, generalised urticaria, angioedema, h ypotension (e.g. dizziness or 
syncope), shock and acute respiratory  distress (e.g. tightness of the chest, wheezing). 
PEGy lation of proteins is a well- established technology  which is used in the treatment of a variety  
of clinical disorders9and the nonclinical safety  profiling of N8 -GP has not identified an y safet y 
concerns in relation to humans in the dose range prop osed for the present trial.
N8-GP is currentl y being investigated in previously treated patients. The first human dose trial 
(NN7088 -3776) demonstrated that a single dose of N8- GP is generally  well -tolerated, and that N8 -
GP has a prolonged half- life compar ed to commercially  available FVIII products. No safet y 
concerns have been raised based on review of data (cut-off date was 12-Feb- 2013) from patients 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 22 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 23of 114
  enrolled in the pivotal safety  and efficacy  trial (NN7088- 3859) and the risk/benefit ratio for N8 -GP 
is therefore expected to be favourable. 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 23 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 24of 114
  4Objective(s) and endpoint(s)
4.1 Objective(s)
Primary Objective
To evaluate immunogenicity  of N8-GPin previously  untreated patients (PUPs) with severe 
haemophilia A
Secondary Objectives
To evaluate safet y other than immunogenicit y ofN8-GP in PUPs with severe haemophilia A
To evaluate efficacy  of N8-GP in PUPs with severe haemophilia A
oin long -term proph ylaxis treatment (bleeding preventive effect)
oin the treatment of bleeding episodes 
4.2 Endpoint(s)
4.2.1 Primary Endpoint
Incidence of FVIII inhibitors 
4.2.2 S econdary Endpoint
Frequency  of Adverse events (AEs) including serious AEs and Medical Events of Special 
Interest (MESI).* 
Incidence of confirmed high titre inhibitors (define das inhibitor ti tre > 5BU) *
Number of breakthrough bleeding episodes during prophy laxis with N8- GP(annualised 
bleeding rate).*
Haemostatic effect of N8 -GP in treatment of bleeding episodes, assessed by a predefined 4-
point haemosta tic response scale (“excellent”, “good”, “moderate” and “ none ”).*
Consumption of N8 -GP for proph ylaxis (number of injections and U/Kg per month and per 
year)
Consumption of N8 -GP for treatment of bleeding episodes (number of injections and U/Kg 
required per bleeding episode)
Total consumption of N8 -GP per patient (p revention and treatment of bleeding episodes) per 
month and annualised value
*Key  supportive secondary  endpoint prospectivel y selected for posting on clinicaltrials.gov
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 24 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 25of 114
  5Trial design
5.1 Type of trial
This is a multi -national, non- randomised, open label phase 3 trial investigating the safet y (including 
immunogenicit y) and efficacy of N8 -GP in prophylaxis and treatment of bleeds in a paediatric 
population of PUPs (age below 6 y ears) with severe haemophil ia A (FVIII baseline level < 1%). 
There will onl y be one treatment arm and no comparator. 
The trial design is based on the guideline on clinical investigation of recombinant and human 
plasma -derived factor VIII products developed b yCommittee for Medicina l Products for human use 
(CHMP )in EU.7
The number of patients to be investigated in this trial follows the minimum EU guideline 
requirements for approval of the indication in PUPs, which will be based on a pre -authorisation 
clinical trial in a minimum of 50 PUPs evaluated for efficacy  and safet y during at least 50 EDs, 
connected with a post- approval commitment to follow -up at least 100 PUPs for a minimum of 100 
EDs.7
According to the EMA Guideline treatment with N8 -GP in the pathfinder™6 PUP trial may  start 
when 20 patients participating in the paediatric PTP trial (pathfinder™5) are available (including 
data from a minimum of 10 paediatric patients below 6 y ears of age), and pharmacokinetic 
investigations in paediatric PTPs are completed.7
For the individual patient the trial consists of four parts; screening, main phase and extension phase
and a proph ylaxis period until end of trial Figure 5–1. 
In the main phase of the trial patients will receive treatment with N8 -GP until they  reach a 
minimum of 50 N8- GP EDs each, or until they  develop high -titre inhibitors. An ED is defined as 
any day during which the patient has been exposed to N8 -GP, including doses given for treatment 
of bleeding episodes, prophy laxis, surgery  and for the purpose of PK assessment. If N8- GP is 
administered more than once during the same day , this will still count as one ED. When at least 50 
patients have reached a minimum of 50 EDs each in the main phase, t he analy sis and evaluation for 
the main trial report will be performed. EDs during immune tolerance induction therapy (ITI)will 
not count in the determination of when a patient has reached 50 EDs.
Patients will be followed in the extension phase until at least 100 patients have reached at least 100 
EDs each. Results from all patients in all parts of the trial will be reported as supportive results 
when the last patient has completed or left the trial.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 25 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 26of 114
Patients who develop inhibitors during the trial may continue treatment with N8-GP and will 
follow a n alternative treatment regimen and visit schedule, see Section 5.3.6. These patients will be 
considered as a separate cohort and will be evaluated accordingl y.
If needed, the patients can undergo minor or major surgical procedures during the trial. Upon 
completion of the surgery the patient can continue proph ylaxis treatment with N8 -GP as before the 
surgery .
5.2 Rationale for trial design
The trial design follows current standards for similar trials, and the EMA “Guideline on the clinical 
investigation of recombinant and human plasma- derived factor VIII products”7.
The trial design will provide information on safet yandefficacy  of N8 -GP in paediatric PUPs below 
6 years of age with severe haemophilia A (FVIII activity  level of < 1%).
The purpose of the present trial is to evaluate immunogenicit y of N8 -GP and to document the safety  
and efficacy  of N8 -GP in long -term prophy laxis and treatment of bleeding episodes in paediatric 
PUPs. 
The main phase of the trial will generate s afety and efficacy , aiming for a minimum of 50 EDs per 
patient. This number of EDs is required b y the EMA guideline7for evaluation of new FVIII 
products. The trial does not include a placebo control group, as it is considered unethical to 
administer an ineffective treatment to patients with haemophilia. An active control has not been 
included a s extensive compara tive data from recently  registered rFVIII products are available in 
comparable global populations including patients from EU and US.14,15Furthermore, the EMA 
guideline does not require a comparison to neither placebo nor an active comparator.
There will be no randomisation due to the single -arm nature of the trial.
A multinational design has been chosen to ensure a sufficient screening pool of patients with this 
rare disorder, to meet local regulatory requirements and to reflect the anticipated patient po pulation.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 26 . -  | 1
 |
CONFIDENTIAL
Protocol
Trial ID: NN7088 -3908
UTN: U1111 -1148 -1897
EudraCT No.: 2013 -004025 -88 
Figure 5–1Patient flow chart
5.3 Treatment of patients
Trial visit schedule will be as shown in 
According to common practise in haemophilia care, most children will initially  receive 
(episodic )treatm ent for minor skin/mucosa bleedings episodes
muscle or severe bleed, switch to prophy laxis in order to prevent bleeds and musculoskeletal 
damage. This is usually  done when the child is between 1 and 2 years of age. 
The main phase of the trial is designed to reflect 
on the decision made b y the investigator and the child’s parent(s)
directly  with N8 -GP prophy laxis (prior to any  experienced bleeds) or with N8
treatment (pre -prophylaxis treatment), and subsequently  switch to proph ylaxis
investigator and patient’s parent(s)/LAR(s) whether to start on proph ylaxis or pre
For each patient at least the two initial doses of N8
setting enabling observation for potential adverse reactions. The patient must be observed for at 
least 1 hour after dosing. Afterwards, home treatment with 
parent/caregiver/support person can be initiated if no safet y concerns were raised after 
administration of the initial doses of N8
parent/caregiver/support person is sufficientl y trained an
both prophy laxis and treatment of bleeding episodes. The patients can come to the clinic/trial site 
for their N8- GP injections until they  are comfortable with home treatment.
CONFIDENTIALDate:
Version:
Status:
Page:
Patient flow chart
patients
Trial visit schedule will be as shown in Figure 5–1 .
According to common practise in haemophilia care, most children will initially  receive 
ent for minor skin/mucosa bleedings episodes and after the first joint and/or 
muscle or severe bleed, switch to prophy laxis in order to prevent bleeds and musculoskeletal 
damage. This is usually  done when the child is between 1 and 2 years of age. 
The main phase of the trial is designed to reflect common practice in haemophilia treatment. Based 
on the decision made b y the investigator and the child’s parent(s) /LAR(s) patients can either begin 
GP prophy laxis (prior to any  experienced bleeds) or with N8
phylaxis treatment), and subsequently  switch to proph ylaxis
investigator and patient’s parent(s)/LAR(s) whether to start on proph ylaxis or pre
For each patient at least the two initial doses of N8 -GP will be administered in a hospital/clinic 
setting enabling observation for potential adverse reactions. The patient must be observed for at 
least 1 hour after dosing. Afterwards, home treatment with i.v. self -injection by  the 
parent/caregiver/support person can be initiated if no safet y concerns were raised after 
administration of the initial doses of N8 -GP. The investigator should ensure that 
parent/caregiver/support person is sufficientl y trained an d confident with home treatment, including 
both prophy laxis and treatment of bleeding episodes. The patients can come to the clinic/trial site 
GP injections until they  are comfortable with home treatment.
04 November 2013 Novo Nordisk
1.0
Final
27of 114
According to common practise in haemophilia care, most children will initially  receive on-demand 
and after the first joint and/or 
muscle or severe bleed, switch to prophy laxis in order to prevent bleeds and musculoskeletal 
damage. This is usually  done when the child is between 1 and 2 years of age. 
common practice in haemophilia treatment. Based 
patients can either begin 
GP prophy laxis (prior to any  experienced bleeds) or with N8 -GP on-demand
phylaxis treatment), and subsequently  switch to proph ylaxis. It is decided b y the 
investigator and patient’s parent(s)/LAR(s) whether to start on proph ylaxis or pre -prophy laxis.
GP will be administered in a hospital/clinic 
setting enabling observation for potential adverse reactions. The patient must be observed for at 
injection by  the 
parent/caregiver/support person can be initiated if no safet y concerns were raised after 
GP. The investigator should ensure that 
d confident with home treatment, including 
both prophy laxis and treatment of bleeding episodes. The patients can come to the clinic/trial site 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 27 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 28of 114
The duration of a single patient’s tre atment in the main phase of the trial is until 50 N8 -GP EDs is 
reached, or until development of high -titre inhibitors , but will be maximum 26 weeks if the 
recommended twice weekly dosing is used for prophy laxis. 
The duration of N8 -GP treatment in the exte nsion phase is at least 50 EDs or up to a minimum total 
100EDs (for both the main and extension phases ) for each patient. Once a patient has achieved 
100EDs, he may be offered the option to continue in the extension phase until either N8 -GP is 
commerciall y available in the relevant country or until the marketing authorisation application for 
N8-GP is rejected in the relevant country  unless the N8-GP trial, part of the trial or a trial site is 
terminated b y Novo Nordisk or a relevant authority for an y reason .In an y event, the Last Patient 
Last Visit for the trial will be no later than 13 May 2019 whether or not the product is commerciall y 
available in the relevant country . Novo Nordisk will not provide any  patient with trial medication 
after the end of the trial.
Treatment with FVIII products other than the investigational product, N8 -GP, is not allowed.
Previous exposure to FVIII products is not allowed in this trial. Previous exposure to maximum 5 
plasma infusions, Pd -aPCC, and/or cry oprecipitate is allowed.
5.3.1 Pre-prophylaxis treatment
At the beginning of the main phase of the trial, slow start prophy laxis and on-demand treatment of 
bleeds with trial product (N8 -GP) will be allowed at the discretion of the investigator and patient’s 
parent(s) /LAR(s) . The decision regarding pre -prophy laxis treatment will be made at visit 0 or 1. 
The N8 -
GP dose for pre- prophy laxis treatment (except for bleeding episodes) is approximately  60 
U/Kg bod y weight (bw) (within the dosing range of 50- 75 U/Kg) to be administer ed as a single 
bolus dose intravenously
 (i.v.) less than once every 7 day s
 (at the discretion of the investigator). 
Whole mL dosing is allowed from above 3 mL , explained in the trial material manual.  For treatment 
of bleeding episodes see
 Table 5–1.
Switching from pre-p rophy
laxis treatment to prophylax is should follow guideline in Section 5.3.3.
For regular safet y monitoring (including blood sampling for inhibitor analysis) pre -proph ylaxis 
treated patients must attend regular site visits
 (see Table 2–1). 
5.3.2 Prophylaxis treatment
Prophy laxis with regular N8- GP administration must be initiated no later than at the patient ’s age of 
24 months, or after 20 EDs in pre -proph ylaxis, whateve r comes first.
The N8 -GP dose for prophy laxis treatment is approximately  60 U/ Kg bw to be administered as a 
single bolus dose i.v. at each administration day , preferabl y in the morning. However, it is allowed 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 28 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 29of 114
  to dose within the dose range 50 -75 U/ Kg bw, en abling whole mL dosing. Whole mL  dosing is 
allowed from above 3 mL .
During the main phase of the trial patients should receive prophy laxis with i.v. injections of N8 -GP 
preferabl y twice weekl y, with doses to be separated by  at least 3 calendar day s and no more than 4 
calendar day s. An increase in N8 -GP dose frequency  from twice weekl y to every  third day  is 
permitted at the investigators discretion (should be based on patient’s individual bleeding pattern). 
Furthermore it is allowed to start prophylaxis in the main phase with a once -weekl y dosing regimen, 
if considered sufficient for bleeding prevention by the investigator. 
In the extensio n phase, all patients should continue the proph ylaxis dosing regimen as prescribed at 
the end of the main phase. However, preferabl y after being 12 months on the same proph ylaxis 
regimen (main phase and extension phase combined), the investigator is permitted to incre ase or 
decrease the N8 -GP dosing interval within the range of every  3rdday to every  7thday (every  3rdday, 
twice weekly , every  4thday, every  5thday, every  6thday or every  7thday (once weekl y))based on 
the patient ’sbleeding pattern. 
The dose can be administered +1 day  of the planned dosing date.
Furthermore, if considered relevant, the investigator is permitted to prescribe administration of extra 
N8-GP bleeding preventive doses before demanding ph ysical activities (e.g. sports).The next 
regular pro phylaxis dose should not be postponed due to an extra prophy laxis dose, but still be 
administered on the usual dosing day . 
In the event of a concern about reduced treatment efficacy  an unscheduled visit can be scheduled 
where a PK session may  be performed to investigate the elimination (recovery , clearance and half-
life) of N8- GP. 
Antibody tests should be taken if not done recently .The PK data may  potentially  be 
used to adjust the dose or dosing regimen . 
5.3.3 Treatment of bleeding episodes
Patient’s parent (s)/LAR(s
)will be instructed b y the trial site on how to treat a bleeding episode at 
home and record in the electronic diary  (eDiary ).Treatment requiring bleeding episodes should 
immediately  (i.e., when the patient experiences the first clinical s ymptoms of a bleeding episode) be 
treated with N8 -GP at doses of 20 -75 U/ Kg bw, depending on severity  and location of the bleeding 
episode , see Table 5–1. For tr eatment of severe/life- threatening bleeding episodes administration of 
higher doses of N8 -GP is permitted at the investigators discretion. For recommended dose levels 
see Table 5–1 .
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 29 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 30of 114
  At least the first 2 treatment-requiring bleeding episodes should be treated in the presence of a 
qualified health care professional. If the patient cannot be brought quickly  to the trial site , the trial 
sitemust be contacted for treatment instructions or transport. A severe bleeding episode should 
immediately  be treated at home or at the local emergency  room, and the trial site must be contacted 
for further instructions or transport . For severe bleeding epis odes before the 2nd EDs the treatment 
must take place at the site.
In case of treatment requiring bleeding episodes prior to home treatment, these should immediately  
be treated at trial site. In case the bleeding episode occur s outside trial site opening h ours, the 
bleed ing episode should be treated according to local practice.
The need for a second dose of N8 -GP should be evaluated within 8 hours of the initial dose. If two 
doses are not sufficient to treat the bleeding episode, and immediatel y in the ca se of a severe 
bleed ing episode ,the trial site must be contacted as soon as possible for further instructions and/or 
transport to the trial site for an unscheduled visit. 
Total number of N8- GP doses and frequency  of dosing for treatment of a bleed ing epi sode is 
decided b y the investigator based on the individual bleed ing episode characteristics and haemostatic 
response to treatment, and/or based on local guideline or standard of practice. Dosing guidance may 
be provided at a scheduled or unscheduled visit at the clinic or by  telephone contact to the trial site . 
If a haemostatic response to treatment cannot be achieved (i.e. the bleed does not stop) within 48 
hours after initiating treatment with N8- GP, another FVIII product may  be selected at the discreti on 
of the investigator , and the patient must be withdrawn from the trial. 
If a bleeding episode occurs on a planned prophy laxis dosing day  before administration of the 
prophy laxis dose, or if a bleeding episode extends into such a day , the bleeding episode must be 
treated with the full prophy laxis dose (this dose should be recorded as treatment of a bleeding 
episode) (does not apply for surgeries) . The patient should at all times follow the original 
prophy laxis dosing scheme unless a dose has already been given to treat a bleeding episode during 
the same day .
Treatment of bleed ing episodes with N8- GP will be included in the overall count of ED.
5.3.4 Treatment of suspected ble eding episodes
In case of an abdominal or head trauma where there is a risk of a severe traumatic bleeding episode 
it is allowed to initiate treatment before clinical symptoms arise. This is defined as preventive 
treatment of suspected severe traumatic bleeding episode. The recommended dose is equivalent to 
treatment of a severe bleeding episode
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 30 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 31of 114
5.3.5 Surgery
Minor surgeries, dental extractions and placement of central venous access ports can be performed 
while participating in this trial by  administering extra doses of N8 -GP equivalent to the dose for a 
severe bleeding episode (see Table 5–1 ), or aligned to local standard of practice, or guidelines for 
treatment of patients with haemophilia A with FVIII in the perioperative period. 
Major s urgery  will only  be allowed after the individual patient has reached 50 N8- GP EDs, and 
upon completions of the pathfinder™3 surgery  trial (NN7088- 3860). The treatment regimen for 
major surgery  will be based on results from the pathfinder™3 surgery  trial (NN7088-3860) and PK 
data obtained in the pathfinder™5 trial (NN7088 -3885) in paediatric PTPs. Novo Nordisk will 
communicate when major surgeries are allowed in this trial.     
Definition of minor surgery
Minor surgery  is defin ed as an invasive operative procedure where onl y the skin, the mucous 
membranes or superficial connective tissue is manipulated. For this trial, examples of minor surgery  
include:
Implanting and removing ports in subcutaneous tissue
Skin excisions
Drainage of abscess
Simple denta l procedures
Circumcision
Definition of major surgery
Major surgery  is defined as a ny invasive operative procedure that require several day s of FVIII 
substitution therapy  and/or where an y one or more of the following occu r: 
A body  cavit y is entered
A mesench ymal barrier (e.g., pleura, peritoneum or dura) is crossed
A fascial plane is opened
An organ is removed
When n ormal anatomy  is operativel y altered
Major elective orthopaedic surgery
Treatment with N8 -GP during surgery  will be included in the overall count of N8 -GP EDs. Upon 
completion of the surgical/invasive procedure the patient can continue prophy laxis treatment with 
N8-GP as before the surgery .
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 31 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 32of 114
5.3.6 Treatment of patients with FVIII inhibitors
Approximately  20–30% of PUPs with severe haemophilia A develop inhibitors to infused FVIII 
rendering use of such replacement therap y ineffective. Patients who develop inhibitory  antibodies 
remain at higher risk for morbidity  and mortality  associated with recurrent or uncontrolled bleeding 
events.
The majori ty of haemophilia patients with inhibitors develop high -titre (> 5 BU) inhibitors, and 
demonstrate an anamnestic rise in their inhibitor titre when re-exposed to FVIII. In these patients 
even frequent, high -dose FVIII substitution therapy  becomes ineffecti ve in controlling bleeding 
episodes as the infused coagulation factor products are neutralised by  the inhibitor. Administration 
of FVIII b ypassing agents (rFVII or activated prothrombin complex concentrates) becomes 
necessary  for treatment of bleeding epis odes. 
Treatment of bleeding episodes with by -passing agents, i.e. rFVIIa or APCC according to local 
standard care, is allowed for patients who develop FVIII inhibitors within this trial. By -
passing 
agents are not considered trial medication.
The ultimate goal of treatment in patients with high -titreinhibitors is to permanently  eradicate the 
inhibitor by  immune tolerance induction therapy (ITI), thereby  making it possible for the patient to 
be treated routinel y with FVIII replacement therapy. The therapeutic concept is based on long -term 
uninterrupted high exposure to FVIII in an effort to sufficiently  tolerize the immune sy stem. In that 
state, the clinical responsiveness to FVIII replacement therap y is restored. 
Based on the available evidence, all patien ts with high- titre inhibitors (> 5 BU) should undergo ITI 
using the same t ype of product that the patient was using at the time of inhibitor developmen t.10
This approach is supported by an international expert panel11which concurred with treatment 
guidelines which recommend that ITI should be conducted with the same concentrate as the one 
against which antibodies were developed.12,13This should ensure successful tolerance induction and 
reduce the risk of further inhibitor development to new molecules. It may  therefore be expected that 
N8-GP will be favourable over the use of commercially  available FVIII products for ITI in patients 
who developed FVIII inhibitors within this trial. 
Novo Nordisk plans that patients who develop inhibitors, within this trial, will be offered continued 
treatment with N 8-GP, including ITI for a maximum of 24 months. I TI with N8 -GP will not be 
initiated until Novo Nordisk has reviewed the clinical data available after completion of the N8 -GP 
pivotal and surgery  trial (pathfinder™2 and pathfinder™3), and of the paediatric PTP trial 
(pathfinder™5) data needed for opening the paediatric PUP trial according to EMA requirements.
It is expected to use a N8 -GP dosing regimen for ITI  similar to local standard care/guidelines 
applied for IT I with marketed FVIII products. For each i ndividual patient, ITI  regimens with N8- GP 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 32 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 33of 114
would have to be reviewed by  the investigator every  month, and more formally  reviewed every  3 
months by  Novo Nordisk.
Based on experience with marketed FVIII products, a successful ITI can be expected in about 60 –
80% of cases receiving ITI  with N8 -GP, leading to several important benefits for the patient, 
including:
allowing regular FVIII replacement therap y in case of bleeding and surgery
enabling proph ylactic treatment with FVIII to prevent haemophilic arthropath y and life -
threatening bleedings
improving the patient`s quality  of life (less morbidity  etc.)
With current knowledge, the benefit/risk ratio for using N8-G P for ITI is expected to be favourable, 
and similar as being described in Section 3.3. Non-clinical and clinical data on N8-G P do not 
suggest an y alteration to the established safety profile of current rFVIII products. I t is evaluated as 
unlikely that clinical si gnificant adverse events will occur in humans specifically as a result of N8-
GP being used for ITI. However, close monitoring is strongl y recommended when N8- GP will be 
used for IT I in this trial.
It may
 also be decided by the Investigator and/or parent/le gal representative to withdraw the patient 
who developed FVIII inhibitors.
Patients will be evaluated a
fter 12 months of ITI treatment, based on the level of inhibitors. I f 
inhibitors are still positive after 12 months, but the decline from peak titre level is
 ≥ 20%, ITI may
 
continue for a maximum period of 24 month in total.
If needed and decided b y the I nvestigator, the initiation of the ITI can be 
delay ed but it has to start 
within 6 months from the time of diagnosis of inhibitor. I nhibitor patients that commence ITI with 
N8
-GP will follow an alternative treatment regimen and visit schedule (see Section  8.1.11). If the 
inhibitor disappears during the ITI
 (see Section 8.4.2.2
, the patient should resume prophyl axis 
treatment as recommended in Section  5.3.2. For patients still with positive inhibitors after 12 
months ITI, continued trial participatio
n will be evaluated by the investigator and sponsor based on 
the level of inhibitors, within the predefined specifications of withdrawal criteria 8, see Section  6.4. 
Howe ver, if the inhibitor persists after 24 months of ITI, th e patient will be withdrawn from the 
trial. 
For patients who develop low
 titre and/or clinically
 insignificant inhibitors (< 5 BU), the dose level 
and dosing frequency of N8- GP will be decided by the Investigator based on clinical evaluation.  
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 33 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 34of 114
  Table 5–1 Intravenous N8- GP treatment
Indication Dosage Frequency
Pre-prophylaxis
(pt. less th an 24 months of age)Approximately 60 U/ Kg (50-75U/Kg) On-demand or slow  start prophylaxis 
(less than weekly dosing)
Prophylaxis –main phase Approximately 60 U/ Kg (50-75U/Kg) Every 3rdday, twice weekly or every 
7thday(±1 day)
Prophylaxis –extension phase Approximately 60 U/ Kg (50-75U/Kg) Every 3rdday, twice weekly, every 4th
day, every 5thday, every 6thday or 
every 7thday(±1 day)
Mild/moderate bleeding episode 20-60 U/ Kg On-demand (breakthrough bleeding 
episodes)
Severe bleeding episode 40-75 U/ Kg
For treatment of severe/life -
threatening bleeding episodes 
administration of higher doses of N8 -
GP is permitted at the investigator’s 
discretionOn-demand 
Minor surgery 40-75 U/ Kg In accordance w ith local standard of 
practice of the participating trial site
Major surgery, only allowed after 50 
EDsRecommended doses regimens will 
be provided w hen the N8 -GP surgery 
trials completed On-demand
Low titre inhibitor Recommendation 60 U/ Kg(50-75 
U/Kg) for prevention and treatment 
of bleed ing episode sDosing interval as needed
Maximum dose/day 200 U/Kg Total maximum dose over 24 hours
5.3.7 Vaccinations
Vaccination are allowed before entering the trial but should preferably  not take place until 3 months 
after the first N8 -GP exposure, as vaccination activates the immune sy stem of the patient, thereby
potentially increasing the risk of inhibitor development.
5.4 Treatment after end of trial
After trial end the investigator will agree with the patient’s parent(s)/LAR(s) upon the best available 
treatment for the patient. 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 34 . -  | 1
 |
CONFIDENTIAL
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 35of 114
  When discontinuing trial product the patient should be switched to a suitable marketed product at 
the discretion of the inve stigator .
It is expected that N8 -GP will be granted marketing authorisation and is commercially available 
when the patients complete this trial. However, this cannot be guaranteed .
5.5 Rationale for treatment
Lack of compliance with a frequent injection schedu le is one of the most commonly  cited reasons 
for failure of proph ylaxis with coagulation factor treatment8. The increased half -life of N8-GPwill 
allow for proph ylaxis with fewer injections than currentl y available products and will most likely  
result in improving compliance.
The dose level is based on PK data from the phase 1 PK trial (NN7088-
3776) which showed that 
the t ½of N8 -GP was prolonged b y approximately  1.6-fold compared to the patient’s previous FVIII 
product. In the pivotal trial , pathfinder™2 (NN7088 -3859), a fixed dose of 50 U/ Kg bwis 
administered i.v. every  fourth day . Due to an anticipated higher clearance of FVIII in children, 
compared with adults 14a slightly  higher and more frequent dose schedule has been chosen for this 
trial. With the longer plasma half -life of N8 GP it is expected that 2 administrati ons of N8- GP per 
week will provide the same prophy lactic effect as 3 or 4 weekl y injections with currentl y marketed 
FVIII products. 
Please refer t o the IB and any update shere of for further pre -clinical and clinical data.5
The rationale for introducing the dose level of 60 U/Kgis, primarily  to explore and utilise the full 
potential of the molecule, by reducing the burden of treatment due to less frequent dosing .Please 
refer to the IB and an y updates hereof for further non -clinical and clinical data.
The rationale behind the once weekl y dosing is to enable slow start proph ylaxis as often done in 
clinical practice. This every  7 day  dosing may  continue if considered sufficient.  
The reason for providing the possibility  of ITI ofpatients who develops high-titreinhibitors is to 
permanentl y eradicate the inhibitor, thereb y making it possible for the patient to be treated routinely 
with FVIII replacement therap y. Base d on the available evidence patients should undergo ITI using 
the same ty pe of product that the patient was using at the time of inhibitor development. This 
approach is supported b y an international expert panel which concurred with treatment guidelines 
which recommend that ITI  therapy  should be conducted with the same concentrate as the one 
against which antibodies were developed. This should ensure successful tolerance induction and 
reduce the risk of further inhibitor development to new molecules. 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 35 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 36of 114
  6Trialpopulation
6.1 Number of patients
Number of patient s planned to be screened: 150
Number of patients planned to be started on trial product: 125
Number of patients e xpected to complete the tria l: 100
6.2 Inclusion criteria
1.Informed consent obtained before an y trial -related activities. Trial- related activities are an y 
procedures that are carried out as part of the trial, including activities to determine suitability for 
the trial
2.Male, a ge<6 yearsof age at the time of signing inform edconsent
3. D iagnos isof severe haemophilia A (FVIIIactivity  level < 1% ) based on medical records or 
central laboratory  results
4.No prior use of purified clotting factor products ( 5 previous exposures to blood components is 
acceptable)
For an eligible patient , all inclusion criteria must be answered “y es”.
6.3 Exclusion criteria
1.Any history  of FVIII inhibitor (defined by  medical records)
2.Known or suspected h ypersensitivity to trial product or related products
3. Previous participation in this trial. Participation is defined as first dose administered of trial 
product
4.Receipt of an y investigational medicinal product within 30 day s before screening
5. Congenital or acquired coagulation disorder other than haemophilia A
6.Any chronic disorder or severe disea se which, in the opinion of the Investigator ,might 
jeopardise patient ’s safety  or compliance with the protocol .
7.Patient’s parent(s)/LAR(s) mental incapacity , unwillingness to cooperate, or a language barrier 
precluding adequate understanding and cooperation  
For an eligible patient, all exclusion criteria must be answered “no”.
6.4 Withdrawal criteria
The patient may  withdraw at will at an y time either b y the patient or b y the patient’s parent(s) or the 
patient’s LAR . The patient’s request to discontinue must alway s be respected.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 36 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 37of 114
  The patient may  be withdrawn from the trial at the discretion of the investigator due to a safet y 
concern or if judged non-compliant with trial procedures.
The patient must be withdrawn if the following applies :
1. Dosed in the trial, but not fulfilling the inclusion and/or exclusion criteria
2.Anaph ylactic reaction to the trial product, for definition see Section 11.1
3.Major surgery before 50 EDs, see Section 5.3.4
4.Significant t hromboembolic event , see Section 11.1
5.Incapacity  or unwillingness to follow trial procedures
6.Use of coagulations factors other than N8 -GP or anti -coagulants un less in relation to ITI
7.ITI treatment has not been started within 6 months from the date of confirmation of positive 
FVIII inhibitor (BU ≥ 0.6/mL )
8. FVIII inhibitor titre decline from peak level is less than 20% after 12 months of ITI treatment
9. FVIII inhibit or is positive (BU ≥ 0.6/mL ) after 24 months of I TI treatment.
10. After completed ITI treatment (maximum 24 months), proph ylaxistreatment as described in the 
protocol is not resumed/started.
If a patient experiences treatment failure where haemostatic respon se is rated as none according to 
Section 8.6 , the investigator should consider if it is in the patient’s best interest to continue in the 
trial.
Alldata collected prior to withdrawal may  be used in the trial anal yses if considered relevant b y 
Novo Nordisk.
6.5 Patient replacement
Withdrawn patients may  be replaced to ensure that 100 patients complete the trial with at least 100 
EDs. Assuming a drop- out rate of 2 0%, it is estimated that 125patients must be started on N8 -GPto 
obtain the 100completed patients. This may , however, be adjusted during the trial based on the 
actual drop- out rate.
6.6 Rationale for trial population
The selection of the trial popul ation is based on the specific requirements found in the final 
g
uideline on the clinical investigation of recombinant and human plasma -derived factor VIII 
products7from the CHMP and in the paediatric investigational plan ( PIP)in agreement with the 
Paediatric Committee (PDCO).
Children are among those who benefit
significantly  from proph ylaxis. L ess frequent injections with 
N8-GP as compared to other treatment options are likely  to improve compliance, avoid 
interruptions of daily  life and thereby  increase the quality  of life of the patients.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 37 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 38of 114
  6.6.1 Rationale for inclusion criteria
Criterion no. 1 is included in accordance with International Conference on 
Harmonisation/Good Clinical Practice (ICH- GCP).1,2
Criteri on no . 2 is included due to N ovo Nordisk has decided to use an age cut -off of 6 
years.
Criteria no. 3, 4 are included to select the patient group based on the 
CHMP guideline7.
6.6.2 Rationale for exclusion criteria
Criterion no.1
is included to exclude patients with FVIII inhibitors since inhibitor 
development is the primary  safet y endpoint of the trial.
Criteria 2 and 6areto prevent unnecessary  exposure of potentiall y fragile patient to a 
new compound.
Criterion no. 3 is included to ensure that a patient only counts once in the data anal yses 
and to ensure the patient is a PUP.
Criteri on no. 4 is included to minimise any  effect of external compounds on the 
patient's coagulation and immune sy stem.
Criterion no. 5 is chosen to exclude patients with endogenous abnormalities of the 
coagulation system, other than haemophilia A
.
Crite rion no 7 is included to ensure enrolment of patients likely  to be compliant with 
the protocol, and to preclude enrolment of particularly  vulnerable patients.
6.6.3 Rationale for withdrawal criteria
Criteria nos. 1 -
6areincluded to protect the patient's safety and reliability  of the data .
Criteria nos. 7 -10 are included to ensure appropriate treatment of inhibitor patients.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 38 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 39of 114
  7Milestones
Planned duration of r ecruitment period (FPFV –LPFV):approximately  42months 
Planned FPFV: 01- May-2014
Planned LPFV:02 -Apr-2018
End of trial is defined as LPLV: 13-May-2019
The duration of the trial for each individual country  will vary . However, the end of trial will be no 
later than 13 May  2019.
The end of the clinical trial is defined as last visit of the last patient .
Planned completion of clinical trial report (CTR): November 2019.
The duration of N8 -GPtreatment in the trial is a minimum total 100EDs for a particular patient. 
Once a patient has achieved 100EDs, they  may  be offered the option to continue in the trial until 
either N8 -GPis commercially  available in the relevant country  or until the market ing authorisation 
application for N8-GPis rejected in the relevant country  unless the N8-GPtrial, part of the trial or a 
trial site is terminated by  Novo Nordisk or a relevant authority  for any  reason. I n any  event, the 
LPLV for the trial will be no late
r than 30 June 2018 whether or not the product is commerciall y 
available in the relevant country . 
The following exceptions will be made:
Patients with inhibitor will be allowed to receive ITI  treatment for up to 24 months.
Recruitment
The screening rate will be followed closely via the interactive voice/web response s ystem 
(IV/WRS) in order to estimate when to stop screening. All investigators will be notified 
immediately  when the recruitment period ends, after which no further consent will be sought from 
additional families and the IV/WRS, will be closed for further screening , unless additional 
screening is needed due to patient replacement. 
Trial registration
Information of the trial will be disclosed at clinicaltrials.gov ,novonordisk -trials.com and 
clinicaltrials.jp . According to the Novo Nordisk Code of Conduct for Clinical Trial Disclosure, it 
will also be disclosed according to other requirements such as those of the International Committee 
of Medical Journal Editors (ICMJE)15, the Food and Drug Administration Amendment Act 
(FDAAA)16, European Commission Regulation for EudraCT17and other relevant recommendations 
or regulations. If a patient requests to be included in the trial via the Novo Nordisk e -mail contact at 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 39 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 40of 114
these web sites, Novo Nordisk may  disclose the investigator’s contact details to the patient. As a 
result of increasing requirements for transparency , some countries require public disclosure of 
investigator names and their affiliations.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 40 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 41of 114
  8Methods and assessm ents
8.1 Visit procedures
Specific procedure s, assessments and methods for the scheduled visits are descr ibed in the section 
below, and the list of assessments for each visit is presented in the flow chart, see Table 2–1, and 
visit flow diagram
Figure 8–1 Visit flow diagram 
Screening and enrolment log
The investigator must keep a patient screening log, a patient identification code list anda patient 
enrolment log.The screening log and patient enrolment log may  be combined in one list.
At screening, patients will be provided with a trial card stating that they  are participating in a trial 
and giving contact address(es) and telephone number(s) of relevant trial site staff. Patient’s
parent (s)/LAR(
s) should be instructed to return the trial card to the investigator at the last trial visit 
or to destro y the trialcard after the last visit.
It must be stated in the medical records that the patient is participating in the trial , including the 
patient num ber.
Informed consent procedure
The patient’s parent(s) /LAR(s) will be provided with full written and verbal information about the 
trial prior to conduct of any  trial-related procedures/activities, in accordance with GCP and local 
requirements , see Section 17.1. 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 41 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 42of 114
  A child assent form will be provided to patients above 3 years of age according to local 
requirements .This can be performed on a separ ate day . As this is a long term trial the investigator
should check the progressing maturation of the child and its ability  to assent throughout the trial .
Informed consent for obtaining genot yping must be collected, if applicable.
Screening failures
Scree ning failures are defined as patients for whom the parent(s)/LAR (s)have signed the Informed 
Consent Form, but fail to comply  with the inclusion and /orexclusion criteria or if the consent is 
withdrawn prior to dosing. 
For screening failures the screening failure form in the electronic case report form (eCRF) must be 
completed with the reason for not continuing in the trial. Serious and non- serious adverse events
(AE) from screening failures must be transcribed by the investigator i nto the eCRF . Follow -up of 
SAEs 
must be carried out according to Section 11.3.A screening failure session must be made in 
the IV/WRS. The case book must be signed.
Re-screening is not allowed after the first dose of trial product –see excl usion criteri on no. 3 in 
Section 6.3 . 
For withdrawn pat ients
Withdrawn patients are defined as patients who meet the withdrawal criteria after dosing, see 
Section 6.4
If a patient is withdrawn from the trial, the investigator must aim to perform theEnd of trial visit,as 
soon as possible . 
The end of trial form must be completed, and final drug accountabilit y must be performed even if 
the patient is not able to come to the trial site. A withdrawal session must be made in the IV/ IWRS
andcase book must be signed in the eCRF. 
All data collected in the period the patient participated in the trial must be documented . 
Although a patient or patient’s parent(s)/LAR(s) is not obliged to give his/her reason(s) for 
withdrawing from a trial, the investigator should make a reasonable effort to ascertain the reason(s), 
while fully  respecting the patient ’s rights. Where the reasons are obtained, the primary  reason(s) for 
discontinuation must be specified on the end of trial form in the e CRF e.g.:
Adverse events
Protocol violation
Lack of efficacy
Lost to follow up
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 42 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 43of 114
  Withdrawal by  patient or parent (s)/LAR(s)   
Technical problems
Other
End of trial 
The end of trial (EOT) form should be filled in at the End of trial visit or the last visit of the patient. 
If a patient is withdrawn prior to completion of the trial, all attempts must be made to schedule the
end of trial visit for the patient. 
In general
Review of eDiaryreports, laboratory  reports etc. must be documented either on the front page of the 
documents and/or in the patient ’s medical record.
If clarification of entries or discrepancies in the eDiary is needed, the patien t’s parent(s)/LAR(s)
must be questioned and a conclusion made in the medical record. Care must be taken not to bias the 
patient ’s parent(s)/LAR(s) .
8.1.1 V isit 0 –screening visit
The p atient ’
sparent(s)/LAR(s) must give signed and dated informed consent prior to any  trial 
related activities. All patients will be provided with a cop y on the patient information and a cop y of 
the signed and dated Informed Consent Form.
For all patients with a signed Informed Conse nt/Assent form, the patient will be assigned aunique 6 
digits patient number , which will follow the patient throughout the trial.
A screening period (interval between V isit 0(V0) and V1) isallow eduntil the first dose of N8- GP 
is required. 
The screening visit 
(V0) can be combined with the first treatment of N8-GP(V1), hereb y allowing 
patients to be enrolled in the trial and treated for their first bleeding episode immediately  after 
having confirmed inclusion and exclusion criteria.
All results necessary  for evaluating the in clusion and exclusion criteria must be available before 
determining whether or not the patient can continue in the trial and whether it will be poss ible to 
receive the first dose of N 8-GPatthe same day . 
If the scre enings results do not become available during the screening visit, and if the next visit is 
not planned, the patient and parent(s)/LAR(s) must be informed when eligibility  has been evaluated 
by investigator.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 43 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 44of 114
Assessments for V0 are listed in Table 2–1 .
Reminders
Dispense trial card, see Section 8.8.1
AScreening call in the IV/WRS, see Section 10
Discuss treatment regimen: prophy laxis versus pre -proph ylaxis
In case V1 is not planned or performed within 3 month from visit 0 the investigator must
contact the patient’s parent(s)/L AR(s) at least every  12 weeks ± 1week, see Sections 8.8.4 and
8.1.9 .
During the screening period the patient cannot be treated with commerci ally available F VIII
products
8.1.1.1 Pre-prophylaxis treatment
Pre-proph ylaxis is optional and is the period before start of regular proph ylaxis.
During pre -prophy laxis the following dosing regimen applies: 
approximately  60 U/Kg  N8-GP within the range of 50-7 5 U/Kg bw, see Section 5.3
individualised prophylactic dosing intervals but less frequent than every 7th day(o nce weekly)
on-demand treatment of bleeding episodes
See further Section 5.3.1 .
Dosing visits during the pre-p rophylaxis period can be performed at any time until ED 20 being 
either part of visits in Table 2–1 or being registered as an unscheduled visit if the dose is  not part of 
Table 2-1. Visits during the pre-p rophylaxis period w ithout dosing should be performed as 
unscheduled visits, see Section 8.1.9. 
The site must make sure that the patient’s parent(s)
/LAR(s) are contacted at least at least every 12 
weeks ± 1week if no planned visits, Sect ion 8.8.4. 
Visit s 1-6 are when the patient needs treatment of a bleeding episode and/or 
planned individually 
per patient at the investigator and pat ient’s parent(s)/L AR(s) discretion.
8.1.1.2 Prophylaxis treatment
A patient may  change from pre -proph ylaxis to prophy laxis at any  time during the pre -prophy laxis 
period or must be initiated when the patient has reached 20 EDs , or has turned 24 months of age , 
whatever comes first. 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 44 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 45of 114
  The dosing frequency  during main phase is indi vidualised within the following interval: twice 
weekl y, ever y 3rdday or every  7thday. Changes to the regimen should be recorded in the IV/WRS . 
If changes occur between visits, it shou ld be recorded in an unscheduled visit, see Section 8.1.9 .
For patients th at enter the prophy laxis treatment after a period of pre -prophy laxis the next visit in 
the sequence will be determined by  the numbers of EDs. 
8.1.1.3 Wash -out prior to visits
A washout period is required prior to visits including inhibitor testing. The required w ash-out 
period is at least 72 hours.
In case the wash- out period has not been fulfilled the scheduled visit should be re -scheduled unless 
the visit is due to a bleeding episode treated at site during the pre -prophy laxis period or prior to 
initiating home treatment.
8.1.2 V isit 1 –first dosing with N8- GP
V1willtake place af ter the screening visit (V0 )whenever the first treatment of N 8-GP is 
administered , if not already  combined with V0.
In case of subjective signs of illness and/or fever within 48 hours prior to the first injection of N8 -
GP the dose should be postponed, if possible.
The patient will continue treatment on either:
Pre-prophylaxis treatment . See Sections 5.3.1 and 8.1.1.1 .
Prophylaxis treatment .See Sections 5.3.1 and8.1.1.2 .
Assessments for V1 are listed in Table 2–1 . In case V0 and V1 have been combined into one visit, 
assessments should only  be performed once.
Reminders
Next visit should be scheduled if applicable, see Sections 8.1.1.1 and 8.1.1.2 .
In case V2 is not planned or performed within 3 month from visit 1 the Investigator must contact 
the patient’s parent(s)/LAR(s) at least every 12 weeks ± 1week. See Sections 8.8.4 and 8.1.9
Drug accountabi lity of trial product at V1 must be recorded in the IV/WRS, see Section 10
Recording of bod y weight , see Section 8.3.1 , anddispensing of N8-GPfor trial sitedosing via 
IV/WRS, see Section 10.
8.1.3 V isit 2 , 3, 4 -6 –main phase
The 2 first N8- GP injection smust take place at trial site (V1+V2 ). Hereafter the injections can be 
administered at the trial site or outside the trial site.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 45 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 46of 114
  If the treatment is given at site the doses should be registered in the eCRF. If not given at site ,the 
dose should be registered in the eDiary . 
Visits at ED: 2, 5 ± 1 ED, 10 ± 2 EDs, 15 ± 2 EDs , 20 ± 2 EDs . 
The visits should be scheduled taking into account the patient’s regular dosing day (s) in the week.
Assessments for V2- V6 are listed in Table 2–1 .
Reminders
In case next visit is not planned or performed within 3 month from the previous visit the 
investigator must contact the patient’s parent(s)/LAR(s) at least every  12 weeks ± 1week. See 
Sections 8.8.4 and 8.1.9
All visits must be planned to allow for the required wash -out of 72 hours , see Section 8.8.3.1
Recording of bod y weight, see Section 8.3.1 , and dispensing of N8 -GP for trial site dosing and 
home treatment from visit 2 must be performed via IV/WRS, see Section 10
Drug accountability  of trial product must be recorded in the IV/WRS, see Section 10
Investigator must ensur e that patient’s parent(s)/LAR(s) return any  trial medication that would 
expire during the next home treatment period
eDiary  dispensing at V2 or when treatment outside trial si te is initiated, see Section 8.8.3.1
eDiary  training, see Section 8.8.3
8.1.4 V isit 7-8 –main phase
From V 6 all patients (including patients previous lyon pre -proph ylaxis) will be on proph ylaxis 
treatment with N8-GPon twice weekly , every  3rdday or every  7thday. Between the visits the 
patient will receive N 8-GP treatment at home if comfortable with home administrations or at the 
site, see Section 8.1.12 .
Visits at EDs: 30 ± 2 EDs, and 40 ± 2 EDs .
The visit should be scheduled taking into account the patient’s dosing day.
Assessments for V 7-V8 are listed inTable 2–1 .
Reminders 
An appointment for the next visit should be made
All visits must be planned to allow for the required wash -outof 72 hours, see Section 8.8.3.1
Recording of bod y weight, see Section 8.3.1 , and dispensing of N8 -GP for trial site dosing/home 
treatment must be performed via IV/WRS, see Section 10
Drug accountability  of trial product must be recorded in the IV/WRS, see Section 10
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 46 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 47of 114
Home treatment training , if the trial site suspects that the patient’s parent(s)/L AR(s) is not full y
confident with administration and how to deal with safet y related signs and symptoms, see
Sections 8.5 and 8.6
eDiary  training, see Section 8.8.3
eDiary  compliance review, see Section 12.3.
8.1.5 V isit 9 – end of main phase
Visit 9 should take place at either ED 50, ED 51 or ED 52.
Assessments for V9are listed inTable 2–1 .
Reminders 
An appointment for the next visit should be made
Next visits must be planned to allow for the required wash -outof 72 hours, see Section 8.8.3.1
Recording of bod y weight , see Section 8.3.1 ,and dispensing of N8 -GP for trial site dosing/home
treatment must be performed via IV/WRS, see Section 10
Drug accountability  of trial product must be recorded in the IV/WRS, se e Section 10
Home treatment, if the trialsite suspects that the patient ’s parent(s)/LAR(s) is not fully  confident
with administration and how to deal with safet y related signs and s ymptoms, see Sections 8.5
and 8.6
eDiary  training, see Sectio n 8.8.3 and 12.3
eDiary  compliance review , see Section 12.3
8.1.6 V isit 10-13 – extension phase
The patient will continue prophy laxis throughout the extension phase, with 60 U/ Kg in the regimen 
of every 3rd day, twice weekl y, every 4th
 day, every 5th day, every 6th day or every 7th day. See Table 
5–1. Changes to the regimen should be recorded in the eCRF. If changes occur between visits, it 
should be recorded in an unscheduled visit, see
 Section 8.1.9.
Visit a t EDs : 60 ± 2 EDs, 70 ± 2 EDs, 80 ± 2 EDs, and 90 ± 2 EDs.
The v
isits should be scheduled taking into account the patient’s dosing day .
The duration of the extension phase
 is between 6 months and 1  year depending on the dosing 
frequency , for a patient to achieve a total of 100 EDs .
Assessments for V 10-V13 are listed in  Table 2–1.
Reminders
An appointment for the next visit should be made
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 47 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 48of 114
  Next visits must be planned to allow for the required wash- out of 72 hours, see Section 8.8.3.1
Recording of bod y weight, see Section 8.3.1 , and dispensing of N8 -GP for trial site dosing/home 
treatment must be performed via IV/WRS, see Section 10
Drug accountability  of trial product must be recorded in the IV/WRS, see Section 10
Home treatment, see Sections 8.1.12 and 8.8.2 .
eDiary  training, see Section 8.8.3
eDiary  compliance review, see Section 12.3
8.1.7 V isit 14 - end of extension phase
Visit 1 4should take place at either ED 100, ED 101 or at ED 102.
Assessments for V 14are listed inTable 2–1 .
Reminders 
An appointment for the next visit should be made
Next visit must be planned to allow for the required wash -outof 72 hours, see Section 8.8.3.1
Recording of bod y weight , see Section 8.3.1 , and dispensing of N 8-GP for trial site dosing/home 
treatment must be performed via IV/WRS, see Section 10
Drug accountability  of trial product must be recorded in the IV/WRS, see Section 10
eDiary  compliance review , see Section 12.3
8.1.8 V isit 15-Xuntil end of trial
If N8 -GP is not commercially  available in a patient’s country  at the time of visit 14, the trial period 
may be extended with visits that are scheduled 24 weeks ± 4 weeks. These additional visits are 
referred to as visit 15 to visit X, where X can be any  visit from 16 and onwards. This option for the 
patient to continue in the extension phase of the trial may be offered until either N8 -GP becomes 
commerciall y avail able in the relevant country , or until the marketing authorisation application is 
rejected in the relevant country  unless the N8- GP trial, part of the trial or a trial site is terminated by  
Novo Nordisk or a rel evant authority  for any  reason, t he End of Tr ial visit must be scheduled within 
1month provided alway s that the Last Patient Last Visit for the proph ylaxis period until en dof trial
will be no later than 13 May  2019 whether or not the product is commercially  available in the 
relevant country  at this time. 
At every  dosing visit from V15 -VX, drug will be dispensed to cover up to 3 months of treatment. 
Depending on patient’s treatment regimen, additional dispensing visits might need to be scheduled 
to cover treatment in the period between visits.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 48 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 49of 114
Assessments for V15- VX are listed in Table 2–1.
8.1.9 End of trial visit
The EOT visit can take place at any
 time after completion of 100EDs or if the patient is withdrawn 
from the trial.
Assessments for the EOT are listed in Table 2–1
Reminders 
Drug accountability of trial product must be recorded in the IV/WRS, see Section 10
eDiary compliance review, see
 Section 12.3
eDiary LogPad collection, see Section 8.8.3.1
Complete EOT form
8.1.10 Unscheduled visit 
Unscheduled visits of trial related character can be performed at an y time during the trial and the 
purpose must be doc umented.
The following forms can be found in the unscheduled visit in the eCRF :
Central lab
Bleeding episodes
Dosing of N8 -GP
Surgery
PK session
Change of regimen
8.1.11  ITI Visit
N8-GP treatment may continue in case of low titre F VIII inhibitor ( ≤5BU) confirmed b y central 
laboratory , that does not result in clinically ineffective treatment with  N8-GP. Patients may follow 
the visit flow either as described in 
Table 2–1, or visits at the discretion of the investigator.
In case of high titre F VIII inhibitor (>5BU) confirmed by central laboratory  the investigator must  
decide
 how to proceed with treatment. Novo Nordisk will communicate when ITI is allowed in this 
trial, see Section 5.3.6.
If ITI is initiated, the patient
 will follow a visit schedule prescribed b y the
 investigator and 
according to local standard of practice. Monthl y visits are recommended, and the below listed 
assessment s 
are recommended to be performed :
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 49 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 50of 114
Adverse Events
Concomitant medication
Sampling for inhibitor test
Sampling for FVIII activity test
Bleeding episode eval uation
Review of eDiary
Body measurements, see Section 8.3.1
Treatment of bleeding episodes with by passing agents is allowed at the discretion of the investigator 
according to local practice, see Section 11.2. 
Reminder
Follow up on an y AEs according to Section 11.2
For patients returning to regular proph ylaxis N8-GP treatment, the visit schedule is taken up from 
V9 end of main phase Table 2–1, even when the corresponding total ED does not match.
8.1.12 Home treatme nt
Home treatment with N 8-GP can commence an y time after the first 2 EDs and the patient’s 
parent(s)/LAR(s) are comfortable with the reconstitution and administration process , see Section 
5.3.
8.1.12.1 Prophylactic home treatment
After 2 doses home treatment can be initiated with prophy laxis doses of approximately  60U/Kg 
(50-75U/Kg) . The regimen should follow Table 5–1 , and adjusted as needed during the trial.
Bleeding episodes must be treated as described in Section 8.6.
The following procedures must be performed during home treatment between visits :
N8-GP administrations according to regimen pre scribed by  investigator.
Contact tothe investigator/medically  qualified person in case of severe bleeding episodes
Completion of the patient eDiary , including details of all bleeding episodes and N 8-GP
administrations (see Section 8.6)
8.1.12.2 Home treatment of bleeding episodes
Bleeding episodes must be treated as soon as identified according to Table 5–1andSection 8.6. 
Patient’s parents(s)/LAR(s) will be instructed b y the investigato r on how to treat their child for a 
bleeding episode at home and how to record this in the eDiary .
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 50 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 51of 114
  The following procedures must be performed
N8-GP administration for treatment of treatment requiring bleeding episodes, see Section 8.6
Completion of the patient eDiary , including details of all bleeding episodes and N 8-GP 
administrations (see Section 8.6).
8.2 Patient related information
8.2.1 Concomitant illness and medical history
Aconcomitant illness is any  illness that is present at the start of the trial at the first visit (V0) . All 
concomitant illnesses should be reported including disease under investigation.
Medical history is a medical event that the patient has experienced in the past, which should be
obtained during the screening procedure including haemophilia treatment history . In the event that a 
diagnosis is unknown, the description of s ymptoms will be recorded. All significant symptoms 
and/or illnesses since birth should be recorded.
The information collected for concomitant illness and medical history  should include diagnosis, 
date of onset anddate of resolution or continuation , as applicable .
Any change to a concomitant illness should be recorded during the trial. A clinically  significant 
worsening of a concomitant illness must be reported as an AE.
8.2.1.1 Details on haemophilia
All available information on haemophilia, prior to screening should be recorded including 
diagnostic FVIII activity  level , if known. I
fpossible , information about relatives with haemophilia 
A and inhibitors should be obtained. 
8.2.1.2 Allergies
Any allergies , including any drug sensitivities should be recorded. 
8.2.2
Concomitant medication
A concomitant medication is any  medication including vaccination , other than the investi gational 
medicinal product ( N8-GP), which is taken during the trial until EOT .
Details of an y concomitant medication must be recorded at the first visit (V0) . Changes in 
concomitant medication must be recorded at each visit as they  occur.
The information collected for each concomitant medication includes (at a minimum) trade name or 
generic name, indication, start date and stop date or continuation.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 51 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 52of 114
  If a change in medication is due to an AE, then this must be recorded and reported according to 
Section 11.2. If the change influences the patient ’s eligibility  to continue in the trial, the monitor 
must be informed.
8.2.3 Treatment of bleed ing episodes in inhibitor patients
Bleeding episodes in inhibitor patients that do not respond sufficiently  to N 8-GP treatment may  be 
treated with by -passing agents according to local practice .
8.2.4 Prohibited medication
Treatment with other FVIII concentrates are not allowed during the course of the trial.
If possible, use 
of Tranexamic acid should be avoided.
Heparin sealing of central venous access ports and cannulae is allowed .
8.2.5 Demograph y
Demographic data will be collected as allowed per local law:
Date of birth, year or age
Ethnicity  
Race
8.3 Clinical assessments 
Clinical assessments should preferabl y be performed prior to blood sampling and prior to 
administration of N8-GP unless it is stated otherwise.
8.3.1 Body measurements
Height at screening
Body weight, wearing light clothing only ( Kg)
Body weight should be measured in connection with regularl y visit where trialdrug is dispensed .
For practical purposes when dispensing trial drug the weight from an earlier measurement (or visit) 
can be used if the measurement was performed within the previous 10weeks (in 
children <3 years 
of age, within 6 weeks)
.If new bod y weight is not needed to be measured at a visit, the body  weight 
from last weighing should be used.
8.3.2 Physical examination
The phy sical examinations will be performed according to local procedure and should include:
General appearance
Head, ears, ey es, nose, throat and neck
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 52 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 53of 114
Lym phnode palpation
Abdomen
Skin
Respiratory  system
Musculoskeletal sy stem
Central and peripheral nervous sy stems
8.3.3 Vital signs
When dosing at the trial site (V1) , vital signs s hould be recorded pre -dose and post -dosing of N8-
GP. Hereafter vital signs will only  be measured pre -dose and according to Table 2–1 .
Before measurement of vital signs the patient should preferabl y rest comfortably for at least 
three minutes and all measurements should, if possible, be performed using the same method and 
position ( e.g.sitting) throughout the trial for each individual patient. 
Vitals signs include assessment of:
Body temperature (C/F)
Blood pressure (BP) (mm Hg)
Pulse (beats/min)
If not possible to perform some or all of the above measurements, it is allowed to evaluate the child 
for normal appearance checking for signs and s ymptoms of acute or chronic disease.
If a change in clinical assessments after V0 is due to an AE, then this must be recorded and reported 
accordi ng to Section 11.2 .
8.4 Laboratory assessments
Blood samples for laboratory analysis of safety, and efficacy parameters will be drawn as outlined 
in Table 2–1.
 Approximate total volumes of blood to be taken from each patient see Section 8.4.3.
The sample taken 30 minutes (
10 minutes) post-dose must not be taken from the same vein as used 
for administration of N8-G P.
Laboratory results being out of normal range must be categorised as “out of normal range, not 
clinically significant” or “out of normal range, clinically significant”. A laboratory result evalu
ated 
as “out of normal range, clinically significant” must be recorded as an AE, or if present at V0 it 
should be recorded as concomitant illness. 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 53 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 54of 114
  The laboratory  equipment may  provide anal yses not requested in the protocol but produced 
automatically  in connection with the requested analy ses according to specifications in the laboratory  
standard operating procedures. Such data will not be transferred to the eCRF or the trial database, 
but abnormal values must be reported to the investigator. 
The investigator must review all laboratory  results for concomitant illnesses and AEs and report 
these according to this protocol.
8.4.1 Local laboratory assessments 
Local laboratory  results are considered as source data and must be signed, dated and categorised b y 
the investigator. 
Storage handling, and disposition of samples analysed at local laboratories will be performed 
according to local laboratory  procedures. 
8.4.1.1 F VIII activity
FVIII activity  will be analy sed at the predefined time point as at a central laboratory  selected by  
Novo Nordisk but the investigator can at an y time during the trial assess FVIII activity at his/her 
discretion. 
If V0 and V1 are combined, as one combined screening visit, and if FVIII activity  <1% has not 
been documented in the patient medical records, it should be analy sed locally  and documented in 
the patient medical records. I n this case the local laboratory  should use their standard FVII I activity  
assay  with the assay  calibrator routinel y used for FVIII activity  anal ysis.
A N8 -GP reference standard must be used as assay  calibrator in the FVIII activity  assay  after the 
patient has been dosed with N8 -GP. The reference standard will be provi ded by  Novo Nordisk 
together with a description of how to the reference standard should be handle d, stored and use d.
8.4.2 Central laboratory assessments 
Central laboratory  will throughout the protocol cover both the central laboratory  as well as 
specialised la boratory  analy sing samples for all sites. The central laboratory will analy se and report 
all laboratory  data to Novo Nordisk electronically in a manner that anon ymity of patients will be 
maintained. The central laboratory  results will be reported to the in vestigator .  
The quality  control of the central laboratory  test results will be performed according to the 
regulations and specifications set by  the authorities at the location of the central laboratory  used for 
this trial.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 54 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 55of 114
  A detailed description of procedures for sampling, handling, shipment of laboratory  samples and all 
materials such as test tubes and labels will be provided in the laboratory  manual by  the central 
laboratory . The central laboratory  manual and the central l aboratory  results will include the 
reference ranges.
8.4.2.1 F VIII activity 
The anal ysis of plasma FVIII activity  will be performed at a laboratory  selected by  Novo Nordisk or 
at a Novo Nordisk laboratory . The procedures for anal yses will follow the recommendatio ns 
provided b y Novo Nordisk. A description of the method will be included in the final report of this 
trial.
FVIII activity  should be measured according to Table 2–1.
FVIII activity  will be measured b y the use of two different assays developed and validated for N8-
GP: 
FVIII chromogenic assay
FVIII one -stage clotting assay
In each assay  both an N8 -GP reference standard and a human plasma standard calibrated against the 
WHO international FVIII standard are used as assay calibrators. 
FVIII chromogenic assay
The FVIII chromogenic assay  measure s the activity  of the compound wit h a two-stage method. The 
FVIII activity  is determined by  measuring the FVIIIa/FIXa -mediated activation of coagulation 
factor X (FX) activation (first stage) and the subsequent cleavage of a chromogenic activated 
coagulation factor X (FXa) substrate (secon d stage).
The F VIII one-stage clotting assay
The FVIII one stage assay  isa modified activated partial thromboplastin time (aPTT) assay . The 
one-stage assay  measures the activity  of the compound in a specific process (cl ot formation). 
8.4.2.2 Antibody assessment s  
The anal ysis will be performed at a laboratory  selected by  Novo Nordisk or at a Novo Nordisk 
laboratory . The procedures for analy ses willfollow the recommendations provided b y Novo 
Nordisk. A description of the method will be included in the final report of this trial.
Plasma samples will be collected for assessment of:
N8-GP/FVIII binding antibodies 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 55 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 56of 114
  PEG antibodies
FVIII inhibitor 
Antibody  assessment should be measure d according to Table 2–1 .
N8-GP/FVIII binding antibod ies
Screening for antibodies is based on assay s that are validated according to international recognised 
guidelines.18-20Samples measured above the assay  cut-point will be subject to a confirmation test. 
Samples positive in the confirmatory  test will be characterised for specificity  to N8 -GP, rFVIII and 
PEG. I sotyping o f the anti -drug antibodies will possibly  also be performed. 
If a patient develops N8 -GP binding antibodies and the recovery  value at that visit is less than 60% 
of recovery  values after the first N8 -GP administrations and FVIII level at time of inhibitor 
sampling (pre -dose) is more than 0.020 U/mL, Novo Nordisk will ask the Investigator to call the 
patient for an unscheduled visit for collection of a new sample for assessment of inhibitors and 
binding antibodies which should will be taken after a 7 day s wash out period. 
A patient that tests negative for inhibitors following a 7 days wash out will confirm a negative 
inhibitor test and the patient will continue in the trial. 
This algorithm will not apply  for those who enter the trial with positive test for 
N8-GP binding 
antibodies and will not be triggered more than twice for an individual patient, unless increases in 
antibody  levels are observed. Furthermore, a 7 day s wash out period will only  be applied if the 72 
hours wash out is not sufficient to avoid d rug interference in the inhibitor assay .
Samples will be analy sed regularl y for N8 -GP binding antibodies, results will be reported to 
investigators at the end of trial and will be included in the CTR.
PEG antibodies
Screening for PEG antibodies is based on assay s that are validated according to international 
recognised guidelines.18-20Samples measured above the assay  cut-point will be subject to a 
confirmation test.
Samples will be analy sed for PEG binding antibodies at the end of trial.  
FVIII inhibitors
Assessment for FVIII inhibitors will be carried out using a heat modified Nijmegen FVIII Bethesda 
assay analysed at the central laboratory . The assay is validated according to international recognised 
guidelines.18, 21The assay is based on measurement of the FVIII activity  (inhib itory  activit y) in 
plasma samples mixed with a fixed amount of normal plasma pool in buffer. Inhibitors will be 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 56 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 57of 114
  considered: 0.6 BU ≤ low titre inhibitor ≤ 5 BU, high titre inhibitors are defined as > 5 BU.
Inhibitors will be recognised by  comparison to a clinical cut -point of ≥ 0.6 BU. 
If FVIIIinhibitor development is suspected during the course of the trial due to for instance 
increased number of bleeding episodes, bleeding episodes difficult to treat, recovery  and trough 
levels below expected values or a positive local inhibitor test, the patient must attend an 
unscheduled visit as soon as possible and a plasma sample must be shipped to the central laboratory  
for inhibitor anal ysis.
Any sampling for the inhibitor test must be performed at least 4 day safter last administration of 
N8-GP to allow for wash- out of the drug.
If the result of the inhibitor test is positive, a second confirmatory  inhibitor test should be performed 
by 
the central laboratory. The confirmatory  samples should be collected as soon as possible, but no 
sooner than 4 day safter the last dose of N8-GP.
Assessments of FVIII activity  (recovery )and 
binding antibod iesmust be performed. If considered relevant a lupus anticoagulant test can be 
performed. 
A positive confirmed inhibitor is considered to have disappeared if the inhibitor titre is < 0.6 BU on 
2 consecutive inhibitor tests (performed with 1 month intervals) and the FVIII recov ery is ≥66% of 
expected values. A patient with repeated positive test result will count only once in the 
determination of the inhibitor inci dence rate.
If an investigator decides to perform inhibitor testing locally ,he/she must send a duplicate sample 
for inhibitor testing at the central laboratory . The results from the 
central laboratory  will be used in 
the anal ysis of trial data. A positive inhibitor test must alway s be reported as a MESI irrespective of 
the test being performed locally  or at the centra llaboratory (refer to Section 11.2). 
PK assessment (optional)
In the event of a concern about reduced treatment efficacy  in a patient with or without confirmed 
positive test for binding antibodies towards N8 -GP/ or inhibitors an unscheduled visit can be 
scheduled where a PK session may  be performed with a dose of 60 U/Kg to investigate the 
elimination (recovery , clearance and half- life) of N8 -GP. The PK data may  potentiall y be used to 
adjust the dose or dosing regimen. 
The following time -points for blood sampling for the PK profile are suggested: pre -dose, 30 
minutes (± 10 min), 1h (± 10 min), 24h (± 8 hours), 48h (± 8 hours), and 96h (± 8 hours).
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 57 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 58of 114
8.4.2.3 HIV testing and CD4+ lymphocyte count 
All patients will be assessed for HIV a t visit 0, if status is unknown, or HIV negative results in 
medical record are older than 6 months. Sampling can be postponed to the earliest convenient visit 
to ensure that the allowed blood volume is not exceeded.
Tests for CD4+ l ymphocy te count and HIV viral load are onl y required for HIV positive patients. 
HIV positive patients should have CD4+ l ymphocy tes >200/µL  and the viral load <400 ,000 
copies/mL . If the patient is not immunocompetent according to the above mentioned criteria 
relevant anti -HIV treatment should be initiated.
Results can be transferred from the medical records if obtained within the last 6 months. 
HIV 1 and 2 antibodies
CD4+ ly mphocy te count
HIV viral load
HIV and CD4+ assessments should be measured according to Table 2–1 .
8.4.2.4 Haematology
Haemoglobin (mmol/L )
Haematocrit (%)
Leucocy tes (x109/L)
Thrombocy tes (x109/L)
If test results for the above mentioned haematology  parameters are available from within one month
prior to V0, they can be used for the V0 haematology  assessment, if older, a new sample must be 
drawn and assessed at the central laboratory .
Haematology  should be measured according to Table 2–1.
8.4.2.5 Biochemi stry
Creatinine ( µmol/L )
Alanine aminotransferase (ALT) (IU/L)
C-reactive protein (CRP) (mg/L)
If test results for the above mentioned biochemistry parameters are available from within one month 
prior to V0, they can be used for the V0 biochemistry assessment, if older, a new sample must be 
drawn and assessed at the central laboratory .
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 58 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 59of 114
Biochemistry should be measured according to Table 2–1.
8.4.2.6 F8and HLA genotype testing 
At Visit 0, all patient ’sparent (s)/LAR(s) will be asked about documentation of previous Factor VIII 
gene ( F8)and Human Leucocyte Antigen (HLA) genoty pe tests. If not available or if it needs to be 
re-tested, based on the i nvestigators discretion, F8and HLA genot ype testing will be offered if 
allowed according to local law. The F8and HLA genot ype anal ysis will be performed at a 
laboratory  selected by  Novo Nordisk, using DNA isolated from leucocy tes from the patient’s blood. 
No anal ysis will be performed concerning other genes than F8and HLA. Samples will be disposed 
appropriatel y after the test and all test results are kept confidential.
Investigator and/or patient’s parent(s) /LAR (s)have the right to refuse to provide patient’s F8and 
HLA genot ype documentation or to refuse genot yping. This will not prevent the patient from
participati ngin the trial.
F8and HLA genotype can be measured an y time from visit 0 to visit 8. 
F8and HLA genot ype can be measured according to Table 2–1 .
Applicable for Japan only : If documentation of the patient´s genot ype already exists, the patient is 
offered to provide his data for the trial. If no previous data exists and genotyping cons ent is 
obtained, FVIII and HLA genot ype anal ysis is performed at the laboratory  in Bonn, Germany , using 
DNA isolated from leucocy tes from the patient’s blood. No anal ysis will be performed concerning 
other genes than F8 andHLA. Samples will be disposed appropriately  after the test and all test 
results are kept confidential.
Applicable for Israel only: No genot ype testing or genot ype information will be collected.
8.4.2.7 Allergic reaction testing 
Allergic reaction testing will only be performed in patients developing severe allergic reactions 
related to N8-GPtreatment as judged b y the Investigator. The baseline sample will be anal ysed for 
asses sment of the allergic reaction .
If asevere a llergic reaction related to treatment occurs, blood samples should be taken at an 
unscheduled visit as soon as convenient, and not later than 2 months after the event .The allergic 
reaction assessments will be performed at a laboratory  selected by  Novo Nordisk or at a Novo 
Nordisk laboratory .
Test to be performed :
N8-GP IgE antibodies
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 59 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 60of 114
FVIII IgE antibodies
FVIII inhibitors
N8-GP/rF VIIIbinding antibodies
Optional tests at the discretion of the investigator:
HCP IgE antibodies
Murine IgG antibodies
If relevant, baseline levels for optional test can be set using samples from other patients enrolled in 
the trial.
Patients developing severe allergic reaction should be carefull y investigated and followed up for 
inhibitor development. 
8.4.3 Blood sampling in infants and children
The blood sampling vol ume for the patient must not exceed 1% of the total blood volume at one 
occasion or 3% within in 28 day s. This is in accordance with European regulatory  guidelines 
(Directive 2001/20/EC)22. 
The total volume of blood to be collected for each patient per visit will not exceed 10 m L. 
Detailed instructions will be provided to the trial sites regarding blood sampling volumes and 
prioritisation of the sa mples. If trial sites as part of routine assessments perform additional blood 
draws, they  must ensure that the blood sampling volume will not exceed the above requirements.
It is recommended not to attempt venepuncture more than 3 times for the purpose of obtaining 
sufficient blood sampling. Documentation must be available in medical record.
Port-a
-caths and other central v enous access device sshould preferabl y not be used for blood 
sampling due to a risk of dilution or contamination with drugs (e.g. heparin). Should itbenecessary  
to use such a device, it should preferabl y have beenlocked with saline prior to use. 
8.4.4 Storage of samples
Storage and disposition of samples anal ysed at local laboratories will be performed according to 
local laboratory procedures. 
All remaining blood samples stored at the central laboratory will be destroyed after finalisation 
of the CTR, except for samples 
for antibody
 assessment and biospecimens, see Section 23.2.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 60 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 61of 114
  Antibody  samples (samples for binding antibodies and inhibitors) will be stored until drug approval 
by Food and Drug Administration (FDA) and/or European Medicines Agency  (EMA ).
8.5 N8- GPadministration
N8-GPwill be administered while the patient is in a comfortable position according to 
Table 5–1 . 
During ED 1- 2 with treatment at the trial site (V1 -V2):
The first 2 N8- GPdoses should be administered at trial site by , or under direct supervision of an 
attending ph ysician.
Trial injection kits (butterflies etc) will be provided by  Novo Nordisk. Choice of butterfly  or 
cannula for N8-GPinjections is at the discretion of the investigator
The actual time of completion of the injection will be recorded and corresponds to trial time 
po
int= 0. 
During ED 3- 100 with treatment at trial site and at home (after 
V2):
Home treatment with administration of N8- GPcan start after 2 EDs if the patient or the patient’s 
parent(s)/LAR(s) are comfortable with the reconstitution and administration process. If not the drug 
administration can take place at site.
Home treatment may  be given by  the patient ’sparent(s)/ LAR(s) or a home nurse, as applicable.
The injection should be performed as an i.v. bolus injection ( approximately  2 min for an 
injecti on). The date and the actual time of completion of the injection must be recorded in the 
patient’s eDiary . 
All treatment requiring bleeding episode sshould be treated and registered independent ly of the 
on-going proph ylaxis treatment regimen.
If a bl eeding episode occurs earlier at the same day  as the planned prophy laxis, the dose should 
be registered for the bleeding episode and not as prophy laxis and the planned prophy laxis dose 
later the same day  should be omitted. The dose for the treatment of ble eding episode on a 
prophy laxis day  should be approximately  60 U/ Kg
, and then the proph ylaxis dose should not be 
taken.
When a proph ylaxis dose has been taken and a bleeding episode occurs later the same day , the 
bleeding episode should be treated and regis tered independent lyof the prophy laxis dose. 
8.6 Bleeding episodes
All bleeding episodes and treatments with N8- GP must be recorded in the eCRF by  the investigator 
or in the eDiary  by the patient’s parent(s)/LAR(s). 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 61 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 62of 114
8.6.1 Assessments of bleeding e pisodes and t reatment response
The severity of bleeding episodes is defined as
Mild/moderate: Bleeding episodes that are uncomplicated joint bleed ing episode s, muscular
bleed ing episode s without compartment sy ndrome, mucosal -or subcutaneous bleed ing
episode s. These bleeding episodes can be treated at home after V 2and details of the bleeding
episodes should be entered in the eDiary  by the patient’s parent(s)/LAR(s).
Severe: All intracranial, retroperit oneal, iliopsoas and neck bleeding episodes must be
categorised as severe. Muscle bleed ing episode s with compartment sy ndrome and /orbleed ing
episode s associated with a significant decrease in the haemoglobin level (>3g/dl ) should also be
reported as severe (it is the investigators decision if haemoglobin measurements sh ould be
performed) . The investigator must be contacted in case of a severe bleeding episode .
In case of treatment requiring bleeding episode outside the trial site opening hours prior to 2 EDs 
the patient must be treated according to local procedures.
Bleeding Episode – information to be collected
Information about bleeding episodes prior to the 2 ED (V2) should alway s be recorded in eCRF. In 
case the patient is treated outside the trial site the trial site should be informed in case of a bleeding 
episode and the details hereof. After 2 EDs bleeding episodes must be recorded either in the eDiary  
(if treated at home) or in the eCRF (if treated at the trial site), see Section 12.3.
Date and time the bleeding episode started
Date and time the bleeding episode stopped
Cause of the bleeding epi
sode
i.e. spontaneous, traumatic
 or due to surgery
Anatomical location of bleeding episodes
Treatment of bleeding episodes
Amount, and time of each dose of N8-G P
Haemostatic response assessed by the 4-point scale defined in Table 8–1
Table 8–1 4 -point scale
Classification Description
Excellent Abrupt pain relief and/or clear improvement in objective signs of bleeding 
within approximately 8 hours after a single injection
Good Definite pain relief and/or improvement in signs of bleeding within 
approximately 8 hours after a single injection, but possibly requiring more than 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 62 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 63of 114
  Classification Description
one injection for complete resolution
Moderate Probable or slight beneficial effect within approximately 8 hours after the first 
injection , but usually requiring more than one injection
None No improvement, or w orsening of symptoms 
Re-bleed
Classification of re -bleed will be performed at the time of the statistical analy sis, according to the 
following criteria: 
A re-bleed is defined as a new bleed within 72 hours after stopping of a previous bleed at the 
same or a subset of the same anatomic al locations
If a bleeding episode occurs in the same location later than 72 hours after stopping the treatment it 
is considered as a new bleeding episode.
8.7 Surgery
Preventive N 8-GP treatment before minor surgery  including placement or removal of central 
venous access port can be performed within this trial at the investigator’s discretion according to 
local guidelines. A dose of 40-75 U/Kg N8-GP prior to minor surgery  is recommended to prevent 
perioperative bleeding episodes , see Table 5–1 .Major surgeries are only  allowed after 50EDs and 
when the result from the pathfinder™3 ( NN7 088-3860) is available, see Section 5.3.4 . 
Preventive N 8-GP treatment prior to surgery  should be captured in eCRF or in the eDiary .
8.7.1 Minor surgery
Definition of minor surgery , see Secti on 5.3.4 .
For minor surgery  the following should be recorded:
Date ,time and volume of preventive dose before surgery
Type of surgery
Indication for surgery
Date of surgery
Start time of surgery
8.7.2 Major surgery
Definition of major surgery , see Section 5.3.4 .
FVIII inhibitor sample should be taken prior to surgery  and anal ysed at the central laboratory .
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 63 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 64of 114
  For major surgery  the following should be recorded in the eCRF :
Date ,time and volume of preventive dose before surgery
Type of surgery
Indication for surgery
Date of surgery
Start and stop time of surgery
Clinical evaluation of haemostatic response, see Table 8–1
Clinical narrative of the procedure
Injections with N8 -GP administered after surgery has been completed should be reported either in 
the eCRF (injections administered at site) or in the eDiary  (injections administered at home) , see
Section 12.3
8.8 Training and reminders
8.8.1 Trial card dispensing
At V0 the patient ’s parent(s)/L AR(s) will receive a trial card stating that the patient is participating 
in a clinical trial. Telephone numbers and contact persons at the trial site will be listed.
8.8.2 Home treatment training
Home treatment training with administration of N8-GPcan start after a dministrations of the first 
dose at the trial site (see Section 8.1.12 ), and should continue until the patient’s parent(s)/ LAR(s)
are comfortable with the reconstitution and administration process .
A home treatment guide for the reconstitution and administration process will be available as hands -
out for the patient’s parent(s)/L AR(s) . Training in reconstitution and administration must be 
performed until parent(s)/L AR(s) feel comfortable in handling the treatment. The training must be 
documented in the medical records.
All patient ’s parent(s)/ LAR(s) must be carefull y instructed in recognising and dealing with signs 
and sy mptoms of an anaphy lactic reaction. This includes knowledge of which medical facility  to 
contact in this situation. 
If the patient does not follow the planned dosing schedule, the investigator must retrain the patient’s 
parent (s)/LAR(s) . 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 64 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 65of 114
  8.8.3 Electronic diary (eDiary)
Pre-proph ylaxis treatment, prophy laxis treatment and bleeding episodes should be recorded in the 
eCRF for the first 2 EDs. When the first 2 EDs have been administe red, t
he data will be captured
either in eCRF or eDiary  according to S ection 12.3.
Parent(s)/LAR(s) should be trained in using the eDiary  before or when they  receive the eDiary . If 
needed the training must be repeated until t he parent(s)/L AR(s) use the eDiary  as intended.
It will be the responsibility  of the investigator to assess the eDiary  data throughout the conduct of 
the trial and to ensure entry  compliance.
During the home treatment period the patient’s parent(s)/LAR(s) must ensure that all pre -
prophy laxis and proph ylactic home treatment, bleeding episodes, treatment of bleeding episodes as 
well as haemostatic evaluation of the treatment of bleeding episode sare captured in the eDiary . 
8.8.3.1 eDiary dispensing and collection
The eDiary  will be dispensed to the patient’s parent(s)/LAR(s) at V 2.
For details regarding patient’s eDiary, please refer to Section 12.3. 
For pat ients completing the trial or in case of withdrawal, the eDiary  will be collected at the EOT 
visit.
8.8.4 Contact between the investigator/medically qualified person and the patient
The investigator and/or medically qualified person must establish contact with the patient’s 
parent(s)/ LAR(s) at least every  12 weeks ± 1 week, if sitevisits are more than 3 months apart , either 
by visits at the trial site or other contact e.g. telephone calls. All contact must be captured in eCRF .
The patient and patient’s parent(s)/LAR(s) should be notified that they  will be contacted according 
to the protocol. 
The communication will focus on the well-being of the patient, includ ingenquiry  toall AEs , and 
any medical treatment (including treatmen t of bleeding episodes) since the last contact. The 
investigator/medically  qualified person should not suggest specific AEs to patient’s 
parent(s)/ LAR(s) , but should inquire e.g. “how is y our child doing ?” and “ has y our child had any  
medical problems since the last contact?” , and “have y ou remembered to enter all treatment in the 
eDiary?”.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 65 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 66of 114
  The expiry  date of the drug that the patient has received should be checked by the site staff before 
the patient’s next visit to determine if an extra dispensing is relevant and to inform the patient of 
which unused vials to return to the site .
All attempts to contact the patient’s parent(s)/LAR(s) must be documented in a source document. If 
a successful contact cannot be made after 3 documented attempts, no further attempts are required.
If the patient’s parent(s)/LAR(s) have withdrawn consent, this must be documented.
At each contact the investigator will at a minimum capture/evaluate 
Assessment of bleeding episodes
Adverse events 
Concomitant Medication
eDiary  compliance
N8-GPadministration compliance
8.8.5 Interactive voice/web response system
Please refer to Section 10regarding the IV/WRS. 
For details on how to use the IV/WRS, please refer to the trial specific IV/WRS user documents 
provided to the trial site. 
8.9 Patient compliance
Throughout the trial the investigator will remind the patient’s parent(s)/LAR(s) to follow the trial 
procedures and requirements to ensure patient compliance. If a patient is found to be non -compliant, 
the investigator will remind the patient’s parent(s)/L AR(s) of the importance of following the 
instructions given including taking the trial products as described. 
Assessment of patient compliance with protocol procedures for determination of continuation of the 
trial will be done bythe investigator’s discretion. 
Failure to compl ywith scheduled visits and N8- GPadministration may  result in withdrawal in 
accordance with the protocol withdrawal criteria , see Section 6.4.
Treatment with F VIII concentrates, other than N8- GP, during the trial is not allowed and violation 
of this may  lead to withdrawal due to non -compliance (please refer to Section 8.2.4) . Regarding b y-
passing agents, see Section 8.2.3 .
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 66 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 67of 114
  Compliance with N8- GPtreatment must be addressed at each visit. Compliance check includes a 
cross check between number of injections recorded in e Diary, expected number of doses and the 
used/returned vials.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 67 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 68of 114
9Trial supplies
Trial supplies comprise trial product and auxiliary supplies. Additional details regarding trial 
supplies can be found in the Trial Material Manual (TMM) and Handling instruction.
Trial product must not be dispensed to any  person not included in the trial (excluding patient’s 
parent(s)/LAR(s)).
Auxiliary  supplies comprise supplies other than trial product, e.g. needles and sy ringes.
9.1 Trial product
The following trial product will be provided by Novo Nordisk , Denmark :
Table 9–1 Trial Product
Trial product Strength Dosage form Route of 
administration
N8-GP (turoctocog 
alfapegol)500 U/vial ,
53µg/vial
2000 U/vial ,
211µg/vialFreeze -dried Powder 
for solution for 
injectioni.v.injection
N8-GPis supplied as a sterile freeze -dried powder for solution for injection in single use vials with 
a nominal content of 2000 U/vial or 500 U/vial to be reconstituted with 4.3 m L0.9% Sodium 
Chloride Solution .After reconstitution each vial contains 500 U/mLor 125 U/m L N8- GP, 
respectivel y. The reconstituted solution is colourless and clear to almost -clear with a pH of 6.9 . The 
reconstituted solution must not be diluted further. Trial product must not be used if it does not 
appear colourless and clear to almost- clear.
After reconstitution the appropriate volume of the vials will be drawn into a syringe. The content of 
several vialsmay be combined in one sy ringe. N8-GPmay not be added to or mixed with any other 
material.
Administration of the appropriate volume of N
8-GPwill be given as i.v. bolus injection over 
approximately  2 minutes (from start to completion of injection) .
The investigator must explain to the patient
’s parent(s) /LAR(s) the injection process of N8- GPat 
home. 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 68 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 69of 114
  The maximum dose to be administered to a patient within 24 hours is 200 U/K g, with a maximum 
individual dose of 75 U/Kg.
These doses are onl y relevant in case of trauma, severe bleedings or 
surgery .
Novo Nordisk will not supply  any Non Investigational Medical P roduct s(NIMPs) .
9.2 Packing, l abelling and dispensing
Labelling of the trial product will be in accordance with Annex 1323, local regulations and trial 
requirements. Novo Nordisk A/S will be responsible for labelling and packaging of the trial 
product. Third part y vendors may  be employ ed.
N8-GPand Sodium Chloride will be provided in boxes. The boxes will be provided with labels 
containing the following information: product name, expi ry date, storage conditions. Each trial 
product boxwill have a unique Dispensing Unit Number (DUN) for identification and traceabilit y. 
The details of the packaging and labelling of the trial product will be provided in the TMM supplied 
by Clinical Supplies Coordination, Novo Nordisk.
The IV/WRS will allocate the trial product in uniquely  numbered DUs to the patient at each 
dispensing visit. The DUs will be dispensed in accordance with the patient’s body  weight. Trial 
product will be dispensed at dis pensing or assessments visits, as appropriate.
The investigator must document that direction for use is given to the patient’s parent(s)/LAR(s) 
orally  and/or in writing at each dispensing visit according to the H andling instruction.
9.3 Storage
Table 9–2 Storage
Storage must be done 
according to the table belowStorage conditions(not -in-
use)In-use conditions
N8-GP (turoctocog alfa pegol) 2-8˚C 
Protect from light4 hours below 30˚C 
Do not freeze
Avoid direct sunlight
0.9 % Sodium Chloride 
Solution2-30°C
Protect from light N/A
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 69 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 70of 114
  The trial product N8-GPpowder and Sodium Chloride Solution must be stored in a secure place at
trialsite. For N8-GPunder refrigeration at 2 -8°C, and for Sodium Chloride Solvent at 2- 30°C , both 
protected against light and are hereb y stable until the expiry  date given. It is recommended to use 
thereconstituted N8-GPimmediately  following reconstitution. If not used immediately , the 
reconstituted product can be stored in the vial f or up to 4 hours below 30°C. Exposure to direct 
sunlight as well as freezing must be avoided after reconstitution. As for other parenteral 
preparations, the product should be inspected visually  for particulate matter and discoloration prior 
to administrati on and discarded if either is present.
Thetrialsite must carefully  instruct the patients’ parent(s)/LAR(s) in how to store the trial product. 
No temperature monitoring is required after the trial product istaken home by  the patient.
The investigator mus t ensure the availability  of proper storage conditions, and record and evaluate 
the temperature. The investigator must inform Novo Nordisk immediately  if any  trial product has 
been stored outside specified conditions ( e.g.outside temperature range).
Unused trial product must be stored separatel y from used trial product .
Trial product that has been stored improperl y must not be dispensed to an y patient before it has 
been re -evaluated and approved for further use by Novo Nordisk. The investigator must t ake 
appropriate action to ensure correct storage.
9.4 Drug accountability and destruction
Drug accountability  is the responsibility  of the investigator. The investigator or delegated person, 
eg, a trial nurse will perform drug accountability  in the IV/WRS Drug Accountability  Module. 
Once a patient is dosed, all trial drug product vials (dispensed, used, partly  used or unused, returned 
and lost/damaged) must be recorded in the I V/WRS Drug Accountability
 Module. 
Drug accountability  is notrequired for Sodium Ch loride Solution used for reconstitutions.
Returned trial product (used/partly used or unused including empt y packaging material) can be 
stored at room temperature and must be stored separatel y from non -allocated trial product(s).
All trial drug product must be retained for drug accountability  
checked bythemonitor . The monitor 
will, upon completion of drug accountability , arrange for the destruction of used, expired ,unused 
and broken vials of the supplied trial drug product.
Destruction will be done according to local procedures after accountability  is finalised and verified 
by the monitor. Destruction of product must be documented.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 70 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 71of 114
  For Japan only: Responsibility  for storage and drug accountabilit y of the trial drug product at the 
trial site rests with the head of the trial site. The head of the trial site could assign some or all of the 
responsibilities for accountability  of the trial drug product at the trial sites to a trial product storage 
manager (a pharmacist in principle ). The trial product storage manager should control and take 
accountability  of the trial drug product in accordance with procedures specified by  Novo Nordisk. 
The head of the trial site or the trial product storage manager must ensure the availability  of proper 
storage conditions, and record and evaluate the temperature.
9.5 Auxiliary supply
Auxiliary  supplies are equipment such as needles, sy ringes, butterflies, sterile swabs, vial adaptor 
etc.These will be provided by  Novo Nordisk.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 71 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 72of 114
  10Interactive voice/web r esponse system (IV/WRS)
A trial specific IV/WRS will be set -up, and can be accessed at an y time via internet or via 
telephone .Access to the IV/WRS must be restricted to and controlled by  authorised persons.
IV/WRS is used for :
Screening
Screening failure
Medication arrival
Dispensing
Withdrawal
Completion
Drug accountability
Data change
IV/WRS call can be done the day  before the actual visit.
IV/WRS user guides will be provided to each trial site.  
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 72 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 73of 114
  11Adverse events and technical complaints 
11.1 Definitions
Adverse event:
An adverse event (AE) is any  untoward medical occurrence in a patient administered a product, 
and which does not necessarily  have a causal relationship with this treatment.
An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory  
finding), s ymptom or disease temporally  associated with the use of a product, whether or not 
considered related to the product. 
An AE includes:
A clinically  significant worsening of a concomitant illness.
A clinical laboratory  adverse event (CLAE): A clinical laboratory  abnormality  which is 
clinically  significant, ie an abnormality  that suggests a disease and/or organ toxicity  and is of a 
severit y that requires ac tive management. Active management includes active treatment or 
further investigations, for example change of medicine dose or more frequent follow -up due to 
the abnormality .
The following should not be reported as AEs:
Bleeding episodes and other s ymptoms (eg s ynovitis, arthralgia, injection site haematoma) in 
connection with bleeding episodes should not be reported as AEs/SAEs unless the event is fatal, 
life-threatening or evaluated by  the investigator as related to trial product or trial procedure. In 
case of life -threatening bleeding episode, it should alway s be reported as a SAE. All bleeding 
episodes and other findings related to underl ying disease will be in Section 8.
Pre-existing conditions, including those found as a result of screening procedures (pre -existing 
conditions should be reported as medical history  or concomitant illness).
Pre-planned procedu res unless the condition for which the procedure was planned has worsened 
from the first trial related activity  after the subject has signed the informed consent.
The following three definitions are used when assessing an AE:
Severity assessment
Mild - no or transient symptoms, no interference with the patient 's dail y activities.
Moderate -marked s ymptoms, moderate interference with the patient's daily  activities.
Severe -considerable interference with the patient 's dail y activities; unacceptable.
Causality assessment
The following terms are used when assessing the relationship between an AE and the relevant 
trial product (s):
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 73 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 74of 114
Probable -Good reason and sufficient documentation to assume a causal relationship.
Possible - A causal relationship is conceivable and cannot be dismissed.
Unlikely -The event is most likely  related to aetiology  other than the trial product.
Final outcome of an AE
Recovered/resolved -The patient has full y recovered, or b y medical or surgical treatment
the condition has returned to the level observed at the first trial -related activity  after the
patient’s parent(s)/LAR(s) signed the informed consent.
Recovering/resolving - The condition is improving and the patient is expected to recover
from the event. This term is only  applicable if the patient has completed the trial or has
died from another AE.
Recovered/resolved with sequelae -The patient has recovered from the condition, but
with lasting effect due to a disea se, injury , treatment or procedure. If a sequela meets an
SAE criterion, the AE must be reported as an SAE.
Not recovered/not resolved -The condition of the patient has not improved and the
symptoms are unchanged, or the outcome is not known.
Fatal -This term is only  applicable if the patient died from a condition related to the
reported AE. Outcomes of other reported AEs in a patient before he/she died should be
assessed as "recovered/resolved", "recovering/resolving", "recovered/resolved with
sequelae" or "not recovered/not resolved". An AE with fatal outcome must be reported as
an SAE.
Unknown -This term is only  applicable if the patient is lost to follow -up.
Serious adverse event:
A serious adverse event (SAE) is an experience that at an y dose results in any  of the following:
Death.
A life-t hreateninga experience.
In-patient hospitalisationb or prolongation of existing hospitalisation.
A persistent or significant disability or incapacityc.
A congenital anomaly or birth defect.
Important medical events
 that may not result in death, be life threateninga
 or require  
hospitalisationb may be considered an SAE when -  based on appropriate medical 
judgement - they
 may jeopardise the patient and may require medical or surgical  
intervention to prevent one of the outcomes listed in the definition of SAEd.
Suspicion of transmission of in
fectious agents via the trial product a nd formation of  
inhibitory antibodies must always be considered an SAE.
FVIII inhibitory antibodies (confirmed by two consecutive tests see Section 8.4.2.2) must  
alway
s be considered a SAE
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 74 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 75of 114
  a. The term "life threatening" in the definition of SAE refers to an event in which the patient was at 
risk of dea th at the time of the event. It does not refer to an event which hy pothetically  might have 
caused death if it was more severe.
b. The term "hospitalisation" is used when a patient: 
Is admitted to a hospital or in- patient, irrespective of the duration of p hysical stay , or 
Stays at the hospital for treatment or observation for more than 24 hours
Medical judgement must alway s be exercised, and when in doubt, the hospital contact should be 
regarded as a hospitalisation. Hospitalisations for administrative, tr ial related and social purposes do 
not constitute AEs and should therefore not be reported as AEs or SAEs. Hospital admissions for 
surgical procedures, planned before trial inclusion, are not considered AEs or SAEs.
c. A substantial disruption of a patient 's ability  to conduct normal life functions (eg following the 
event or clinical investigation the patient has significant, persistent or permanent change, 
impairment, damage or disruption in his/her body  function or structure, ph ysical activity and/or 
quality of life).
d. For example intensive treatment in an emergency room or at home of allergic bronchospasm, 
blood dy scrasiasis or convulsions that do not result in hospitalisation or development of drug 
dependency  or drug abuse.
Non-serious adverse event
A non-serious AE is an y AE which does not fulfil the definition of an SAE.
Medical event of special interest
A medical event of special interest (MESI) is an event which, in the evaluation of safet y, has a 
special focus. A MESI  is an AE (SAE or non- serious A E) which fulfils one or more of the below 
defined MESI criteria.
1.Medication errors concerning trial product:
Administration of wrong drug 
Wrong route of administration 
Administration of an overdose with the intention to cause harm (eg suicide attempt)
Accidental administration of a lower or higher dose than intended. The administered dose 
must deviate from the intended dose to an extent where clinical consequences for the trial 
patient were likel y to happen as judged b y the investigator, although not ne cessarily  did 
happen
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 75 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 76of 114
  2.Inhibitor formation against F VIII. Blood samples for measurement of F VIII inhibitors will be 
analysed at a central laboratory  selected by  Novo Nordisk. If an investigator obtains 
information of a positive central laboratory  result or a ny indication of inhibitor formation by  
clinical signs or local laboratory  results, this should be reported as a MESI prior to 
confirmation b y two central laboratory results.
3. Thromboembolic events (clinic al signs or laboratory indications of arterial and v enous 
thrombosis including myocardial infarction, pulmonary  embolism, cerebral 
infarction/thrombosis, deep vein thrombosis, other clinically  significant thr omboembolic events 
and peripheral artery  occlusion, see definitions below)
4.Anaph ylactic reaction as defined b y Sampson et al 200624(see below).
5. Allergic reaction including, but not limited to, any acute immunoglobulin E (IgE) mediated 
reaction of delay ed type hypersensitivity  (clinical signs may  include various ty pes of skin 
rashes) that does not meet the definition of anaph ylaxis as described by Sampson et al 200624
Definition of an acute, evolving, or recent myocardial infarction:
Either one of the following two criteria satisfies the diagnosis for an acute, evolving or recent 
myocardial infarction:
1.Typical rise and gradual fall in troponin T or more rapid rise and fall in creatine kinase, muscle 
and brain or biochemical markers of m yocardial necrosis with at least one of the following:
oIschaemic s ymptoms
oSubsequent de velopment of pathologic Q waves on the ECG
oECG changes indicative of ischaemia (ST segment elevation or depression)
oCoronary  artery  intervention (eg angioplast y)
2.Pathologic findings of an acute m yocardial infarction (i.e., pathologic findings of an acute 
myocardial infarction will be defined when criteria a and b below are fulfilled):
oIncrease in troponin T above the "diagnostic" limit: i.e. > 0.03 µg/L
oPatients with:
ST-segment elevation: New ST-segment elevation at the J point in two or more 
contiguous l eads with the cut- off points >= 0.2mV in leads V1, V2 or V3 and 0,1 
mV in other leads (contiguity  in the frontal plane is defined b y the lead sequence 
aVL, I inverted aVR, II, aVF, III)
No ST -segment elevation: ST -segment depression and or T -wave inversion in two or 
more contiguous leads >= 0.1 mV
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 76 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 77of 114
  Definition of pulmonary embolism:
Obstruction of a pulmonary  artery  or one of its branches, most frequentl y by detached fragments of 
thrombus from a leg or pelvic vein, diagnosed b y at least one of the following:
Positive findings in ventilation/perfusion scan
Positive findings in a spiral(helical) computed tomograph y or angiograph y
Positive findings in a magnetic resonance imaging
Positive findings in a pulmonary  angiography
Definition of cerebral thrombosis/inf arction:
Acute neurological injury that persists for at least 24 hours and occurs as a result of either a 
thrombosis or embolic process, diagnosed b y at least one of the following:
Computerised tomography
Magnetic resonance scan
Magnetic resonance angiogram
Cerebral angiograph y
Deep vein thrombosis: 
Venous thrombosis demonstrated by compression ultrasound, duplex ultrasound, or colour Doppler 
imaging.
Definition of other clinically significant thromboembolic events:
Sign or suspicion of clinically  signifi cant thromboembolic event, eg:
visceral arterial embolus/thrombus, 
extremity  arterial embolus/thrombus or 
portal venous thrombosis.
Superficial thrombophlebitis is not considered a clinically significant thromboembolic event unless 
evaluated so b y the investigator.
Peripheral artery occlusion: 
Clinical signs of acute arterial occlusion verified by either ankle -brachial index test, Doppler or 
ultrasound (Duplex) imaging, computed tomographic angiograph y, magnetic resonance 
angiograph y, or conventional angiograph y.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 77 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 78of 114
  Clinical criteria for diagnosing anaphylaxis (Sampson et al. 200624): Anaphy laxis is highly  
likely when any  one of the following 3 criteria are fulfilled:
1. Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, 
or both (eg, generalized hives, pruritus or flushing, swolle n lips- tongue -uvula) AND AT LEAST 
ONE OF THE FOLLOWING 
a.Respiratory  compromise (eg, dy spnea, wheeze- bronchospasm, stridor, reduced PEF, 
hypoxemia)
b. Reduced BP or associated sy mptoms of end- organ dy sfunction (eg, hy potonia 
[collapse], sy ncope, incontinence) 
2. Two or more of the following that occur rapidly after exposure to a likely allergen for that patient 
(minutes to several hours): 
a. Involvement of the skin- mucosal tissue (eg, generalized hives, itch -flush, swollen lips -
tongue -uvula) 
b. Respiratory  compromise (eg, dy spnea, wheeze -bronchospasm, stridor, reduced PEF, 
hypoxemia)
c. Reduced BP or associated sy mptoms (eg, hy potonia [collapse], sy ncope, incontinence) 
d. Persistent gastrointestinal sy mptoms (eg, crampy  abdominal pain, vomiting) 
3. Reduced BP after exposure to known allergen for that patient (minutes to several hours):
a. Infants and children: low sy stolic BP (age specific) or greater than 30% decrease in 
systolic BP* 
b. Adults: sy stolic BP of less than 90 mm Hg or greater than 
*30% decrea se from that person’s baseline
Technical complaint
A technical complaint is any  written, electronic, or oral communication that alleges product 
(medicine or device) defects. The technical complaint may  be associated with an AE, but does not 
concern the AE itself.
Examples of technical complaints:
The phy sical or chemical appearance of trial product (eg discoloration, particles or 
contamination)
The packaging material (eg leakage, cracks, rubber membrane issues or errors in labelling text)
11.2 Reporting of adve rse events
All events meeting the definition of an AE must be collected and reported. This includes events 
from the first trial- related activity  after the patient’s parent(s)/LAR(s) has signed the informed 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 78 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 79of 114
  consent until the end of trial visit. The events m ust be recorded in the applicable CRF forms in a 
timely  manner. See timelines below and Figure 11–1 .
AEs between consent and first dosing should only be reported if associated with trial related 
activities.
During each contact with the trial site staff (trial site visits and telephone conta cts), the patient 
and/or patient’s parent(s)/L AR(s) must be asked about AEs and technical complaints, e.g. “Have
you experienced an y problems since the last contact?”
All AEs, either observed by  the investigator or reported by  the patient, must be reported by the 
investigator and evaluated. Novo Nordisk assessment of expectedness is performed according to the 
following reference documents: i nvestigator’s brochure,5N8-GP, current version and an y updates 
thereto.
All AEs must be recorded by  the investigator on an AE form. The investigator should report the 
diagnosis, if available. If no diagnosis is available, the investigator should record each sign and 
symptom as an individual AE using separate AE forms.
For each SAE and MESI an electronic Safet y Information Form (eSIF) s hould be completed in 
addition to the AE form in the eCRF, see Figure 11–1. If several s ymptoms or diagnoses occur as 
part of the same clinical picture, one eSIF may  be used to describe all the SAEs. All concerned AE 
numbers must be included in the AE number field on the e SIF.
MESI s, regardless of seriousness, must be reported using both the AE form and the safety  
information form. For MESI s of allergic a etiology, the hy persensitivity  questionnaire must be 
completed.
The AE form for a non -serious AE should be signed when the event is resolved or at the end of the 
trial.
Timelines for initial reporting of AEs:
The investigator must complete the following forms in the eCRF within the specified timelines:
SAEs: The AE form within 24 hours and the safety  information form within 5 calendar days 
of the investigator's first knowledge of the SAE.
Both forms must be signed within 7 calendar days from the date the information was entered in the 
eCRF. 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 79 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 80of 114
  Non-serious AE fulfilling the MESI criteria : The AE form and the safety information form 
within 14 calendar day s of the investigator’s first knowledge of the event.
If the eCRF is unavailable, the concerned AE inform ation must be reported on paper forms and sent 
to Novo Nordisk by  fax, e -mail or courier within the same timelines as stated above. When the 
eCRF becomes available again, the investigator must re- enter the information on the appropriate 
forms in the eCRF. 
Contact details (fax, telephone, e -mail and address) are provided in the investigators trial file.
Figure 11–1Initial reporting of AEs
Reporting of trial product -related SUSARs by the sponsor:
Novo Nordisk will notify the investigator of trial product- related suspected unexpected serious 
adverse reactions (SUSARs) in accordance with local requirements and GCP1. In addition, the 
investigator will be informed of an y trial -related SAEs that may  warrant a change to any  trial 
procedure.
In accordance with regulatory  requirements, Novo Nordisk will inform the regulatory  authorities, 
including EMA, of trial product -related SUSARs. In addition, Novo Nordisk will inform the 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 80 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 81of 114
IRBs/IECs of trial product -related SUSARs in accordance with local requirement and GCP1, unless 
locally  this is an obligation of the investigator.
11.3 Follow -up of adverse events
The investigator must record follow -up information by  updating the forms in the eCRF.
Follow up information must be reported to Novo Nordisk according to the following:
SAEs: All SAEs must be followed until the outcome of the event is "recovered/resolved",
"recovered/resolved with sequelae" or "fatal", and until all queries have been resolved. Ca ses of
chronic conditions, cancer or AEs ongoing at time of death (where death is due to another AE)
may be closed with the outcome "recovering/resolving" or "not recovered/not resolved". Cases
can be closed with the outcome of "recovering/resolving" when the patient has completed the
follow -up period and is expected by  the investigator to recover.
The SAE follow -up information should only  include new (eg corrections or additional) information 
and must be reported within 24 hours of the investigator's first knowledge of the information. This 
is also the case for previously  non- serious AEs which subsequently  become SAEs. 
Non-serious AEs: Non-serious AEs must be followed until the outcome of the event is
"recovering/resolving", "re covered/resolved" or "recovered/resolved with sequelae" or until the
end of the follow -up period stated in the protocol, whichever comes first, and until all queries
related to these AEs have been resolved. Cases of chronic conditions, cancer or AEs ongoin g at
time of death (where death is due to another AE) may  be closed with the outcome
"recovering/resolving" or "not recovered/not resolved". Cases can be closed with the outcome of
"recovering/resolving" when the patient has completed the follow- up period and is expected by
the investigator to recover.
Non-serious AE fulfilling the MESI criteria: Follow -up information on MESI s should only
include new (eg corrections or additional) information and must be reported within 14 calendar
days of the investigator' s first knowledge of the information. This is also the case for previously
reported non
-serious AEs which subsequentl y fulfil the MESI  criteria.
The investigator must ensure that the worst case severit y and seriousness of an event is kept 
throughout the t rial. A worsening of an unresolved AE must be reported as follow up with re -
assessment of severity  and/or seriousness of the event.
Queries or follow -up requests from Novo Nordisk must be responded to within 14 calendar days
from the date of receipt of the request, unless otherwise specified in the follow- up request.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 81 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 82of 114
  11.4 Technical complaints and technical complaint samples
11.4.1 Reporting of technical complaints 
All technical complaints on any  of the following products:
N8-GP 500 U/vial
N8-GP 2000 U/vial
Sodium Chloride 0.9 % vial
Novo Nordisk trial injection kit 
which occur from the time of first usage of trial product until the time of the last usage of the
product, must be collected and reported to Customer Complaint Center, Novo Nordisk. 
Contact details (fa x, e-mail and address) are provided in Attachment I to the protocol.
The investigator must assess whether the technical complaint is related to any  AE(s), SAE(s) and/or 
MESI (s). 
Technical complaints must be reported on a separate technical complaint form for each product 
listed. I f the technical complaint involves more than one batch, lot number or more than one DU, a 
technical complaint form for each batch, lot number or for each DU must be completed.
The investigator must complete the technical complaint form in the eCRF within the following 
timelines of the trial site obtaining knowledge of the technical complaint:
Technical complaint assessed as related to an SAE within 24 hours
All other technical complaints within 5 calendar days
If the eCRF is unava ilable or when reporting a technical complaint that is not patient related, the 
information must be provided on a paper form b y fax, e -mail or courier to Customer Complaint 
Center, Novo Nordisk, within the same timelines as stated above.
11.4.2 Collection, storage and shipment of technical complaint samples
The investigator must collect the technical complaint sample and notify  the monitor within 5 
calendar days of obtaining the sample at trial site. The monitor must coordinate the shipment to 
Customer Compl aint Center, Novo Nordisk (the address is provided in Attachment I) and ensure 
that the sample is sent as soon as possible. A print or cop y of the technical complaint form must be 
sent with the sample.
The investigator must ensure that the technical compla int sample contains the batch, lot number 
and, if available, the dispensing unit
number (DUN)
.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 82 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 83of 114
  If the technical complaint sample is unobtainable, the investigator must specify  on the technical 
complaint form wh y it is unobtainable. 
Storage of the technica l complaint sample must be done in accordance with the conditions 
prescribed for the product). The shipment of the technical complaint sample should be done in 
accordance with the same conditions as for storage , see Section 9
11.5 Precautions and/or overdose
As with any protein injected i.v. hypersensitivity  reactions may  occur. The possible events include 
rash, pruritus, fever, nausea, headache, vomiting and changes in blood pressure. If an y of these 
events are suspected, further N 8-GP administration should be stopped and the patient should receive 
treatment as appropriate according to the hospital practice and guidelines. 
If an overdose of N8 -GPis suspected further N 8-GP administration should be stopped prior to an y 
further N8 -GP administration and the patient should receive treatment as a ppropriate according to 
hospital practice and guidelines.
11.6 Committees related to safety
11.6.1 Novo Nordisk safety committee
Novo Nordisk will constitute an internal safet y committee to perform ongoing safet y surveillance of 
N8-GP. The safet y committee works accor ding to a written guideline and will meet regularl y to 
discuss and evaluate the overall safety for N8 -GP for this trial and all other N8
-GP trials. The Novo 
Nordisk safet y committee can take action with regard to the patient safet y for the trial based upon
observations of the overall information for N8 -GP. Pre -defined rules for setting the enrolment on 
hold is described in Section 11.6.2 .
The safet y committee might meet to evaluate data at any  time point during the conduct of the trial if 
deemed necessary .
11.6.2 Rules for putting the enrolment on hold
A safet y anal ysis will be performed to evaluate the development of inhibitor at the following 
predefined tim e point:
• after the first 25 patients have been to visit 6 (20-25 exposure day s )
The expected rate of inhibitors is about 30% in PUPs with severe haemophilia A.4In case of 
confirmed FVIII inhibitor formation in 12 or more of all exposed patients, all cases of inhibitor 
formation will be evaluated by  the N8 -GP safet y committee. During these evaluations, ongoing 
treatment in the trial will continue, however new patients will not be enrolled in the trial. The 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 83 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 84of 114
  evaluation will provide the basis for a decision on any  actions required for the tr ial to allow for 
continuation of enrolment or decision to terminate the trial, and will be documented in the safet y 
committee meeting minutes.
During the evaluation the s afety committee will also evaluate risk factors for inhibitor formation 
such as ethnic ity, famil y history  of inhibitors, FVIII gene mutation t ype, age at first FVIII 
treatment, reason for first treatment, treatment duration after first treatment, the details of an y 
surgery  (including t ype of surgery, amount of product used, and outcome), an y recent infection and 
any recent vaccination. Furthermore the time of occurrence of inhibitor formation (after how many  
exposures) and whether the inhibitor is a high or low titre will be evaluated. 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 84 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 85of 114
  12Case r eport forms 
Novo Nordisk will provide a s ystem f or the electronic case report forms (eCRF). This sy stem and 
support services to the s ystem will be supplied by  a vendor. The activities of this vendor will be 
under the direction and supervision of Novo Nordisk.
The investigator or delegated person should ensure that all relevant questions are answered, and that 
no empty  data field exists.
If a test or an assessment has not been done and will not be available, or if the question is irrelevant 
(eg is not applicable), indicate this according to the date entr yinstructions.
The following will be provided as paper CRF:
1.Hypersensitivity  questionnaire
In addition paper AE forms , safet y information forms and Technical Complaint forms will be 
provided. These must be used when access to t he eCRF is revoked .
On the paper CRF forms print legibl y, using a ballpoint pen. Ensure that all questions are answered, 
and that no empty  data blocks exist. Ensure that no information is recorded outside the data blocks.
If a test or an assessment has not been done and will not be available, indicate this by  writing “ND” 
(not done) in the appropriate answer field in the CRF. If the question is irrelevant (eg is not 
applicable) indicate this by  writing “NA” (not applicable) in the appropriate answer field. Further 
guidance can be obt ained from the instructions in the CRF.
The investigator must ensure that all information derived from source documentation is consistent 
with the source information. By electronicall y signing the 
case book in the eCRF , the investigator 
confirms that the i nformation in the eCRF including related forms isreviewed, complete and 
correct.
12.1 Corrections to case report forms
Corrections to the eCRF data may  be made by  the investigator or the investigator's authorised staff. 
An audit trail will be maintained in th e eCRF application containing as a minimum: the old and the 
new data, identification of the person entering the data, date and time of the entry  and reason for the 
correction.
If corrections are made by  the investigator's authorised staff after the date th e investigator has 
signed the case book, the case book must be signed and dated again by  the investigator.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 85 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 86of 114
  Corrections to the data in paper CRFs may  only be made b y drawing a straight line through the 
incorrect data and then writing the correct entry  next to the data that were crossed out. Each 
correction must be initialled, dated and explained (if necessary ) by the investigator or the 
investigator’s authorised staff. 
Corrections necessary  after the p aper CRFs have been removed from the investigator’s trialsite 
must be documented on a data clarification form (DCF) or a monitor -initiated discrepancy  form 
(MIDF). 
12.2 Case report form flow 
The invest igator must ensure that data is recorded in the eCRF as soon as possible, preferabl y 
within 5 daysafter the visi t. Once data have been entered, itwill be available to Novo Nordisk for 
data verification and validation purposes.
Site specific e CRF data (in an electronic readable form at) will be provided to the trial site 
before 
access to the eCRF is revoked. This data must be retained at the trial site.
When the final CTR is available, the data will be archived b y Novo Nordisk.
12.3 Electronic diary
Novo Nordisk will provide the patient’s parent(s)/LAR(s) with an eDiary  for electronic recording of 
details of their child’s prophy laxis administration, bleeding episodes , surgery and treatment hereof, 
see Sections 8.1.12.1 and 8.6. The eDiary  and related support services will be supplied by  a vendor 
working under the direction and supervision of Novo Nordisk. 
At visit 2, the patient’s parent(s)/ LAR(s) will receive the eDiary  and they will be trained in the use 
hereof b y the investigator or delegated person. After visit 2(after 2 EDs) and onwards ,data will be 
entered b y the patient’s parent(s)/LAR(s) in the eDiary  device during home treatment.  
During trial site visits, data will be recorded in the eCRF 
by the trial staff, and should not be entered 
by the patient’s parent(s)/L AR(s) in the eDiary . 
The eDiary  will be returned by the patient’s parent(s)/ LA
R(s)at the EO Tvisit.
All data entered wi ll be transferred from the device to an electronic database, where it is kept as a 
certified cop y of the source data. Data entered in the device will upon confirmation of a successful 
back-up be deleted from the device . 
The eDiary  will have built in edit checks and reminders, to ensure that all relevant questions are 
answered. 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 86 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 87of 114
  eDiary  data transferred to the electronic database will be viewable to relevant trial site staff and 
Novo Nordisk personnel on a secure, password protected web portal.
It is the responsibility  of the I nvestigator to review and thereby  ensure the eDiary  data quality . 
Following must be checked as minimum that the eDiary  data is complete, consistent and according 
to the requirements defined in this protocol. Upon review the Investigator must document that the 
review has taken place and any  actions required e.g. retraining of patients.
It must be confirmed b y the patient’s parent(s)/LAR(s) if missing eDiary  data need to be entered 
and/or if the transferred eDiary  data needs t o be corrected. This is done by  filling in and forwarding 
a Data Correction Request to the eDiary  vendor . An audit trail will be maintained.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 87 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 88of 114
  13Monitoring pr ocedures 
During the course of the trial, the monitor will visit the trial site to ensure that the pr otocol is 
adhered to, that all issues have been recorded, to perform source data verification and to monitor 
drug accountability . 
The first monitoring visit will be performed as soon as possible after FPFV and no longer than 4 
weeks after. The monitoring intervals will depend on the outcome of the remote monitoring of the 
eCRFs, the trial site's recruitment rate and the compliance of the tri al site to the protocol and GCP. 
The intervals between monitoring visits must not exceed 12 weeks whilst patients are in the trial. 
The monitor must be given direct access to source documents (original documents, data and 
records). Direct access includes permission to examine, anal yse, verify  and reproduce an y record(s) 
and report(s) that are important to the evaluatio n of the trial .If the electronic medical record does 
not have a visible audit trail, the investigator must provide the monitor with signed and dated 
printouts. I n addition the relevant trial site staff should be available for discussions at monitoring 
visits and between monitoring visits (eg b y telephone).
For all data recorded the source document must be defined in a source document agreement at each 
trial site. There must only be one source defined at any  time for any  data element.
All data must be verif iable in source documentation other than the eCRF, except for the following 
data that may  be recorded directly  in the eCRF and will then be considered source data:
Ethnicity
Race
The patient will only  be identified by  patient number and the monitor will v erify  and ensure that the 
eCRFs and eDiary  are completed. Also it must be checked that the eDiary  data review has been 
documented b y investigator and that the needed action has been taken, if any
Monitors must review the patient’s medical records and other source data (eg the diaries) to ensure 
consistency  and/or identify  omissions compared to the eCRF. If discrepancies are found, the 
investigator must be questioned about these.
A follow -up letter (paper or electronic) will be sent to the investigator follo wing each monitoring 
visit addressing an y action to be taken.
For screening failures: Data for the screen ing visit must be entered in the eCRF within preferabl y 
3 day s after data are available and the Screening Failure Form must be completed. Source data 
verification is not re quired except for informed consent, reason for screening failure and for data 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 88 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 89of 114
  relating to an y AEs if applicable . All data entered in the eCRF will be transferred into the trial 
database.
For withdrawn patien ts:All data collected in the period the patient participated in the t rial will be 
entered into eCRF .
All information captured during visits to the trial site will be collected in the eCRF. When home 
treatment is initiated all bleeding episodes and injections with N8- GP occurring outside the trial site 
should be entered in the eDiary  by the patient’s parents/LAR (see Section 8.8.3 ). The completed 
eDiar y is considered source data. 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 89 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 90of 114
  14Data m anagement
Data management is alway s the responsibility  of Novo Nordisk. 
Data management may  be delegated under an agreement of transfer of responsibilities to another 
data management unit within Novo Nordisk or an external Clinical Research Organisation (CRO).
Appropriate measures, including encry ption of data files containing person identifiable data, will be 
used to ensure confidentiality  of patient data, when they  are transmitted over open networks. 
Laboratory  data from central laboratories will be transferred electronically  from the laboratory  
performing the anal yses. In cases where laboratory  data are transferred via non -secure electronic 
networks, data will be encry pted during transfer.
The central and local laboratories will provide laboratory  reports to the investigator for storage at 
the trial site . The laboratory  report must be signed and dated by  the investigator or delegated person 
and stored at the trial site as source data.
The patient and any biologic al material obtained from the patient will be identified by  patient
number and trial identification number. Appropriate measures such as encryption or leaving out 
certain identifiers will be enforced to protect the identity  of patients in all presentations and 
publications as required by  local, regional and national requirements.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 90 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 91of 114
  15Com puterised systems
Novo Nordisk will capture and process clinical data using computerised s ystems that are described 
in Novo Nordisk Standard Operating Procedures (SOPs) and I T architecture documentation. The 
use and control of these sy stems are documented.
Investigators working on the trial may  use their own electronic s ystems to capture source data. 
Novo Nordisk will collect information on the practical use of these s ystems w ithin the conduct of 
this clinical trial. 
Novo Nordisk will use the Global Haemophilia Network Investigator Portal to distribute and share 
trial-related documents and information with the participating sites.
The eDiary  software and hardware implementatio n are compliant with the requirements of FDA 21 
CFR Part 11 and ICH E6 (EU directive for personal data protection) .1,25After trial completion, each 
trial site wil l be supplied with long -life CDs. These CD s will contain site -specific patient records 
including the patient’s eDiaries and audit trail including an y data additions and co rrections made on 
each form. The eDiary  vendor will furthermore retain and securel y store copies of all archived 
documents and data for 15 years or as required b y local data retention laws for trial data. 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 91 . -  | 1
 |
CONFIDENTIAL
Protocol
Trial ID: NN7088 -3908
UTN: U1111 -1148 -1897
EudraCT No.: 2013 -004025 -88 
  16Statistical considerations
Novo Nordisk will be re sponsible for the statistical analy sis.
The main statistical reporting of the trial 
phase (minimum 25weeks) with at least 50 EDs
will not count in the determination of when a patient has reached 50 EDs. 
having completed the main phase and data
point will be included up to late
and will form the basis for the paediatric indication
and for the extension phase separatel y as well as combined. 
Except for the conf idence interval for inhibitor rate and for annualised bleeding rate
of data will be based on descriptive statistics, i.e. summary  tables, listings and figures. 
An updated reporting of the trial with supportive data will be performed when 1
at least 100 EDs. Data from all patients will be included up to latest visit prior this cut
data will be presented for the main 
100 EDs) separatel y as well as 
All data ,, will be reported separately  in a final report when 
Figure 16–1Individual patient flow and time period
Multiple bleeding locations occurring from the same event (e.g., due to a fall) or at the same time 
point will be counted as one bleeding episode.
CONFIDENTIALDate:
Version:
Status:
Page:
Statistical considerations
sponsible for the statistical analy sis.
main statistical reporting of the trial will be performed when 50 patients have completed 
weeks) with at least 50 EDs and completed visit 9.EDs during IT I treatment 
will not count in the determination of when a patient has reached 50 EDs. Data
having completed the main phase and data from patients that have entered extension phase
latest visit prior to this cut -off date. This report will cover all endpoints, 
and will form the basis for the paediatric indication . The data will be presented for the main phase 
and for the extension phase separatel y as well as combined. 
idence interval for inhibitor rate and for annualised bleeding rate
of data will be based on descriptive statistics, i.e. summary  tables, listings and figures. 
reporting of the trial with supportive data will be performed when 1
at least 100 EDs. Data from all patients will be included up to latest visit prior this cut
data will be presented for the main + extension phase and theextended prophy laxis period (bey ond 
separatel y as well as combined. 
will be reported separately  in a final report when the trial is completed.
Individual patient flow and time period sfor trial report ing
occurring from the same event (e.g., due to a fall) or at the same time 
point will be counted as one bleeding episode.
04 November 2013 Novo Nordisk
1.0
Final
92of 114
patients have completed main 
EDs during IT I treatment 
Data from patients not y et 
extension phase at this 
This report will cover all endpoints, 
The data will be presented for the main phase 
idence interval for inhibitor rate and for annualised bleeding rate , the evaluation 
of data will be based on descriptive statistics, i.e. summary  tables, listings and figures. 
reporting of the trial with supportive data will be performed when 1 00 patients have had 
at least 100 EDs. Data from all patients will be included up to latest visit prior this cut -off date. The 
extended prophy laxis period (bey ond 
is completed.
ing
occurring from the same event (e.g., due to a fall) or at the same time 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 92 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 93of 114
  All bleeding endpoints will be evaluated based on bleeding episodes treated with N8-GPunless the 
bleeding was considered clinically  insignificant (non -treatment requiring bleeding episode) and the 
associated treatment given was part of proph ylaxis.
Patients initiating I TItreatment will for the statistical anal yses be considered like withd rawals and 
data collected during ITI treatment period will be summarised and reported separately . Evaluation 
of these data will be considered exploratory  only.
If necessary , a statistical anal ysis plan (SAP) may  be written in addition to the protocol, including a 
more technical and detailed elaboration of the statistical anal yses. If created, the SAP will be 
finalised before the first database lock. 
16.1 Sample size calculation
No formal sample size calculations have been performed. The sample size of 100completers is 
based on EMA guideline7.
16.2 Definition of analysis sets
Descriptions and analy sis of efficacy data will be based on the Full Analy sis Set (FAS), as defined 
in ICH E9 guidelines.26The FAS includes all patients expos edto N8-GP. The safet y analysis and 
descriptions will be based on the Safet y Anal ysis Set (SAS). The SAS will consist of all patients 
exposed to N
8-GP.
16.3 Primary endpoint
The primary  endpoint is a safet y endpoint defined as incidence of inhibitory antibodies against 
FVIII.
The rate of inhibitory  antibodies will be reported and a 1- sided 97.5% upper confidence limit will 
be provided based on an exact calculation for a binomial distribution. For the calculation of the rate 
the numerator will include the patients with inh ibitors, while the denominator will include all 
patients with a minimum of 10exposure day s plus any  patient with less than 10 exposure day s but 
with inhibitors. 
16.4 Secondary endpoints
16.4.1 Confirmatory secondary endpoints
There are no confirmatory secondary  endp oints in this trial
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 93 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 94of 114
  16.4.2 S upportive s econdary endpoints
16.4.2.1 Number of bleeding episodes during prophylaxis
Annualised bleeding rate will be summarised and a 95% two sided confidence interval will be 
provided based on a negative binomial regression model with number of bleeding episodes 
requiring treatment with N8- GP as the outcome variable, and adjusting for exposure time . For 
comparison with previous trial, a sensitivity  anal ysis based on a Poisson regression model allowing 
for over -dispersion will also be performe d. 
Since it must be expected that some patients will withdraw, it becomes essential to account for how 
such withdrawals may affect the anal yses of the prophy laxis effect. The analy ses above alread y 
account for possible different treatment durations by  using treatment duration as an offset. This is a 
proper adjustment if withdrawal is not related to the observed bleeding frequency . However, since it 
is possible that patients will withdraw exactly  because of the observed bleeding rate it is important 
to perf orm sensitivity  analy ses that may  account for withdrawn patients possibly  being qualitatively 
different from completing patients.
Specificall y this will be done by performing sensitivity  anal yses for all prophy laxis analy ses using a 
last observation carrie d forward (LOCF) approach for all patients with at least 1 month prophy laxis 
treatment duration b y calculating the yearly bleeding episode rate for withdrawn patients and use 
that as an endpoint. As an example a patient with 6 bleeding episodes in 4 months will have an 
endpoint value of 18 corresponding to a maintained bleeding rate of 18 bleeding episodes per y ear. 
For patients withdrawing within 1 month this method is considered to give too uncertain LOCF 
values, hence imputation will not be attempted for such patients.
Annualised bleeding rate will also be summarised by  type of bleeding episode.
16.4.2.2 Haemostatic effect
Description of the haemostatic effect of N 8-GP when used for treatment of bleeding episodes will 
be summarised and listed according to the four point scale for haemostatic response ( none, 
moderate, good and excellent). 
A success rate will be calculated based on counting good or excellent as successes and none and 
moderate as failures, and based onl y on reported outcomes. 
For the calculation of the success rate the numerator will include all treated bleeding episodes with 
a reported haemostatic response of good or excellent, while the denominator will include all treated 
bleeding episodes with a reported haemostatic response. A sensitivity  analy sis will also be 
conducted where the denominator also includes treated bleeding episodes with missing response 
(i.e., missing response is counted as a failure).
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 94 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 95of 114
  Haemostatic effect will be determined based on haemostatic response for bleeding episodes 
occurr ing both during pre -proph ylaxis and prophy laxis period.
Haemostatic response will also be summarised by  type of bleeding. 
16.4.2.3 Incidence of high tit reinhibitors
The rate of high tit reinhibitors (defined as inhibitor titre > 5BU) will be reported similar to the 
primary  endpoint
16.4.2.4 F VIII consumption
Total amount of N8 -GP used, a mount of N8- GPused for proph ylaxis(U/Kg/month/y ear)and 
amount consumed per bleeding episode ( number of injections and U/Kg bw/bleeding episode) will 
be summarised and listed. 
16.4.2.5 Safety endpoints
Adverse events including SAEs andMESI
Treatment emergent AEs (TEAEs, defined as AEs occurring after dosing with trial product) and 
treatment emergent SAEs (TESAEs) will be summarised b y frequency of events and frequency  of 
patients with any  event. Similar summaries cross -classified b y severity and by causal relation to 
trial produce will also be made.
MESI s will be summarised similarly  to AEs.
Furthermore, listings will be provided displaying all TEAEs and TESAE s including pertinent 
clinical information.
All additional safet y parameters such as laboratory parameters and ph ysical examinations will be 
summarised and listed.
16.4.2.6 Other assessments
Incremental recovery  (IR30min), FVIII activity at 30 minutes (C 30min) and trough level will be 
assessed at visit according to Table 2–1 .
FVIII trough level is defined as the activity  recorded immediately  before N8 -GP injectio n, and 
reported as (U/mL). IR 30min is defined as the peak activity  recorded 30 minutes after the end of N8 -
GP injection, and reported as [U/mL ]/[U/ Kg]. It is calculated b y subtracting the FVIII trough level 
from the FVIII activity  recorded 30 minutes after ended N8- GP injection, and dividing the 
difference b y the dose injected at time 0 expressed as U/ Kg bw.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 95 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 96of 114
  16.5 Interim reporting
All data from main phase of the trial will be anal ysed and reported when the first 50 patients have 
completed main phase with at least 50 EDs and completed visit 9. This report will cover all 
endpoints, and will form the basis for the paediatric indication. Data from patients that have entered 
extension phase at this point will be included up to latest visit prior this cut -off date .The data will 
be presented for separately  for the main phase and extension as well as combined. 
An updated report will be made when the first 100 patients have had at least 100 EDs. A final report 
with supportive data will be made when all patients have completed both parts of the trial.
16.6 Sequential safety analysis and safety monitoring
Novo Nordisk will constitute an internal safet y committee to perform on -going safet y surveillance. 
The trial will be subject to thresholds evaluated by the safet y committee (see Section 11.6.1 ).
In addition a safet y analysis will be performed to evaluate the development o f inhibitor at the 
following predefined time point:
after the first 25 patients have been to visit 6 (20- 25 exposure day s)
The expected rate of inhibitors is about 30% in PUPs with severe haemophilia A4. In case of 
confirmed FVIII inhibitor formation in 12 or more of all exposed patients, all cases of inhibitor 
formation will be evaluated by  the N8 -GP safet y committee. During these evaluations, ongoing 
treatment in the trial will continue, however new pa tients will not be enrolled in the trial. The 
evaluation will provide the basis for a decision on any  actions required for the trial to allow for 
continuation of enrolment or decision to terminate the trial, and will be documented in the safet y 
committee m eeting minutes (see Section 11.6.2 ). 
16.7 Reporting of F8and HLA genotype
Information about underlying gene defects of F8and HLA will be listed in the clinical trial report , 
except for Israel . No statistical anal ysis will be performed. 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 96 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 97of 114
  17Ethics
Participation in this trial could be a possible benefit for the patient in terms of closer monitoring of 
the patient by  the investigator, compared to standard care and possible avoidance of bleeding
episodes . As with all investigational drugs, there is an anticipated risk of potential side effect1. 
The trial will be conducted in compliance with ICH GCP1and applicable regulatory  requirements, 
and in accordance with the Declaration of Helsinki2. 
17.1 Informed consent 
In seeking and documenting informed consent, the investigator must comply  with applicable 
regulatory  requirement(s) and adhere to IC H GCP1and the requirements in the Declaration of 
Helsinki2.
Before an y trial-related activity , the investigator must give the patient and/or the patient ’s 
parent(s)/LAR(s) ) verbal and written information about the trial and the procedures involved in a 
form that the patient or the patient ’s parent(s)/ LAR (s)can read and understand. This includes the 
use of an impartial witness where required. In this trial the notion of LAR is the legal 
representatives, as defined in Member States’ national laws, who consent on behalf of the child.
The patient or the patient’s parent (s)/LAR(s) must be fully  informed of their rights and 
responsibilities while participating in the trial as well as possible disadvantages of being treated 
with the trial product.
The investigator must ensure the patient and/or patient’s parent(s)/LAR(s) ample time to come to a 
decision whether or not to participate in the trial. 
The req uirement for obtaining informed consent from a patient’s parent(s)/LAR (s)is that the patient 
is unable to provide informed consent, and the process has been approved by  the relevant I RB/IEC.
A voluntary , signed and personall y dated informed consent form mustbe obtained from the 
patient’s parent(s)/LAR(s) before an y trial -related activity . In this trial where informed consent and 
exposure to the N8- GPmay occur on the same day, informed consent form must include a time 
field next to the data field.
Consent : As a child is unable to provide legally binding consent, informed consent must be sought 
from the patient’s parent(s)/L AR on the child’s behalf. The specific and written informed consent of 
the parent(s)/LAR must be sought prior to enrolling a child in t he trial. Information about the trial 
should be given b y an experienced investigator. 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 97 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 98of 114
  For children, from birth to the age of 3 years old, it is not possible to obtain assent and 
understanding of research is not expected22.
Patients above the age of 3 y ears old should sign a child assent form, if capable, and if required by  
local requirements. This can be performed on a separate day ; especially  for l ong-term trials here the 
investigator should check the progressing maturation of the child and its ability  for assent.
The responsibility  for seeking informed consent must remain with the investigator , but the task may  
be delegated b y the investigator to a medicall y qualified person, in accordance with local
requirements. The written informed consent including time must be signed and personall y dated b y 
the person who seeks the informed consent before trial -related activity .
If information becomes available that may  be relevant to the patient’s willingness to continue 
participating in the trial, the investigator must inform the patient and/or the patient’s parent(s)/LAR 
in a timely  manner, and a revised written informed consent must be provided and a new inf ormed 
consent must be obtained.
F8and HLA genotype testing/collection of previous genotype documentation (not applicable 
for Israel ):
Genoty pe testing is offered to the patients participating in this trial. If documentation of the 
patients’ genot ype already  exists, the patient and/or the patient’s parent(s)/LAR (s)must give their 
consent before the data can be collected for trial purpose. Prior to an y trial -related activity , the 
investigator must provide the patient’s parent(s)/LAR(s) with the possibi lity to abstain from the 
genetic testing/collection of previous documentation, but still be able to participate in the trial.
Only  the F8 and HLA genoty pewill be anal ysed by  the central laboratory  selected by  Novo Nordisk 
and no other genomic analy ses wil l be carried out. Samples will be appropriately  disposed of, after 
the test. All test results are kept strictly confidential in sufficient consideration of individual 
information.
17.2 Data handling
If the patient is withdrawn from the trial or lost to follow up, then the patient’s data will be handled 
as follows:
Data alread y collected and data collected at the end of trial visit will be retained by Novo 
Nordisk, entered into the database and used for the trial re port
Safety  events will be reported to the Novo Nordisk and regulatory  authorities according to 
local/national requirements
If data are used, it will alway s be in accordance with local law and IRBs/IECs.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 98 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 99of 114
  17.3 Information to patient, parent(s)/LAR(s) during the trial
The trial site will be offered a communication package to the patient and/or the patient’s 
parent(s)/LAR(s) during the conduct of the trial. The package content is issued by  Novo Nordisk. 
The communication package will contain the letters/booklets intended for distribution to the 
patients. The letters/booklets will be translated and adjusted to local requirements and distributed to 
the patient and/or the patient’s parent(s)/LAR(s) by discretion of the investigator. The patient and/or 
the patient’s p arent(s)/LAR(s) may  receive a "welcome to the trial letter" and a "thank for your 
participation letter" at the end of the trial. Further the patient and/or the patient’s parent(s)/LAR(s) 
may receive trial letters and/or small toy sduring the trial period. 
All information inclusive all material and to ys to the patient s will be submitted to the health 
authorities and IECs/IRBs for approval according to local regulations.
17.4 Premature termination of the trial and/or trial site
Novo Nordisk, the investigator, the IRBs/IECs or a regulatory  authority  may  decide to stop the trial, 
part of the trial or a trial site at any  time, but subject to the following procedure .
If a trial is suspended or prematurel y terminated, the investigator must inform the patients promptly  
and ensure appropriate therap y and follow -up. The investigator and/or Novo Nordisk should also 
promptly  inform the IRBs/I ECs and provide a detailed written explanation. The relevant regulatory  
authorities must be informed.
If, after the termination of the trial, the risk/benefit anal ysis changes, the new evaluation should be 
provided to the I RBs/IECs in case it has an impact on the planned follow -up of 
patients who have 
participated in the trial. If it hasan impact, the actions needed to inform and protect the patients
should be described.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 99 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 100of 114
  18Protocol compliance
Deviations from the protocol should be avoided.
If deviations do occur, the investigator must inform the monitor and the implications of the 
deviation must be reviewed and discussed.
Deviations must b e documented and explained in a protocol deviation b y stating the reason, date, 
and the action(s) taken. Some deviations, for which corrections are not possible, can be
acknowledged and confirmed via edit checks in the eCRF or via listings from the clinica l database. 
Documentation on all protocol deviations must be kept in the investigator’s trial file and Novo 
Nordisk trial master file.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 100 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 101of 114
  19Audits and inspections
Any aspect of the clinical trial may be subject to audits conducted by  Novo Nordisk or inspections 
from domestic or foreign regulatory  authorities or from I RBs/IECs. Audits and inspections may  
take place during and after the trial. The investigator and the trial site staff as well as Novo Nordisk 
staff have an obligation to cooperate and assist in such audits and inspections. This includes giving 
auditors and inspectors direct access to all source documents and other documents at the trial site 
relevant to the clinical trial. This includes permission to examine, analy se, verify  and reproduce an y 
record(s) and report(s) that are relevant to the evaluation of the trial.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 101 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 102of 114
  20Critical documents
An Investigator Portal will be used as media for exchange and handling of investigator trial file 
documents between Novo Nordisk and the trial site and for electronic storage of these documents 
during trial conduct.
Before a trial site is allowed to start screening patients, the following documents must be available 
to Novo Nordisk:
Regulatory  approval and/or acknowledgement of notification as required 
Approval/favourable opinion from I RBs/IECs clearly  identify ing the documents reviewed as 
follows: protoc ol, any  protocol amendments, subject information/informed consent form, any  
other written information to be provided to the patient and patient recruitment materials
List of IRB/IEC members and/or constitution
Curricula vitae of investigator and sub -invest igator(s) (current, dated and signed -must include 
documented GCP training or a certificate)
Signed receipt of investigator's brochure 
Signed and dated agreement on the final protocol
Signed and dated agreement on protocol amendment, if applicable
Financ ial agreement(s)
Source document agreement
Central laboratory  certification and normal ranges
Insurance statement, if applicable
Signed and dated Investigator Agreement
Financial disclosure form from investigator and sub- investigator(s)
Only  applicable for US trial sites: 
For US trial sites: verification under disclosures per Code of Federal Regulations (CFR) of 
Financial Conflict of Interest
For US trial sites: FDA form 1572 must be completed and signed b y each investigator
FDA form 1572:
For US trial sites:
Intended for US trial sites
Conducted under the IND
All US inve stigators, as described above, will sign FDA Form 1572
For trial sites outside the US:
Intended for participating trial siteoutside of the US
Not conducted under the IND
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 102 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 103of 114
  All investigators outside of the US will not sign FDA form 1572
Novo Nordisk will anal yse and report data from all trial sites together.
For local lab parameters the following will be collected:
Laboratory  normal ranges
Laboratory  certification/QA scheme/other documentation
Laboratory  methods
By signing the protocol, each investigator agrees to comply  fully with ICH GCP1,applicable 
regulatory  requirements and the Declaration of Helsinki2. 
By signing the protocol, each investigator also agrees to allow Novo Nordisk making investigator's 
name and information about trial site name and address publically  available if this is required by  
national or international regulations.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 103 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 104of 114
  21Responsibilities
All staff (Novo Nordisk, trial site, laboratory , CRO etc .) will conduct the trial in compliance with 
ICH GCP1, applicable regulatory  requirements and the Declaration of Helsinki2.
The investigator is accountable for the conduct of the trial at his/her trial site. If an y tasks are 
delegated, the investigator must maintain a list of appropriatel y qualified persons to whom he/she 
has delegated specified significant trial -related duties. The investigator must ensure that there is 
adequate training for all staff participating in the conduct of the trial. It is the investigator’s 
responsibility  to supervise the conduct of the trial and to protect the rights, safet y, and well -being of 
the patients.
A qualified ph ysician, who is an investigator or a sub -investigator for the trial, must be responsible 
for all trial -related medical decisions. The investigator must ensure adequate supervision of the 
conduct of the trial at the trial site. 
The investigator will follow instructions from Novo Nordisk when processing data.
The investigator is responsible for filing essential documents (ie those doc uments which 
individually  and collectively  permit evaluation of the conduct of a trial and the quality  of the data 
produced) in the investigator’s trial file. The documents should be kept in a secure locked facility , 
so no unauthorized persons can get acce ss to the data. The patient identification code list should be 
kept securely  and separate from the personal data.
The investigator will take all necessary  technical and organisational safet y measures to prevent 
accidental or wrongful destruction, loss or d eterioration of data. The investigator will prevent any  
unauthorised access to data or an
y other processing of data against applicable law. The investigator 
must be able to provide the necessary  information or otherwise demonstrate to Novo Nordisk that 
such technical and organisational safet y measures have been taken.
During an y period of unavailability , the investigator should delegate responsibility  for medical care 
of patients to a specific qualified phy sician who will be readily  available to patients during that 
time.
If the investigator is no longer able to fulfil the role of investigator (eg if he/she moves or retires), a 
new investigator will be appointed in consultation with Novo Nordisk. 
The investigator and other site personnel must have sufficien t English skills according to their 
assigned task(s).
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 104 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 105of 114
  22Reports and publications
The information obtained during the conduct of this trial is considered confidential, and may  be 
used by  Novo Nordisk for regulatory  purposes and for the general development of the trial product. 
All information supplied by  Novo Nordisk in connection with this trial shall remain the sole 
propert y of Novo Nordisk and is to be considered confidential information. No confidential 
information shall be disclosed to others without prior written consent from Novo Nordisk. Such 
information shall not be used except in the performance of this trial. The information obtained 
during this trial may be made available to other phy sicians who are conducting other clinical trials 
with the trial product, if deemed necessary  by Novo Nordisk.
A principal investigator will be de signated as the signatory  investigator with the responsibility to 
review and sign the main report based on data from when the first 50 PUPs have reached at least 50 
EDs.
22.1 Communication of results
Novo Nordisk commits to communicating, and otherwise making a vailable for public disclosure, 
results of trials regardless of outcome. Public disclosure includes publication of a paper in a 
scientific journal, abstract submission with a poster or oral presentation at a scientific meeting, or 
disclosure b y other means .
The results of this trial will be subject to public disclosure on external web sites according to 
international and national regulations, as reflected in the Novo Nordisk Code of Conduct for 
Clinical Trial Disclosure.
Novo Nordisk reserves the right to d efer the release of data until specified milestones are reached, 
for example when the clinical trial report is available. This includes the right not to release the 
results of interim anal yses, because the release of such information may  influence the results of the 
entire trial.
At the end of the trial, one or more scientific publications may be prepared collaborativel y by the 
investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or 
communication for up to 60 day s toprotect intellectual propert y.
In all cases the trial results will be reported in an objective, accurate, balanced and complete 
manner, with a discussion of the strengths and limitations. All authors will be given the relevant 
statistical tables, figures, and reports needed to evaluate the planned publication. I n the event of an y 
disagreement on the content of any publication, both the investigators’ and Novo Nordisk opinions 
will be fairl y and sufficiently represented in the publication.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 105 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 106of 114
  Where required b ythe journal, the principal investigator from each trial site will be named in an 
acknowledgement or in the supplementary  material, as specified by  the journal. 
Novo Nordisk maintains the right to be informed of plans by  any investigator to publish and to
review an y scientific paper, presentation, communication or other information concerning the 
investigation described in this protocol. Any  such communication must be submitted in writing to 
Novo Nordisk before submission for comments. Comments will be giv en within four weeks from 
receipt of the planned communication.
22.1.1 Authorship
Authorship of publications should be determined in accordance with the Uniform Requirements of 
the International Committee of Medical Journal Editors (sometimes referred to as the Vancouver 
Criteria27).
Authorship credit should be based on :
Substantial contributions to conception and design, acquisition of data, or analysis and 
interpretation of data; 
Drafting the article or revising it cr itically  for important intellectual content; and 
Final approval of the version to be published.
22.1.2 Trial site -specific publication(s) by investigator(s)
For a multi -centre clinical trial, analy ses based on single -site data usuall y have significant statistic al 
limitations and frequently do not provide meaningful information for healthcare professionals or 
patient s, and therefore may  not be supported by  Novo Nordisk. I t is a Novo Nordisk policy  that 
such individual reports do not precede the primary manuscript and should alway s reference the 
primary  manuscript of the trial.
Novo Nordisk reserves the right to prior review of such publications. Further to allow for the 
primary  manuscript to be published as the first, Novo Nordisk asks for deferment of publication of 
individual trial site results until the primary  manuscript is accepted for publication. As Novo 
Nordisk wants to live up to the industry  publication policy , submission for publication of such 
primary  policy  will take place no later than 18 months after trial completion .
22.2 Investigator access to data and review of results
As owner of the trial database, Novo Nordisk has the discretion to determine who will have access 
to the database. 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 106 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 107of 114
  23Retention of clinical trial documentation and human biospecimens
23.1 Retention of clinical trial documentation
Patient ’s medical records must be kept for the maximum period permitted by  the hospital, 
institution or private practice.
The investigator must agree to archive the documentation (this includes both electronic and paper -
based records) pertaining to the trial in an archive after completion or discontinuation of the trial if 
not otherwise notified. The investigator should not destroy  any documents without prior permission 
from Novo Nordisk. If the investigator cannot archive the documents at the trial site, Novo Nordisk 
can refer the investigator to an independent archive provider that has a s ystem in place to allow onl y 
the investigator to access the files.
The investigator must be able to access his/her trial documen ts without involving Novo Nordisk in 
any way . Trial s ite-specific CRFs and other patient data (in an electronic readable format or as 
paper copies or prints) will be provided to the investigator before access is revoked to the s ystems 
and/or electronic dev ices supplied by  Novo Nordisk. These data must be retained by  the trial site. If 
the Novo Nordisk provided data (eg the CD- ROM) is not readable during the entire storage period, 
the investigator can request a new cop y, as a cop y of all data will be stored by Novo Nordisk.
Novo Nordisk will maintain Novo Nordisk documentation pertaining to the trial for as long as the 
product is on the market plus 20 y ears. 
The files from the investigator trial site/institution must be retained for 15 years after the 
comple tion of the trial, or longer if required by national regulations. The deletion process must 
ensure confidentiality  of data and must be done in accordance with local regulatory requirements.
For Japan: The trial site should retain clinical trial documentati on until approval, or 3 years after 
the date of premature termination or completion of the clinical trial. The sponsor should retain 
clinical trial documentation for 5 years after the approval (in case of drug patient to re-examination, 
until re -examinatio n is completed), or 3 years after the date of premature termination or completion 
of the clinical trial.
23.2
Retention of human biospecimens
Storage and disposition of samples anal ysed at local laboratories will be performed according to 
local laboratory  proce dures. 
Antibody  samples (samples for binding antibodies and inhibitors) will be stored until drug approval 
by Food and Drug Administration (FDA) and/or European Medicines Agency  (EMA). 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 107 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 108of 114
  All remaining blood samples will be stored until the trial has been e valuated by  appropriate 
authorities or until the project terminates, but no longer than 15 yearsfrom end of trial . As new 
biomarkers related to the disease and/or safet y, efficacy , or mechanism of action of N8- GP may  
evolve during the conduct of the trial , the anal yses of the stored biospecimens may  also include 
biomarkers that are unknown at present or have not been included in the scientific hy potheses at 
initiation of the trial. The samples will be stored at Novo Nordisk or a Novo Nordisk designated 
referral bio- repository  with access to the samples. Samples might be transferred to other countries, 
if not prohibited by  local regulations. The patient’s identity  will remain confidential and samples 
will only  be marked and identified by  a unique sample I D. No direct identification of the patient 
will be stored together with the samples. The anal yses will not have an y medical consequences for 
the patients or their relatives. Only  Novo Nordisk staff and bio- repository  personnel (if applicable) 
will have access to the stored bio specimens. 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 108 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 109of 114
  24Institutional Review Boards/Independent Ethics Committees and 
regulatory authorities
IRB/IEC:
Written approval or favourable opinion must be obtained from IRB/ IEC prior to commencement of 
the trial.
During the trial, the inve stigator or sponsor, as applicable, must promptly  report the following to the 
IRB/IEC, in accordance with local requirements: updates to IB, unexpected SAEs where a causal 
relationship cannot be ruled out, protocol amendments according to local requirements, deviations 
to the protocol implemented to eliminate immediate hazards to the patients, new information that 
may affect adversel y the safet y of the patients or the conduct of the trial (including new risk/benefit 
analysis in case it will have an impact on the planned follow -up of the patients), annuall y written 
summaries of the trial status, and other documents as required b y the local IRB/IEC.
Protocol amendments must not be implemented before approval or favourable opinion according to 
local regulations , unless necessary  to eliminate immediate hazards to the patients.
The investigator must maintain an accurate and complete record of all submissions mad e to the 
IRB/IEC. The records should be filed in the investigator’s trial file and copies must be sent to Novo 
Nordisk.
Regulatory Authorities :
Regulatory  authorities will receive the clinical trial application (CTA), protocol amendments, 
reports on SAEs, and the CTR according to national requirements.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 109 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 110of 114
25Indemnity statement
Novo Nordisk carries product liability  for its products, and liability  as assumed under the special 
laws, acts and/or guidelines for conducting clinical trials in any  country , unless other s have shown 
negligence.
Novo Nordisk assumes no liability in the event of negligence, or any  other liability  of the sites or 
investigators conducting the trial , or b y persons for whom the said site or investigator are 
responsible.
Novo Nordisk accepts lia bility  in accordance with:
Only applicable for Argentina: Novo Nordisk Pharma Argentina S.A. has contracted insurance 
(policy  reference number 87828 and its respective updates) with the company  Sancor Cooperativa 
de Seguros LTDA. Domiciled in I ndependencia 333, Sunchales, Santa Fé, Argentina. Telephone 
number: 0800 -
444-28500.
Only applicable for Australia: Medicines Australia Guidelines for Compensation for Injury  
Resulting From Participation in a Company -sponsored Clinical Trial. Version 160104B dated 16 
January 2004.
Only applicable for Austria: Arzneimittelgesetz (BGBI. Nr. 185/1983) last amended with BGBl. I 
Nr. 48/2013 
Only applicable for France: The French Public Health Code article L 1121 -10 (law n° 2004 -
806 
of 9 August 2004 art. 88 I, IX Journal Off iciel of 11 August 2004. "The sponsor is responsible for 
identification of the harmful consequences of the biomedical research for the person lending 
himself thereto and for indemnification of his beneficiaries, except in case of proof, incumbent on 
it, that the prejudice is not attributable to his fault of or the fault of an y intervening part y, without 
the sponsor's being entitled to call on acts b y a third part y or the voluntary  withdrawal of the person 
who had initially  consented to cooperating in the re search”.
Only applicaple for Netherlands: Wetgeving betreffende geneesmiddelen; geneesmiddelenwet 1 
juli 2007 (Medicines Law, 1 July  2007). De Wet Medisch- wetenschappelijk Onderzoek met mensen 
(WMO), 1 maart 2006 (Medical Research Involving Human Subjects Act, 1 March 2006). Besluit 
van 23 juni 2003, houdende regels inzake de verplichte verzekering bij medischwetenschappelijk 
onderzoek met mensen (Decree of 23 June 2003, containing rules for compulsory  insurance in 
medical research involving human subjects (Medical Research (Human Subjects) Compulsory  
Insurance Decree) .
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 110 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 111of 114
  Only applicable for Poland: Novo Nordisk carries liability  for the Study  exclusively  in the scope 
defined b y the applicable laws and in particular b y the Civil Code and the Pharmaceutical Law
dated 6 September 2001 (uniform version Journal of Laws of 2008 No. 45 item 271 with 
amendments). In order to support potential claims for liability  attributable to the Study , Novo 
Nordisk and Investigator are covered b y the Insurance Policy issued accord ing to applicable Polish 
law’
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 111 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 112of 114
  26.References
1 International Conference on Harmonisation. I CH Harmonised Tripartite Guideline. Good 
Clinical Practice, 01 -May-1996, Geneva, Switzerland. 1996.
2 WMA. Declaration of Helsinki -Ethical Principles for Medical Research Involving Human 
Subjects. 2010. 
3 Gouw SC, van der Bom JG, Marijke van den BH. Treatment -related risk factors of inhibitor 
development in previously  untreated patients with hemophilia A: the CANAL  cohort study . 
Blood 2007; 109(11):4648-4654.
4 Gouw SC, van der Bom JG, L jung R, Escuriola C, Cid AR, Claey ssens -Donadel S et al. 
Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 
368(3):231-239.
5 Investigator's Brochure, N8- GP, 4th Edition. Novo Nordisk A/S. 2013.
6 Tiede A, Brand B, Fischer R, Kavakli K, Lentz SR, Matsushita T et al. Enhancing the 
pharmacokinetic properties of recombinant factor VIII: first -in-human trial of gl ycoPEG ylated 
recom binant factor VIII in patients with hemophilia A. J Thromb Haemost 2013; 11(4):670-
678.
7 EMA. Committee for medicinal products for human use (CHMP), Guideline on the clinical 
investigation of recombinant and human plasma- derived factor VIII products, 
EMA/CHMP/BPWP/144533/2009. 2011.
8 Geraght y S, Dunkley T, Harrington C, L indvall K, Maahs J, Sek J. Practice patterns in 
haemophilia A therap y --global progress towards optimal care. Haemophilia 2006; 12(1):75 -
81.
9 Ivens IA, Baumann A, McDonald TA, Humphries TJ, Michaels L A, Mathew P. PEGy lated 
therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers. 
Haemophilia 2013; 19(1):11-
20.
10 Astermark J. I mmune tolerance induction in patients with hemophilia A. Thromb Res 2011; 
127Suppl 1:S6 -S9.
11 Benson G, Auerswald G, Elezovic I , Lambert T, Ljung R, Morfini M et al. Immune tolerance 
induction in patients with severe hemophilia with inhibitors: expert panel views and 
recommendations for clinical practice. Eur J Haematol 2012; 88(5):371-379.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 112 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 113of 114
  12 Astermark J, Morado M, Rocino A, van den Berg HM, von DM, Gringeri A et al. Current 
European practice in immune tolerance induction therap y in patients with haemophilia and 
inhibitors. Haemophilia 2006; 12(4):363-371.
13 DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on 
immune tolerance induction: consensus recommendations. Haemophilia 2007; 13 Suppl 1:1-
22.
14 Collins PW, Fischer K, Morfini M, Blanchette VS, Bjorkman S. Implications of coagulation 
factor VIII and IX pharmacokinetics in the proph ylactic treatment of haemophilia. 
Haemophilia 2011; 17(1):2-10.
15 De AC, Drazen JM, Frizelle FA, Haug C, Hoey  J, Horton R et al. 
Clinical trial registration: a 
statement from the International Committee of Medical Journal Editors. N Engl J Med 2004; 
351(12):1250-1251.
16 Food and Drug Administration Amendments Act of 2007. 2007.
17 European Commission Regulation for EudraCT. 2011. 
18 FDA. Guidance for Industry  Assay  Development for I mmunogenicity  Testing of Therapeutic 
Proteins. Draft Guidance. 2009. 31-1-2013. 
19 Mire- Sluis AR, Barrett YC, Devanaray an V, Koren E, L iu H, Maia M et al. Recommendations 
for the design and optimization of immunoassay s used in the detection of host antibodies 
against biotechnology  products. J I mmunol Methods 2004; 289(1- 2):1-16.
20 Shankar G, Devanaray an V, Amaravadi L, Barrett YC, Bowsher R, Finco -Kent D et al. 
Recommendations for the validation of immunoassay s used for detection of host antibodies 
against biotechno logy products. J Pharm Biomed Anal 2008; 48(5):1267 -1281.
21 Gupta S, I ndelicato SR, Jethwa V, Kawabata T, Kelley  M, Mire -Sluis AR et al. 
Recommendations for the design, optimization, and qualification of cell -based assay s used for 
the detection of neutralizing antibod y responses elicited to biological therapeutics. J I mmunol 
Methods 2007; 321(1- 2):1-18.
22 The ad hoc group for the development of implementing guidelines for Directive 2001/20/EC 
relating to good clinical practice in the conduct of clinic al trials on medicinal products for 
human use. Ethical Considerations for Clinical Trials on Medicinal Products Conducted with 
the Paediatric Population. EC Directive 2008.
23 The Rules Governing Medicinal Products in the European Union, Volume 4, EU Gui delines to 
Good Manufacturing Practice, Medicinal Products for Human and Veterianry  Use, Annex 13 
Investigational Medicinal Products. 2010. 
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 113 . -  | 1
 |
CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 November 2013 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 114of 114
  24 Sampson HA, Munoz- Furlong A, Campbell RL , Adkinson NF, Jr., Bock SA, Branum A et al. 
Second sy mposium on the definition and management of anaph ylaxis: summary  report --
second National Institute of Allergy  and Infectious Disease/Food Allergy  and Anaphy laxis 
Network s ymposium. Ann Emerg Med 2006; 47(4):373-380.
25 Food and Drug Administration. Food and Drug Adminis tration: Code of Federal Regulations, 
21 CFR Part 11, Electronic Records, Electronic Signatures . 2009.
26 ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. I nternational 
Conference on Harmonisation E9 Expert Working Group. Stat Med 1999; 18(15):1905-1942.
27 International Committee of Medical Journal Editors (ICMJE): Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals: writing and editing for biomedical 
publication. Haematologica 2004; 89(3):264.
  Protocol  v 13908 NN7088 0  | VV-TMF-1266622
114  of 114 . -  | 1
 |
CONFIDENTIAL
 
16.1.01 Protocol Attachment 
Protocol Attachment I is located in the Trial Master File. 
If applicable , P
rotocol Attachment II is also located in the Trial Master File. 
Content: Global key
 staff and Country key staff. CONFIDENTIALDate: Novo Nordisk
Version:
Status:turoctocog alfa pegol
Trial ID: NN7088-3908
Clinical Trial Report
Appendix 16.1.124 February 2022
1.0
Final
CONFIDENTIAL
Log of Protocol Amendments  UTN: U1111 -1148 -1897  Date:  08 February 2022  Status:  Final  Novo Nordisk  
Trial ID: NN7088 -3908  EudraCT No.: 2013 -004025 -88 Version:  2.0 Page:  1 of 2 
 
 
Log of P rotocol Amendments  
Trial ID:   
Protocol  
amendment no Date  Final,  
Version  Country(ies) and/or trial 
site(s) affected  Brief content  
1 NA NA Portugal  Protocol amendment no 1 was dedicated to 
Portugal but never finalised. Due to SOP 
requirements the countries now have their own 
logs and this log will only cover global 
amendments  
2 20-Mar-2015  2.0 All (Final Version 1.0 never shared)  
Detailed information on Major surgery and ITI, 
extended trial timelines  
3 01-Nov-2016  1.0 All Amendment 3 includes a new secondary 
endpoint to assess the ITI treatment outcome and 
monitoring of antibody development  against  
Host Cell Protein (HCP).   
4 14-Jun-2018  1.0 Israel  Protocol Amendment 4 is for Israel seeking 
permission to obtain the F8 genotype . 
5 13-Jun-2019  1.0 All  Interim analysis when approximately 45 patients 
have reached 50 exposure days, and 
administrative changes  
6 21-jun-2019  1.0 Israel  Protocol amendment 6 for Israel for obtaining 
informed consent from withdrawn patients to 
provide genotype results  VV-TMF-1130009|2.0|NN7088 -3908
  Protocol Amendment  final log|1 of 2
CONFIDENTIAL
CONFIDENTIAL
Log of Protocol Amendments  UTN: U1111 -1148 -1897  Date:  08 February 2022  Status:  Final  Novo Nordisk  
Trial ID: NN7088 -3908  EudraCT No.: 2013 -004025 -88 Version:  2.0 Page:  2 of 2 
 
 
7 02-jul-2019  1.0 Japan  Protocol amendment 7 for Japan is due to the 
regulatory category of this clinical trial should be 
updated in accordance with Japanese regulations. 
This is mandatory before NNPL obtains 
marketing approval of N8 -GP. 
8 15-Jun-2020  1.0 All - Close recruitment of trial NN7088 -3908 with 
between 50 to 100 patients completing, 
(rather than the protocol agreed 100 patients 
completing), but maintain the protocol 
defined trial end date 13 November 2021.  
Anti-PEG IgG + additional IgM antibody 
analyses have been implemented.  
 VV-TMF-1130009|2.0|NN7088 -3908
  Protocol Amendment  final log|2 of 2
CONFIDENTIAL
CONFIDENTIAL
PT  Protocol Amendment  1 pt3908 NN7088 0  | VV-TMF-1014802
5  of 1 . -  | 1
 |Protocol Amendment 
Trial ID: NN7088-3908 
UTN: Ullll-1148-1897 
EudraCT No.: 2013-004025-88 Date: 
CONFIDENTIAL Version: 
Status: 
Page: 
Protocol Amendment 
no 1.0 
to Protocol, final version 1.0 
dated 04 November 2013 
Trial ID: NN7088-3908 30 July 2014 Novo Nordisk 
0.1 
Final 
1 of 5 
An open-label single-arm multicentre non-controlled phase 3a trial 
investigating safety and efficacy of NS-GP in prophylaxis and 
treatment of bleeding episodes in previously untreated paediatric 
patients with severe haemophilia A 
Trial phase: 3a 
Applicable to: Portugal 
Amendment originator: 
Name:  
Department or business area: Medical Department 
CONFIDENTIAL

PT  Protocol Amendment  1 pt3908 NN7088 0  | VV-TMF-1014802
5  of 2 . -  | 1
 |Protocol Amendment 
Trial ID: NN7088-3908 
UTN: Ul 111-1148-1897 
EudraCT No.: 2013-004025-88 CONFIDENTIAL Date: 
Version: 
Status: 
Page: 30 July 2014 Novo Nordisk 
0.1 
Final 
2 of 5 
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties. 
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
PT  Protocol Amendment  1 pt3908 NN7088 0  | VV-TMF-1014802
5  of 3 . -  | 1
 |Protocol Amendment 
Trial ID: NN7088-3908 
UTN: Ul 111-1148-1897 
EudraCT No.: 2013-004025-88 
Table of contents CONFIDENTIAL Date: 
Version: 
Status: 
Page: 30 July 2014 Novo Nordisk 
0.1 
Final 
3 of5 
Page 
1 Introduction including rationale for the protocol amendment ............................................................. 4 
2 Changes ...................................................................................................................................................... 5 
CONFIDENTIAL
PT  Protocol Amendment  1 pt3908 NN7088 0  | VV-TMF-1014802
5  of 4 . -  | 1
 |Protocol Amendment 
Trial ID: NN7088-3908 
UTN: Ul 111-1148-1897 
EudraCT No.: 2013-004025-88 CONFIDENTIAL Date: 
Version: 
Status: 
Page: 30 July 2014 Novo Nordisk 
0.1 
Final 
4 of5 
1 Introduction including rationale for the protocol amendment 
The purpose of this amendment is to include information that is missing in the Protocol Version 1.0, 
according to the Central Ethics Committee in Portugal, referring to the use of the pain control 
measures for venous punctures. 
The amendment will be submitted to the Central Ethics Committee for Approval in Portugal. 
According to local legislation, this amendment does not need to be submitted to Regulatory 
Authorities but only to the Ethics Committee in Portugal. 
In this protocol amendment: 
• Any new text is written in italics. 
• Any text deleted from the protocol is written using strike through. 
CONFIDENTIAL
PT  Protocol Amendment  1 pt3908 NN7088 0  | VV-TMF-1014802
5  of 5 . -  | 1
 |Protocol Amendment 
Trial ID: NN7088-3908 
UTN: Ullll-1148-1897 
EudraCT No.: 2013-004025-88 
2 Changes CONFIDENTIAL Date: 
Version: 
Status: 
Page: 30 July 2014 Novo Nordisk 
0.1 
Final 
5 of 5 
The following sentence will be added at the end of section 5.3 Treatment of Patients, on final 
protocol. 
Only applicable for Portugal: 
For venous punctures, pain control measures are allowed according to local practice. 
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 1of 41
Protocol Amendment
no 2
to Protocol, final version 1.0
dated 04November 2013
Trial ID: NN7088 -3908
Safety and Efficacy of turoctocog alfa pegol (N8- GP) in 
Previous Untreated Patients with Haemophilia A
An open -label single arm multicentre non -controlled phase 3a trial investigating safet y and efficacy 
of N8 -GP in prophy laxis and treatment of bleeding episodes in previous untreated paediatric 
patients with severe h aemophilia A
Trial phase: 3a
Applicable to all countries
Amendment originator:
, International Trial Manager
Department:Haemophilia, Clinical Operations 2
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 1 . -  | 3
 |
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.

Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 2of 41
Table of Contents    
Page
Table of Contents ..............................................................................................................................................2
Table of Figures ................................................................................................................................................2
Table of Tables ..................................................................................................................................................2
1Introduction including rationale for the protocol amendment .............................................................3
2Changes ......................................................................................................................................................6
Table of Figur es   
Page
No table of figures entries found.
Table of Tables   
Page
No table of figures entries found.
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 2 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 3of 41
1 Intr oduction including rationale for  the protocol amendment
Rationale for amendment
Below list is the items that have been changed and the rationales for the amendment. The reason for the 
creating the amendment now is the availability of results from the pathfinder™2 (NN7088 -3859), 
pathfinder™3 (NN7088 -3860) and pathfinder™5 (NN7088- 3885). 
1.Major surgeries has been allowed after having completed the pathfinder™3 surgery trial. (section 5.3.5, 
8.7)
a.Recommendations for doses has been added (section 5.3.5, 8.7)
b.Details on definition of data sampling has been updated and data collection from minor and 
major surgery aligned (section 5.3.5, 8.1.10, 8.7)
c.Haemostatic response for surgery 4 -point scale added (section 8.6.1, 8.7.1)
2.ITI recommendations and requirements have been updates after new data available from pathfinder™2 
pivotal trial, pathfinder™3 surgery trial and pathfinder™5 paediatric trial to support the ITI 
recommendations. (section 5.3.6)
a.Dose recommendations added (section 5.3.6, 8.1.11)
b.Detailing of recommendatio ns for low titre inhibitor patients added (section 5.3.6, 5.5, 6.4, 6.6.3)
c.How to evaluate the ITI treatment before returning to prophylaxis added (section 5.3.6, 6.4, 
6.6.3, 8.1.11, 8.4.2.2, 16 ) 
d.ITI doses will count as overall number of doses (section 5.1)
3.Prolonged recruitment period and prolonged trial. Prolongation is due to postponed submission of the 
application for market approval of N8 -GP (section 5.3, 7, 8.1)
4.Updated text on when trial could start as needed data is available at this point (section 3.1.3, 5.1, 5.3, 
8.7)
5.Addition of mandatory inhibitor test before treatment including addition of a withdrawal criterion if 
positive at visit 1 before first dosing. This has been added because of the risk of developing inhibitors 
after receipt of maximum 5 doses of blood components. (section 2, 6.2, 6.4, 8.1 )
6.Precised when safety committee should meet instead of having an interval for the meeting (section 
11.6.2, 16.6)
7.PK time points have been changed based on the need experienced from the first patients enrolled in the 
trial. (section 8.4.2.2)
8.Allergic reaction sampling updated with 2 new tests, as found relevant based on the experience form the 
first patients enrolled in the trial. (section 8.4.2.7)
9.All wash out periods before pre -dose blood sampling has been aligned to be 72 hours instead of either 
72hour or 4 days. This changed in implemented because of new information from the pathfinder™5 
paediatric trial. (section 8.4.2.2)
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 3 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 4of 41
10.Analyses of binding antibodies and PEG antibodies have been changed to not onl y being analysed at the 
end of the trial to also being analysed when considered relevant, based on experience from first patients 
in the trial. (section 8.4.2.2 )
11.Added a window for sampling of blood at visits to allow more flexibility for the patients and sites 
(section 8.1, 8.4 )
12.Clarified inclusion criterion 4 to be covering only FVIII purified product and not all faction products 
(section 1, 5.3, 6.2)
13.Added cardio vascular to physical examination (section 8.3.2)
14.Elaborated on drug reconstitution and sol vent supplies (section 9)
15.Added informed consent can be signed before first visit (section 8.1)
16.Clarified dosing regimen text and visit windows (5.3, 8.1, 
17.Reminder of monitoring of expiry of solvent, injection kits, and reference standard based on experie nce 
from pathfinder™ and guardian™ programmes. (section 8.1, 8.8.4, 9.4)
18.Added information that the vein used for drug infusion can be used for blood sampling half an hour after 
the infusion to ease the problematic blood draw from infants (section 8.4 )
19.Changed the form of writing visit windows in table 2 -1 after feedback of being difficult to understand 
(section 2)
20.Elaborated figure 8 -1 to be more precise for visits during the pre -prophylaxis period. (Section 8.1)
21.Added that if according to local law a caregiver can take over some of a parent(s)/LAR(s) task to allow 
more flexibility for patients (section 8.1)
22.Added reminders to the visit 15 -X to help site following the trial requirements (section 8.1.3)
23.Requirement for site to be able to analyse FVIII ac tivity and inhibitor samples locally to ensure 
immediate action if needed for the patient’s safety. This has been added based from experience from the 
initiation of the trial (section 8.4.1.1 )
24.Added extra samples to be taken together with the confirmatory inhibitor test to ensure a positive test is 
not a false positive and to ensure sufficient knowledge of the inhibitor (section 8.4.2.2)
25.Added that monitoring visit intervals can be prolonged when site only have patients attending visits 
every 24 weeks, but monitor needs to ensure contact to site at least every 12 weeks (section 13)
26.Added that the e -learning of the protocol is mandatory for Investigator if investigator has not attended 
the investigators meetings (section 21)
27.Deleted specific text for Japan u pon request from Japan (section 23.1)
28.Added required text for Portugal upon amendment 1 (section 25)
29.Clarified table 2 -1 elements (section 2)
30.Updated total blood sampling volume after having finalised lab set- up (section 8.4.3)
31.Clarified where to enter dat a in eCRF and eDiary (section 8.1, 8.2, 8.8)
32.Clarified location to align with rest of protocol (section 5.3)
33.Deleted repetitive text (section 3.2)
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 4 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 5of 41
34.Added required elements from new protocol template. It was decided not to change to the new protocol 
template as this would change the protocol too much for sites convenience, but all relevant elements 
from the new protocol template has been added to the protocol. (section 3, 4, 5, 6, 8, 16, 17, 20, 21, 22, 
23, 24)
Corrected abbreviation order, spelling, grammar and clarifications, text formatting, and incorrect section 
references.
In this protocol amendment:
Any new text is written in italics.
Any text deleted from the protocol is written using strike through .
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 5 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 6of 41
2Changes
General over whole protocol
IV/WRS to IWRS
Bleed toBleeding episode
Spelling corrections and grammatical corrections and corrected section references have not been listed below
List of Abbreviations
CRP C-reactive protein
APTT activated partial thromboplastin time 
1 Summary
Trial population:
Inclusion criteria
…..
No prior use of purified factor VIII containing clotting factor products (5 previous exposure days to blood 
components is acceptable)
2 Flow Chart
Table 2 -1
Visit number 01112 3 4-6 7-8 9 10-13 141815-X19EOT
Time of visit 
(ED(s))2 0 1 2 510, 15, 
203 30,40 5060, 70, 
80, 90100 NA
Visit interval 
(ED(s))2 0 0 3±1 5±2 10±2 10+2 10±2 10+2 24w±4w
Adverse events5X X X X X X X X X X X
Vital signs7X X7X X X
FVIII activity –
recovery (30 min
post-dose)X X X X X X X X
FVIII inhibitor test9X18X X X X X X X X
HIV 1 and 2
antibodies(X)
10
F8+ HLA
genotype testing(X)12(X)12(X)12(X)12(X)12(X)12
eDiary training X14X14X14X14X14X14X14X14X14
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 6 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 7of 41
Compliance check 
of eDiary data, 
protocol 
requirements, and
used drug and 
bleeding episode 
evaluationX X X X X X X X X X
Table 2 -2
3If not already on prophylaxis, all patients must initiate prophylaxis treatment no later than at V6 or shortly after at ED 20 . 
Pre-prophylaxis is only allowed for children below the age of 24 months or up to V6, whatever comes first.
Visits at 10EDs±2EDs, 15EDs±2EDs, 20EDs±2EDs must be performed even the window allows 2 visits to be 2 EDs aside 
(e,g, ED12 and ED13)
5After Informed consent has been obtained all Adverse Events if associated with trial related activities must bereported in the 
eCRF
7Vital signs should be measured prior to dosing at all screening V1, V9, and at V14 and at EOT . In addition vital signs sho uld 
also be measured 30±10minutes after the first injection with N8 -GP at V1.
9Blood samples must be collected prior to dosing at dosing visits. Please check that the required washout period has been met 
for inhibitor testing, see section 8.1.1.3 Before any surgeries are performed an inhibitor test must be taken if this test is more 
than 30 days
12F8and HLA genotype sample is only allowed upon patient’s parent(s)/LAR(s) signing the consent for genotyping and should 
only be done if not already documented in patient’s medical record. The sample can be collected at any visit between V0 and 
V89, taking the limitation of the allowed blood sampling volume into account. Genotype is not applicable for Israel .
18 In case V14 will be the EOT visit, the procedure s for the EOT visit should be followed Inhibitor sample at visit 1 before 
dosing is mandatory
19 V15 to VX will be performed every 24 weeks EDs ± 4 weeks EDs until the End of Trial
3 Background information and rationale for the trial
3.1.1 Haemophilia A
…..
The most serious complication of haemophilia treatment with current FVIII products is FVIII 
inhibitor development. These inhibitors are antibodies formed as an immune response to allogeneic 
FVIII, which reduce or eliminate the activity  of FVIII prote ins. This condition develops in about 
30% of previousl y untreated patients (PUPs) with severe haemophilia A following exposure to 
FVIII products.3,4Availability  of a recombinant human FVIII (rFVIII) product with reduced 
immunogenicit y has been the priority request b y the haemophilia community  for many  years. The 
immunogenicit y of N8 -GP will be monitored in the clinical setting and further investigated in 
nonclinical models to explore preliminary findings of reduced binding and uptake of N8 -GP in 
human antigen presenting cells.
Immune tolerance induction (ITI) therapy is the first -choice approach in patients with high -
responding FVIII inhibitors, and the only proven strategy for eradicating FVIII inhibitors. Based on 
clinical evidence and international consensus recommendations, most patients are attempted 
tolerised with the same product that was being used at the time of inhibitor deve lopment.
…
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 7 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 8of 41
3.1.3 N8- GP clinical data
…
In accordance with the EMA guideline7,N8-GP exposure of PUPs may bewas initiated when 
treatment data from 20 paediatric PTPs with at least 50 N8 -GP EDs arewasavailable from the 
pathfinder™5 trial, including data from a minimum of 10 patients below 6 years, and 
pharmacokinetic investigations in children (below 12 y ears) arewere completed.
….
3.2 Rationale for the trial
The rationale for performing the pathfinder™6 trial is to evaluate the safety  (including 
immunogenicit y) and efficacy of N8 -GP in the treatment of PUPs with severe haemophilia A in 
accordance with EMA requirements.7For Europe, EMA requires a separate investigation in the 
PUP population as part of the de velopment programme to be initiated before market authorisation.7
The approval of the indication in PUPs will be based on a clinical trial in a minimum of 50 PUPs 
evaluated for efficacy  and safet y during at least 50 EDs connected with a post -approval 
commitment to follow up at least 100 PUPs for a minimum of 100 EDs. The 50 patients will 
continue to reach at least 100 EDs, and additional 50 patients will be included also to reach at least 
100 EDs.
Given the prolonged half -life of N8- GP it is expected that bleeding prophy laxis, treatment of acute 
bleeding episodes, and control and prevention of bleeding in the surgical setting may  be achieved 
with a reduced frequency and number of injections as compared to current treatment options. This 
may increase treatment compliance, and thereby  potentially  leading to better clinical outcomes for 
patients with haemophilia A.
3.3 Risk and benefits
……
N8-GP is currentl y being investigated in previously treated patients. The first human dose trial 
(NN7088 -3776) demonstrated that a single dose of N8- GP is generally  well -tolerated, and that N8 -
GP has a prolonged half- life compared to commercially  available FVIII products. No safet y 
concerns have been raised based on review of data (cut -off date was 12-Feb-2013 28-Jul-2014) 
from patients enrolled in the pivotal safet y and efficacy trial (NN7088 -3859) and the risk/benefit 
ratio for N8- GP is therefore expected to be favourable.
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 8 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 9of 41
4 Objective(s) and endpoint(s)
…
4.2.2 Secondary Endpoint
….
*Key  supportive secondary  endpoint prospectivel y selected for posting ( e.g.onclinicaltrials.gov 
and EudraCT ). 
5 Trial design
5.1 Type of trial
…
According to the EMA Guideline treatment with N8 -GP in the pathfinder™6 PUP trial was able to
may start when 20 patients participating in the paediatric PTP trial (pathfinder™5) were are
available (including data from a minimum of 10 paediatric patients be low 6 y ears of age), and 
pharmacokinetic investigations in paediatric PTPs were arecompleted.
….
In the main phase of the trial patients will receive treatment with N8 -GP until they  reach a 
minimum of 50 N8- GP EDs each or until they  develop high titre inhibitor . An ED is defined as an y 
day during which the patient has been exposed to N8 -GP, including doses given for treatment of 
bleeding episodes, prophylaxis, surgery , and for the purpose of PK assessment. If N8 -GP is 
administered more than once during the same day , this will still count as one ED. When at least 50 
patients have reached a minimum of 50 EDs each in the main phase, the analy sis and evaluation for 
the main trial report will be performed. EDs during immune tolerance induction therapy (ITI)will 
notcount in the determination of when a patient has reached 50 EDs.
Patients will be followed in the extension phase until at least 100 patients have reached at least 100 
EDs each. EDs during immune tolerance induction therapy (ITI) will count in the determination of 
when a patient has reached 100 EDs.  
….
5.3 Treatment of patients
Trial overview visit schedule will be as shown in Figure 5 -1.
…. 
For each patient at least the two initial doses of N8- GP given on the first 2 EDs will be administered 
in a site hospital/clinic setting enabling observation for potential adverse reactions. The patient must 
be observed for at least 1 hour after dosing. If no safety concerns were raised after administration of 
these initial doses of N8- GP, Afterwards home treatment with i.v. self -injection by  the 
parent/caregiver/support person can be initiated. If no safet y concerns were raised after 
administration of the initial doses of N8 -GP The investigator should ensure that 
parent/caregiver/suppo rt person is sufficientl y trained and confident with home treatment, including 
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 9 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 10of 41
both prophy laxis and treatment of bleeding episodes. The patients can come to the clinic/trial site 
for their N8- GP injections until they  are comfortable with home treatment.
…
The duration of N8 -GP treatment in the extension phase is at least 50 EDs or up to a minimum at 
least atotal of100 EDs (for both the main and extension phases) for each patient. Once a patient 
has achieved 100 EDs, he may  be offered the option to continue in the extension phase until either 
N8-GP is commerciall y available in the relevant country or until the marketing authorisation 
application for N8 -GP is rejected in the relevant country unless the N8- GP trial, part of the trial or a 
trial site is termi nated by  Novo Nordisk or a relevant authority  for any  reason. I n any  event, the Last 
Patient L ast Visit for the trial will be no later than 13 November 2021 May 2019 whether or not the 
product is commerciall y available in the relevant country . Novo Nordisk will not provide any  
patient with trial medication after the end of the trial. 
Treatment with FVIII products other than the investigational product, N8 -GP, is not allowed. 
Previous exposure to FVIII products is not allowed in this trial. Previous exposure to maximum 5 
plasma infusions, Pd -aPCC, and/or cry oprecipitate is allowed. Maximum 5 previous blood product 
(e.g. plasma, cryoprecipitate, erythrocyte concentrate or platelets) infusions are allowed.
5.3.1 Pre -prophylaxis treatment 
….
The N8 -GPdose for pre -prophy laxis treatment (except for bleeding episodes) is approximately  60 
U/Kg bod y weight (bw) (within the dosing range of 50- 75 U/Kg) to be administered as a single 
bolus dose intravenously  (i.v.) with more than one week between doses less than once every  7 day s
(at the discretion of the investigator). Whole mL  dosing is allowed from above 3 mL . This is
explained in further detail in the trial materials manual. For treatment of bleeding episodes see 
Table 5-1.
…
5.3.2 Prophylaxis treatment
…
During the main phase of the trial patients should receive proph ylaxis with i.v. injections of N8- GP 
preferabl y twice weekl y, with doses to be separated by  at least 3 calendar day s and no more than 4 
calendar day s. Based on the patient’s individual bleeding pattern, a n increase in N8- GP dose 
frequency  from twice weekly  to every  third day is permitted at the investigators discretion (should 
be based on the patient’s individual bleeding pattern). 
… 
In the extension phase, all patients should continue the p rophylaxis dosing regimen as prescribed at 
the end of the main phase. However, preferabl y after having been being 12 months on the same 
prophy laxis regimen for 12 months (main phase and extension phase combined), the investigator is 
permitted to increase o r decrease the N8- GP dosing frequency interval within the range of every  3rd
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 10 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 11of 41
day to every  7thday (every  3rdday, twice weekly , every  4thday, every  5thday, every  6thday or every 
7thday (once weekl y)) based on the patient’s bleeding pattern. 
The dose can be administered ±+1 day  of the planned dosing date (this window is related to the 
dosing regimen and not to the visit window) .
… 
In the event of a concern about reduced treatment efficacy  an unscheduled visit can be scheduled 
where a PK sessi on may  be performed to investigate the elimination ( recovery , clearance and half-
life)of N8 -GP. Antibody tests should be taken if not done recently . The PK data may  potentially  be 
used to adjust the dose of dosing regimen. 
5.3.3 Treatment of bleeding ep isodes
Patient’s parent(s)/LAR(s) will be instructed b y the trial site on how to treat a bleeding episode at 
home and how to record the bleeding episodes, the treatment and the response to treatment in the 
electronic diary  (eDiary ). Treatment requiring bleeding episodes should be treated immediately  
(i.e., when the patient experiences the first clinical sy mptoms of a bleeding episode, or when 
observed by parent(s)/LAR(s)) be treated with N8-GP at dos es of 20 -75 U/Kg bw, depending on 
severit y and location of the bleeding episode, see Table 5-1. 
For treatment of severe/life-threatening bleeding episodes administration of higher doses of N8- GP 
is permitted at the investigators discretion. For recommende d dose levels see Table 5-1. In cases of 
a severe bleeding episode the site must be contacted. 
At least the first 2 treatment-requiring bleeding episodes should be treated in the presence of a 
qualified health care professional. If the patient cannot be b rought quickly  to the trial site, the trial 
site must be contacted for treatment instructions or transport. A severe bleeding episode should 
immediately  be treated at home or at the local emergency  room, and the trial site must be contacted 
for further instructions or transport. For severe bleeding episodes before the 2nd EDs the treatment 
must take place at the site.
In case of Treatment requiring bleeding episodes prior to the start of the home treatment these
should immediately  be treated at thetrial s ite. In case the bleeding episode occurs outside trial site 
opening hours, the bleeding episode should be treated according to local practice. 
5.3.4 Treatment of suspected bleeding episodes
In case of a an abdominal or head trauma where there is a risk o f a severe traumatic bleeding 
episode it is allowed to initiate treatment before clinical symptoms arise. This is defined as 
preventive treatment of suspected severe traumatic bleeding episode and will be recorded in EDC 
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 11 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 12of 41
as other severe bleeding episodes. The recommended dose is equivalent to treatment of a severe 
bleeding episode
5.3.5 Surgery
Patients undergoing surgical procedures while participating in this trial can receive bleeding 
preventive treatments with N8 -GP.Minor surgeries, dental extractions and placement of central 
venous access ports can be performed while participating in the trial by administering extra doses of 
N8-GP equivalent to the dose for a severe bleeding episode (see Table 5-1), or aligned to local 
standard of practice, or guidelines for treatment of patients with haemophilia A with FVIII in the 
perioperative period. 
Major surgery  will only  be allowed after the individual patient has reached 50 N8 -GP EDs. The 
major surgery should be planned and conducted in accordance with recommendation in the WFH 
guidelines for management of haemophilia (ref 29) and local guidelines. Determination of dose and 
dose interval should include close monitoring of FVIII activity trough and peak leve ls considering 
the T½ of N8- GPand clinical evaluation of the haemostatic effect . It is up to the investigator to 
decide how long the post-surgery period should be and when the patient should resume regular 
prophylaxis or pre- prophylaxis treatment. and upo n completions of the pathfinder™3 surgery  trial 
(NN7088 -3860). The treatment regimen for major surgery  will be based on results from the 
pathfinder™3 surgery  trial (NN7088- 3860) and PK data obtained in the pathfinder™5 trial 
(NN7088 -3885) in paediatric PTP s. Novo Nordisk will communicate when major surgeries are 
allowed in this trial.
….
Definition of major surgery
Major surgery  is defined as any  invasive operative procedure that requires several day smore than 3 
days of FV III substitution therap y and/or where any  one or more of the following occur: 
A body  cavit y is entered
A mesench ymal barrier (e.g., pleura, peritoneum or dura) is crossed 
A fascial plane is opened
An organ is removed
When normal anatomy  is operativel y altered 
Major elective orthopaedi c surgery
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 12 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 13of 41
Doses of N8-GP should be aimed at securing haemostasis and in accordance with recommendation 
in the W FH guidelines for management of haemophilia (ref 29) and/or local guidelines. In the 
recovery period the patient should be dosed with N8 -GP acco rding to local standard of practice 
and/or general guidelines for treatment of patients with haemophilia A. Determination of dose and 
dose interval should include close monitoring of FVIII activity trough and peak levels considering 
the T½ of N8- GP.
…
5.3.6 Treatment of patients with FVIII inhibitors
… 
Patients who develop FVIII inhibitors during this trial may receive N8 -GP and/or Treatment of 
bleeding episodes with by-passing agents, e.g. i.e. rFVIIa or APCC for treatment of bleeding 
episodes according to local standard care is allowed for patients who develop FVIII inhibitors 
within this trial . However, N8-GP dose levels used should not exceed 75 U/kg as a single dose and 
not exceed 200 U/kg as a maximum 24 hour dose. Treatment with FVIII concentrates other than 
N8-GP is not allowed. By-passing agents are not considered trial medication. 
The ultimate goal of treatment in patients with high -titre inhibitors is to permanently  eradicate the 
inhibitor by  immune tolerance induction therapy  (ITI), thereby  making it possible for the patient to 
be treated routinel y with FVIII replacement therapy again . The therapeutic concept is based on 
long-term uninterrupted high exposure to FVIII in an effort to sufficientl y tolerise the immune 
system. In that sta te, the clinical responsiveness to FVIII replacement therapy  is restored. 
…. 
Novo Nordisk plans that Patients who develop inhibitors, within this trial, will be offered continued
treatment with N8 -GP, including ITI for a maximum of 24 months. ITI with N 8-GP will not be 
initiated until Novo Nordisk has reviewed the clinical data available after completion of the N8 -GP 
pivotal and surgery  trial (pathfinder™2 and pathfinder™3), and of the paediatric PTP trial 
(pathfinder™5) data needed for opening the paedi atric PUP trial according to EMA requirements.
It is expected to use a N8 -GP dosing regimen for ITI  similar to local standard care/guidelines 
applied for IT I with marketed FVIII products. For each individual patient, ITI  regimens with N8- GP 
would have to b e reviewed by  the investigator every  month, and more formally  reviewed every  3 
months by  Novo Nordisk.
If patients with (usually low titre) inhibitors respond well to treatment with N8 -GP then the patient 
can continue the prophylaxis. These patients can still start ITI treatment within 6 months after the 
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 13 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 14of 41
confirmatory inhibitor test. If the inhibitor is stil l present (BU>/=0.6) at 6 months after the 
confirmatory test the patient must start ITI or withdraw from the trial.
Based on experience with marketed FVIII products, a successful ITI can be expected in about 60 –
80% of cases receiving ITI  with N8 -GP, leadin g to several important benefits for the patient, 
including:
……
5.3.6.1 ITI therapy with N8 -GP
Patients who develop inhibitors, within the pathfinder™6 trial, will be offered continued ITI 
treatment with N8-GP for a maximum of 24 months. ITI therapy with FVIII concentrates other than 
N8-GP is not allowed within the trial. It may  also be decided b y the Investigator and/or parent/legal 
representative to withdraw the patients who developed developing FVIII inhibitors.
Patients will be evaluated after 12 months of I TI treatment, based on the level of inhibitors. I f 
inhibitors are still positive after 12 months, but the decline from peak titre level is ≥ 20%, ITI may  
becontinue dfor athe total maximum period of 24 month in total .
If needed and decided b y the I nvestigator, the initiation of the ITI can be delay ed but it has to start 
within 6 months from the time of diagnosis of inhibitor. I nhibitor patients that commence ITI with 
N8-GP will follow an alternative treatment regimen and visit schedule (see Section 8.1.11). ). For 
each individual patient, ITI regimen with N8- GP will need to be reviewed by the investigator every 
month, and formally reviewed every 3 months by Novo Nordisk.
The used N8-GP dosing regimen is at the discretion of the investigator, but a N8- GP do sing 
regimen similar to the local standard of care applied for ITI with marketed FVIII products is 
recommended. However, daily N8 -GP dose levels used for ITI should not exceed 75 U/kg as a 
single dose and not exceed 200 U/kg as a maximum 24 hour dose.
The FVIII inhibitor level will be evaluated continuously in all patients that receive N8 -
GP for ITI . If 
the inhibitor disappears during the ITI (see Section 8.4.2.2), the patient should resume proph ylaxis 
treatment as recommended in Section 5.3.2. 
Patients wil l be evaluated after 12 months and 24 
months of ITI treatment, based on the level of inhibitors, within the predefined specifications of 
withdrawal, see Section 6.4. If inhibitors are still positive after 12 months, but the decline from 
peak titre level is ≥ 20%, ITI may continue for a maximum period of 24 month in total .For patients 
still with positive inhibitors after 12 months ITI, continued trial participation will be evaluated b y 
the investigator and sponsor based on the level of inhibitors, within the predefined specifications of 
withdrawal criteria 8, see Section 6.4. However, if the inhibitor persists after 24 months of ITI, the 
patient will be withdrawn from the trial. 
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 14 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 15of 41
Criteria for successful ITI therapy with N8- GP:In line with international conse nsus, and based on 
the mean N8- GP half -life observed in adults (18.5h) and children < 6 years of age (15h), successful 
N8-GP ITI outcome is based on the achievement of three stringent efficacy criteria
Undetectable inhibitor titre < 0.6 BU 
Normalized FVII I in vivo recovery, defined as ≥ 66% of expected incremental recovery 
N8-GP half -life ≥ 9 hours after a 72 h treatment-free washout period
Once the inhibitor is confirmed to be negative, FVIII recovery should be measured after an 
injection of 60 U/kg of N8 -GP without washout period. W hen FVIII recovery is shown to be ≥66% 
of the expected incremental recovery, based on PK data obtained in paediatric PTPs, a FVIII half -
life study needs to be conducted after administration of 60 U/kg of N8 -GP after a 72 hour s 
treatment -free washout period. This half -life study should be repeated, if necessary based on 
investigators discretion, until the half -life is confirmed to be ≥ 9 hours. Blood samples for FVIII 
half-life evaluation should be taken pre -dose and 1h, 6h, 24 h, 48 h, and optional 72 h post -dose 
(see Section 8.4.2). If half -life is 9 hours the ITI should continue.
For patients who develop low titre and/or clinically  insignificant inhibitors ( ≤<5 BU), the dose 
level and dosing frequency  of N8 -GP will be decided by  the Investigator based on clinical 
evaluation.  
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 15 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 16of 41
Table 5-1 Intravenous N8- GP treatment
Indication Dosage Frequency
Pre-prophylaxis 
(pt. less than 24 months of age)Approximately 60 U/Kg (50 -75U/Kg) On-demand or slow  start prophylaxis 
(less than weekly dosing more than 
one week between doses )
Prophylaxis –main phase Approximately 60 U/Kg (50 -75U/Kg) Every 3rdday, twice weekly or every 
7thday(±1 day)
Prophylaxis –extension phase Approximately 60 U/Kg (50 -75U/Kg) Every 3rdday, twice weekly, every 4th
day, every 5thday, every 6thday or 
every 7thday(±1 day)
Mild/moderate bleeding episode 20-60 U/Kg On-demand (breakthrough bleeding 
episodes) (site must be contacted if 
more than 2 doses needed)
Severe bleeding episode 40-75 U/Kg
For treatment of severe/life -
threatening bleeding episodes 
administration of higher doses of N8 -
GP is permitted at the investigator’s 
discretion guided by repetitive 
measure ments of trough and 
recoveryOn-demand (site must be contacted)
Minor surgery 40-75 U/Kg In accordance w ith local standard of 
practice of the participating trial site
Major surgery, only allowed after 50 
EDsRecommended doses regimens will 
be provided w hen the N8 -GP surgery 
trials completed In accordance with 
WHF guideline and local standard of 
practice of the participating trial siteOn demand In accordance with WHF 
guideline and local standard of 
practice of the participating trial site
Low titre inhibitor Recommendation 60 U/Kg (50 -75 
U/Kg) for prevention and treatment 
of bleeding episodesDosing interval as needed
High titre inhibitors ITI treatment according to local 
standard. Maximum of 75 U/Kg as 
single dose, maximum of 200 U/Kg 
over 24 hours
Maximum dose/day 200 U/Kg Total maximum dose over 24 hours
…..
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 16 . -  | 3
 |
CONFIDENTIAL
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 17of 41
5.5 Rationale for treatment
…..
The reason for providing the possibility  of ITI of patients who develops high titre inhibitors is to 
permanentl y eradicate the inhibitor, thereb y making it possible for the patient to be treated routinely 
with FVIII replacement therap y….. 
6 Trial population
….
6.2 Trial population
…
4 No prior use of purified factor VIII containing clotting factor products (5 previous exposure 
days to blood components areisacceptable) 
….
6.4 Withdrawal criteria
…
 The patient must be withdrawn if the following applies :
1.Dosed in the trial, but not fulfilling the inclusion and/or exclusion criteria
2.Anaph ylactic reaction to the trial product, for definition see Section 11.1
Major surgery  before 50 EDs, see Section 5.3.4
Significant thromboembolic event, see Section 11.1
Incapacity  or unwillingness to follow trial procedures
Use of coagulatio ns factors other than N8 -GP or anti -coagulants unless in relation to I TI
ITI treatment has not been started within 6 months from the date of confirmation of positive FVIII 
inhibitor (BU ≥ 0.6/ml) unless the FVIII inhibitor has disappeared (BU<0.6) under co ntinuous 
prophylactic treatment within the 6 months.
FVIII inhibitor titre decline from peak level is less than 20% after 12 months of ITI treatment
FVIII inhibitor is positive (BU ≥ 0.6/ml) after 24 months of I TI treatment.
After completed ITI treatment ( maximum 24 months), proph ylaxis treatment as described in the 
protocol is not resumed/started
Positive inhibitor test result from visit 1 before first dosing (a positive sample does not have to be 
confirmed in a confirmatory test)
Participation in another clinical trial throughout the trial.
….
6.6.3 Rationale for withdrawal criteria
Criteria nos. 1 -6 are included to protect the patient's safet y and reliability of the data.
Criteria nos. 7 -1012 are included to ensure appropriate treatment of inhibitor patients.
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 17 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 18of 41
7 Milestones
Planned duration of recruitment period (FPFV –LPFV): approximately  42 months 
Planned FPFV: 26-Jun-2014 01 May  2014
Planned L PFV: 02 October 2020 02 Apr 2018
End of trial is defined as LPLV:  13 November 2021 13 May  2019
The duration of the trial for each individual country  will vary . However, the end of trial will be no 
later than 13 May  2019 13 November 2021
The end of the clinical trial is defined as last visit of the la st patient.
Planned completion of clinical trial report (CTR): November 2019 14 May 2022 .
The duration of N8 -GP treatment in the trial is a minimum total 100EDs for a particular patient. 
Once a patient has achieved 100EDs, they  may  be offered the option to continue in the trial until 
either N8- GP is commercially  available in the relevant country  or until the marketing authorisation 
application for N8 -GP is rejected in the relevant country unless the N8- GP trial, part of the trial or a 
trial site is terminated by  Novo Nordisk or a relevant authority  for any  reason. I n any  event, the 
LPLV for the trial will be no later than 13 November 2021 30 June 2018 whether or not the product 
is commerciall y available in the relevant country. 
8Mathods and assessm ents
…
Fig 8 -1:added to pre -prophy laxis bo x –Visits at: ED 5,10,15,20
…
Screening and enrolment log
….
At screening, patients will be provided with a trial card stating that they  are participating in a trial 
and giving contact address(es) and telephone number(s) of relevant trial site staff. Patient’s 
parent(s)/LAR(s) should be instructed to return the tria l card to the investigator at the last trial visit 
or to destro y the trial card after the last visit. 
Each patient will be assigned a unique 6 -digit number. It must be stated in the medical records that 
the patient is participating in the trial, including the patient number.
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 18 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 19of 41
Informed consent procedure
….
Informed consent for obtaining genot yping must be collected, if applicable. Genotype consent is not 
applicable for Israel.
….
For withdrawn patients
… 
The end of trial form must be completed, and final drug accountabilit y must be performed even if 
the patient is not able to come to the trial site. A withdrawa l session must be made in the IW RS and 
case book must be signed in the eCRF .
…
In general
Review of eDiary  reports, laboratory  reports etc. must be documented either on the front page of the 
documents and/or in the patient’s medical record. 
If considered relevant a caregiver can take over the responsibilities from the parent(s)/LAR(s) of 
handling and administrating the trial drug, filling in the eDiary and attending visits at site. The 
caregiver must be trained equally as the parent(s)/LAR(s) in the relevant responsibilities. Site must 
follow the local law and local guidelines for decision of which task a caregiver can take 
responsibility for.
Site must document correspondence with patient’s parent(s)/LAR(s) concerning returning or 
destruction of trial drug, solvent and injection kits that are to expire or has expired.
….
8.1.1 Visit 0 – screening visit
The patient’s parent(s)/LAR(s) must give signed and dated informed consent prior to any  trial 
related activities. Signing of the informed consent can take place before visit 0, if allowed by local 
law. All patients will be provided with a copy on the patient information and a cop y of the signed 
and dated Informed Consent Form.
….
Pre-prophylaxis treatment
Pre-proph ylaxis is optional and is the period before start of regular proph ylaxis. The pre -
prophylaxis period ends when the patient has reached 20 EDs or has turned 24 months of age, 
whatever comes first, and the patient must begin prophylaxis regimen.
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 19 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 20of 41
During pre -prophy laxis the following dosing regimen applies: 
approximately  60 U/Kg N8-GP within the range of 50-75 U/Kg bw, see Section 5.3
individualised prophy lactic dosing intervals but less frequent than every  7thday(once weekl y)
on-demand treatment of bleeding episodes or minor surgeries
See further Section 5.3.2.
…
8.1.1.2 Prophylaxis treatment
Prophylaxis treatment can begin A patient may  change from pre -prophy laxis to prophy laxis at visit 
1 or at an y time during the pre -prophy laxis period orbutmust be initiated when the patient has 
reached 20 EDs on pre -prophylaxis or has turned 24 months of age, whatever comes first. 
The dosing frequency  during main phase is individualised within the following interval: twice 
weekl y, every 3rdday or every  7thday. Changes to the regimen should be recorded in the IWRS. If 
changes occur between visits, it should be recorded in an unscheduled visit, see Section 8.1.9.
For patient that enter the pr ophy laxis treatement after a period of pre -prophy laxis the next visit in 
the sequence will be determinated by  the numbers of EDs.
…
8.1.2 Visit 1 –first dosing with N8 -GP
V1 will take place after the screening visit (V0) whenever the first treatment of N8 -GP is 
administered, if not already  combined with V0. 
Before the first dose of N8- GP is given as a minimum the inhibitor test must be taken and send to 
central laboratory for analysis. 
…
Assessments for V1 are listed in Table 2-1. In case V0 and V1 have been combined into one visit, 
assessments should only  be performed once, but recorded at both visit in the eCRF .
8.1.3 Visit 2, 3, 4-6 – main phase
The 2 first N8- GP EDs injections must take place at trial site (V1+V2). Hereafter the injections can 
be administered at the trial site or outside the trial site.
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 20 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 21of 41
… 
Visits at ED: 2 (V2), 5 ± 1 ED (V3), 10 ± 2 EDs (V4), 15 ± 2 EDs (V5), 20 ± 2 EDs (V6) . 
….
Reminders
….
Investigator must ensure that patient’s parent(s)/LAR(s) return an y trial medication that would 
expire and avoid use of any expired solvent or injection kit during the next home treatment 
period 
…..
Visit 7-8 – main phase
From V6 or shortly after at ED 20 all patients (including patients previously  on pre -proph ylaxis) 
will be on prophy laxis treatment with N8-GP on twice weekl y, every 3rdday or every  7thday. 
Between the visits the patient will receive N8 -GP treatment at home if comfortable with home 
administrations or at the site, see Section 8.1.12.
Visits at EDs: 30 ± 2 EDs (V7), and 40 ± 2 EDs (V8).
…
Reminders 
….
Drug accountability  of trial product must be recorded in the I WRS, see Section 10
Investigator must ensure that patient’s parent(s)/LAR(s) return any trial medication that would 
expire and avoid use of any expired solvent or injection kit during the next home treatment 
period 
…..
Visit 9 – end of main phase
Visit 9 should take place at either ED 50, ED 51 or ED 52.
Assessments for V9 are listed in Table 2-1.In the extension phase the patient will continue 
prophylaxis with 60 U/Kg in the regimen of every 3rdday, twice weekly, every 4thday, every 5thday, 
every 6thday or every 7thday. See Table 5 -
1. Changes to the regimen should be recorded in the 
eCRF. 
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 21 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 22of 41
Reminders 
….
Drug accountability  of trial product must be recorded in the I WRS, see Section 10
Investigator must ensure that patient’s parent(s)/LAR(s) return any trial medication that would 
expire and avoid use of any expired solvent or injection kit during the next home treatment 
period 
Home treatment training , if the trial site suspects that the patient’s parent(s)/L AR(s) is not full y 
confident with administration and how to deal with safet y related signs and symptoms, see 
Sections 8.5 and 8.6
….
Visit 10-13 – extension phase
…
Visit at EDs: 60 ± 2 EDs (V10) , 70 ± 2 EDs (V11) , 80 ± 2 EDs (V12) , and 90 ± 2 EDs (V13) . 
…
Reminders
…
Drug accountability  of trial product must be recorded in the I WRS, see Section 10
Investigator must ensure that patient’s parent(s)/LAR(s) return any trial medication that would 
expire and avoid use of any expired solve nt or injection kit during the next home treatment 
period 
Home treatment training , see Sections 8.1.12 and 8.8.2.
…
Visit 14 -end of extension phase
….
Reminders 
…
Drug accountability  of trial product must be recorded in the I WRS, see Section 10
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 22 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 23of 41
Investigator must ensure that patient’s parent(s)/LAR(s) return any trial medication that would 
expire and avoid use of any expired solvent or injection kit during the next home treatment 
period 
….
Visit 15- X until end of trial
If N8 -GP is not commerciall y available in a patient’s country at the time of visit 14, the trial period 
may be extended with visits that are scheduled 24 weeks ± 4 weeks. These additional visits are 
referred to as visit 15 to visit X, where X can be any  visit from 16 and onwards. This option for the 
patient to continue in the extension phase of the trial may be offered until either N8 -GP becomes 
commerciall y available in the relevant country , or until the marketing authorisation application is 
rejected in the relevant country  unless the N8 -GP trial, part of the trial or a trial site is terminated by  
Novo Nordisk or a relevant authority  for any  reason. The End of Trial visit must be scheduled 
within 1 month provided alway s that after it has been communicated to site to close the trial the last 
patietn last visit for the prophy laxis period until end of trial butno later than 13 May  2019
November 2021 whether or not the product is commerciall y available in the relevant country  at this 
time. 
At every  dosing visit from V14 V15- VX, drug wil l be dispensed to cover up to 3 months of 
treatment. Depending on patient’s treatment regimen, additional dispensing visits might need to be 
scheduled to cover treatment in the period between visits.
Assessments for V15-VX are listed in Table 2 -1.
Reminders 
An appointment for the next visit should be made
Next visit must be planned to allow for the required wash- out of 72 hours, see Section 8.8.3.1
Recording of body weight, see Section 8.3.1, and dispensing of N8- GP for trial site dosing/home 
treatment must be performed via IWRS, see Section 10
Drug accountability of trial product must be recorded in the IWRS, see Section 10
Investigator must ensure that patient’s parent(s)/LAR(s) return any trial medication that would 
expire and avoid use of any expired solvent or injection kit during the next home treatment 
period 
eDiary compliance review, see Section 12.3
……
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 23 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 24of 41
8.1.10 Unscheduled visit 
…
The following forms can be found in the unscheduled visit in the eCRF:
Central lab
Bleeding episodes
Dosing of N8 -GP
Surgery *
PK session*
Change of regimen
* Surgery and PK session can also be performed during a regular visit but are to be registered 
under unscheduled visits.
8.1.11 ITI Visit 
…
In case of high titre FVIII inhibitor (>5BU) confirmed by  centra l laboratory  the investigator must 
decide how to proceed with treatment. Novo Nordisk will communicate when ITI is allowed in this 
trial, see Section 5.3.6. ITI with N8 -GP must be initiated within 6 months of the confirmatory 
inhibitor test. The used N8 -GPdose and dosing regimen is at the discretion of the investigator but 
should not exceed 75 U/Kg for a single dose, and not exceed a total daily dose of 200 U/Kg. By -
passing agents can be used to treat bleeding episodes.
If ITI is initiated, the patient will follow a visit schedule prescribed b y the investigator and 
according to local standard of practice. Monthl y visits are recommended, and the below listed 
assessments are recommended to be performed:  
….
Bleeding episode evaluation (only if treatment with N8-GP)
…
Reminder
Follow up on an y AEs according to Section 11.2
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 24 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 25of 41
After ITI treatment, when the inhibitor is confirmed to be negative, a FVIII recovery test should be 
performed to confirm the recovery. A dose of 60 U/Kg should be used. Before returning to regular 
prophylaxis treatment a PK session must be performed after a 72 hours treatment -free wash- out 
period, see Section 8.4.2.2 for PK session details.
For patients returning to regular proph ylaxis N8 -GP treatment, the visit schedule is taken up from 
where the patient left the visits according to Table 2-1. The patient must not attend the same visit 
number twice. V9 end of main phase Table 2
-1 even when the corresponding total ED does not 
match.
8.1.12.1 Prophylactic home treatment
…..
The following procedures must be performed during home treatment between visits:
N8-GP administrations according to regimen prescribed b y investigator
Check trial drug, solvent and injection kit fo r expiry date before use
Contact to the investigator/medically  qualified person in case of severe bleeding episodes
Completion of the patient eDiary , including details of all bleeding episodes and N8- GP 
administrations (see Section 8.6)
…..
8.2.1 Concomitant illness and medical history
Aconcomitant illness is any  illness that is present at the start of the trial at the first visit (V0) or 
found as a result of a screening procedure. All concomitant illnesses should be reported including 
disease under investigation.
….
8.2.2 Concomitant medication
A concomi tant medication is any  medication including vaccination, other than the investigational 
medicinal product ( N8-GP), which is taken during the trial until EOT. By-passing agents should 
also be listed as concomitant medication.
….
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 25 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 26of 41
8.3.1 Body measurements
Height at screening
Body weight, wearing light clothing only (Kg)
…
8.3.2 Physical examination
The phy sical examinations will be performed according to local procedure and should include:
…..
Central and peripheral nervous sy stems 
Cardiovascular system
….
8.4 Laboratory assessments
….
Laboratory  results being out of normal range must be categorised as “out of normal range, not 
clinically  significant” or “out of normal range, clinically  significant”. A laboratory  result evaluated 
as “out of normal range, clinically  significant” must be recorded as an AE, or if present at V0 it 
should be recorded as concomitant illness. 
The central laboratories provide results to the trial site in the units preferred by the trial sites while 
the results that are transferr ed to the trial database will always be in SI units.
….
8.4.1.1 FVIII activity 
FVIII activity  will be analy sed at the predefined time point as at a central laboratory  selected by  
Novo Nordisk but the investigator can at an y time during the trial assess FVIII activity at his/her 
discretion. 
Site must be able to analyse for FVIII acti vity and inhibitors locally to ensure immediate results if 
needed to evaluate the patient’s safety.
If V0 and V1 are combined, as one combined screening visit, and if FVIII activity  <1% has not 
been documented in the patient medical records, it should be a nalysed locally  and documented in 
the patient medical records. I n this case the local laboratory  should use their standard FVIII activity  
assay  with the assay  calibrator routinel y used for FVIII activity  anal ysis.
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 26 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 27of 41
A N8 -GP reference standard must be used as assay  calibrator in the FVIII activity  assay  after the 
patient has been dosed with N8 -GP. The reference standard will be provided by  Novo Nordisk 
together with a description of how to the reference standard should be handled handle, stored and 
used.
After the patient has been dosed with N8 -GP, FVIII activity should be measured with an activated 
partial thromboplastin time ( APTT )based one -stage clotting assay calibrated by a N8- GP 
reference standard. The reference standard will be provided by Novo Nordisk together with a 
description of how to handle, store and use. The site must ensure that the reference standard has 
not expired and request a new one when relevant.
Dependent on the type of APTT reagent used by the local lab an exemption from this requiremen t 
can be made, in such cases Novo Nordisk will need to approve the suggested assay on an indiv idual 
basis. For approval of APT T based assays please contact Novo Nordisk. 
If available, FVIII activity may be measured with a chromogenic assay. In such cases a N8 -GP 
reference standard is not needed.
….
8.4.2.1 FVIII activity 
…
FVIII activity  should be measured according to Table 2 -
1.Historical value of FVIII activity can be 
used for inclusion of the patient from any time since the child was born. In relation to visit if an 
activity samples has been taken within ±1 week (for EOT only – 1 week) from the visit and send to 
central lab, this can be used for the visit assessment if the requirements for 72 hours wash out is 
respected.
…
FVIII activity  will be measure d by the use of two different assay s developed and validated for N8
-
GP (except for V0 that will only be analysed in one assay ):
FVIII chromogen assay
FVIII one -stage clotting assay
….
8.4.2.2 Antibody assessments  
…
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 27 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 28of 41
Antibody  assessment should be measured according to Table 2 -1. Antibody samples taken within ±1 
week from the visit (for EOT only –1 week) and send to central lab can be used for the visit 
assessment if the requirements for 72 hours wash out.
N8-GP/FVIII binding antibodies  
……
Samples will be analy sed regularl y for N8 -GP binding antibodies, results will be reported to 
investigators at the end of trial, or whenever considered relevant , and will be included in the CTR.
PEG antibodies
…
Samples will be analy sed for PEG binding antibodies at the end of trial or whenever considered 
relevant.  
FVIII inhibitors 
…
Any sampling for the inhibitor test must be performed at least 4 day s72 hours after last 
administration of N8 -GP to allow for wa sh-out of the drug, unless that patient is known to have 
increased clearance of N8-GP due to the presence of FVIII inhibitors.unless that patient is 
undergoing ITI treatment.
If the result of the inhibitor test is positive, a second confirmatory  inhibitor test should be performed 
by the central laboratory  (except for visit 1 sample that will not need to be confirmed). The 
confirmatory  samples should be collected as soon as possible, but no sooner than 72 hours 4 day s
after the last dose of N8 -GP. S ampling f orassessments of FVIII activity ( trough and recovery ), and
binding antibodies, lupus anticoagulant and PEG antibodies must be performed at the same time. If 
considered relevant a lupus anticoagulant test can be performed. If the result from the lupus 
anticoagulant, the binding antibodies and/or the PEG antibodies analyses are positive we 
recommend the analyses to be repeated regularly.
….
PK assessment (optional)
In the event of a concern about reduced treatment efficacy  in a patient with or without confirmed 
positive test for binding antibodies towards N8 -GP/ or inhibitors an unscheduled visit is 
recommended to canbe scheduled where a PK session may  be performed with a dose of 60 U/Kg to 
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 28 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 29of 41
investigate the elimination ( recovery , clearance and half -life)of N8 -GP. The PK data may  
potentially  be used to adjust the dose or dosing regimen. 
After having completed ITI treatment a PK session must be performed ensuring the N8 -GP half -life 
to be ≥ 9 hours. A dose of 60 U/Kg should be given after a 72 hours trea tment -free wash- out period.
The following time -points for blood sampling for the PK profile are suggested: pre -dose, 30 min (± 
10 min), 1h (± 1030 min), 6h (± 2 hours) , 24h (± 8 hours), 48h (± 8 hours), and optional 72h 96h(± 
8 hours). 
8.4.2.3 HIV testi ng and CD4+ lymphocyte count 
….
Results can be transferred from the medical records if obtained within the last 6 months. 
HIV 1 and 2 antibodies (positive/negative)
….
8.4.2.4 Haematology
Haemoglobin ( mmolg/L )
….
If test results for the above mentioned haematology  parameters are available from within one month 
prior to V0, they  can be used for the V0 haematology  assessment, if older, a new sample must be 
drawn and assessed at the central laboratory . If V1 is more t han a month apart from V0, 
Haematology should be retaken.
Haematology  should be measured according to Table 2 -1.For visit 9, 14 and EOT Haematology 
sample taken within ±1 month (V9 and V14) and -1 month (EOT) and send to central lab can be 
used for the visit assessment . 
8.4.2.5 Biochemistry
….
If test results for the above mentioned biochemistry  parameters are available from within one month 
prior to V0, they  can be used for the V0 biochemistry  assessment, if older, a new sample must be 
drawn and assessed at the central laboratory . If V1 is more than a month apart from V0, 
Biochemistry should be retaken.
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 29 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 30of 41
Biochemistry  should be measured according to Table 2 -1.For visit 9, 14 and EOT Biochemistry 
sample taken within ±1 month (V9 and V14) and -1 month (EOT) and send to central lab can be 
used for the visit assessment . 
8.4.2.6 F8 and HLA genotype testing (not applicable for Israel) 
…..
F8 and HLA genot
ype can be measured an y time from visit 0 to visit 8. 
F8 and HLA genot ype can be measured according to Table 2-1.
….
8.4.2.7 Allergic reaction testing 
Allergic reaction testing will only  be performed in patients developing severe allergic reactions 
related to N8-GP treatment as judged b y the Investigator. The Baseline sample will only be 
analysed for assessment in case of theallergic reactions.
If a severe allergic reaction related to treatment occurs, blood samples should be taken at an 
unscheduled visit as soon as convenient, but andnot later than 2 months after the event. The all ergic 
reaction assessments will be performed at a laboratory  selected by  Novo Nordisk or at a Novo 
Nordisk laboratory . 
Test to be performed : 
N8-GP IgE antibodies
FVIII IgE antibodies
FVIII inhibitors 
N8-GP/FVIII binding antibodies
Optional tests at the discretion of the investigator:
HCP IgE antibodies
HCP IgG antibodies
PEG antibodies
Murine IgG antibodies
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 30 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 31of 41
…
8.4.3 Blood sampling in infants and children
….. 
The total volume of blood to be collected for each patient per visit will not exceed 12.5 10mL. 
…
It is recommended not to attempt venepuncture more than 3 times for the purpose of obtaining 
sufficient blood sampling. Documentation must be available in medical record. The vein used for 
drug injection should not be used for blood sampling until mor e than 30 minutes have passed after 
the injection. The same device use for drug injection may not be used for blood draw post -dose.
…. 
8.4.4 Storage of samples
…. 
All remaining blood samples stored at the central laboratory  will be destroy ed after finalisation of 
the CTR, except for samples for antibod y assessment and other biospecimens, see Section 23.2.
Antibody  samples (samples for binding antibodies and inhibitors) will be stored until drug approval 
by Food and Drug Administration (FDA) and/or European Medicines Agency  (EMA). The retained 
antibody samples may be used for further characterisation for ant ibody responses towards drug if 
required by health authorities or for safety reasons, see Section 23.2.
8.5 N8- GP administration
N8-GP will be administered while the patient is in a comfortable position according to Table 5 -1. 
During ED 1
-2 with treatment at the trial site (V1 -V2):
The first 2 N8- GP doses should be administered at trial site.
Trial injection kits (butterflies etc) will be provided by  Novo Nordisk. Choice ofbetween butterfl y 
or cannula for N8 -GP injections is at the discretion of the inv estigator
The actual time of completion of the injection will be recorded and corresponds to trial time 
point = 0. 
During ED 3-100 and/or until EOT with treatment at trial site and at home (after V2):
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 31 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 32of 41
…
8.6.1 Assessment of bleeding episodes and treatment response
Table 8-1 Haemostatic response for bleeding episode - 4-point scale
8.7 Surgery
Before any surgery is performed blood samples for assessment of inhibitors must be taken and send 
to central lab unless a test has been taken and send to central lab within 30 days (but the results 
does not have to be available before the surgery).
Preventive N8- GP treatment before minor surgery  including placement or removal of central 
venous access port can be performed during within this trial at the investigator’s discretion 
according to local guidelines. A dose of 40 -75 U/Kg N8 -GP prior to minor surgery  is recommended 
to prevent perioperative bleeding episodes, see Table 5 -1. Major surgeries are onl y allowed after 50 
EDs and when the results from the pathfinder™6 (NN7088- 3860) is available . Prior to major 
surgery a dose of maximum 75 U/kg is recommended , see Section 5.3.5.
Preventive N8- GP treatment prior to surgery  should be captured in eCRF or in the eDiary .
Emergency surgeries are allowed in this trial if adequate supply of N8 -GP is available at site to 
ensure haemostasis and wound healing.
Patients undergoing surgery will continue the regular visit schedule, but additional visits may be 
performed in the peri -operative period as decided by the investigator. Surgery will be documented 
as unscheduled visits. It is up to the investigator to decide how long the post -surgery period should 
be and when the patient should resume regular prophylaxis or pre -prophylaxis treatment. All N8 -
GP doses administered in relati on to a surgery must be registered on the surgery from in the eCRF.
8.7.1 Minor surgery
Definition of minor surgery , see Section 5.3.4
For minor surgery  the following should be recorded
Date, time and volume of preventive dose before surgery
Type of surgery
Indication for surgery
Date of surgery
Start time of surgery *
Withdrawal criteria (if other than the trial drug is used)
8.7.1 Data collection during Major surgery
Definition of minor and major surgery , see Section 5.3.5
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 32 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 33of 41
FVIII inhibitor sample should be taken prior to surgery  and anal ysed at the central laboratory .
For major surgery surgeries the following should be recorded in the eCRF:
Date, time and volume of preventive dose before surgery
Type of surgery
Indication for surgery
Date of surger y
Start and stop time of surgery *
Dosing of N8-GP in relation to the surgery
Clinical evaluation of haemostatic response, see Table 8-18-2
Concomitant medication incl. blood products
Adverse events
Clinical narrative of the procedure
Withdrawal criteria (e.g. if other than the trial drug is used)
*Start and stop of surgery is defined as knife -to-skin and last stitch, or similar that seems 
appropriate.
Injections with N8 -GP administered after surgery has been completed should be reported either in 
the eCR F (injections administered at site) or in the eDiary (injections administered at home), see 
Section 12.3
Clinical evaluation of haemostatic response to be evaluated upon completion of the surgical 
procedure by the Surgeon, Anaesthesiologist and/or Investi gator, based on experience as follows:
Table 8–2 Haemostatic response for Surgery 
- 4-point scale
Classification Description
Excellent Better than expected/predicted in this type of procedure 
Good As expected in this type of procedure
Moderate Less than optimal for the type of procedure but haemostatic 
response maintained without change of treatment regimen
None Bleeding due to inadequate therapeutic response with adequate 
dosing, change of regimen required
. 
…
8.8.2 Home treatment training
….
A home treatment guide for the reconstitution and administration process will be available as hands-
out for the patient’s parent(s)/LAR(s). Training in reconstitution and administration must be 
performed until parent(s)/L AR(s) feel comfortable in handling the treatment. The training must be 
documented in the medical records.
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 33 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 34of 41
….
8.8.3 Electronic diary (eDiary)
…
During the home treatment period the patient’s parent(s)/LAR(s) must ensure that all pre -
prophy laxis and prophy lactic home treatment, bleeding episodes, treatment of bleeding episodes as 
well as haemostatic evaluation of the treatment of bleeding episodes are captured in the eDiary . 
The details of bleeding episodes should be entered by the parent(s)/LAR(s) in the eDiary. In case a 
parent(s)/LAR(s) is unable to enter a bleeding episode in the eDiary, or in case the patient is 
hospitalised, the Investigator will report the bleeding episode in the eCRF.
…
8.8.4 Contact between the investigator/medically qualified person and the patient
….
The expiry  date of the drug and solvent that the patient has received should be checked b y the site 
staff before the patient’s next visit to determine if an extra dispensing is relevant and to inform the 
patient of which unused vials to return to the site. Expiry of injection kits should be discussed.
….
9 Trial supplies
9.1 Trial product
….
After reconstitution the appropriate volume of the vials will be drawn into a sy ringe. Maximum 4 
mL can be withdrawn from each vial of reconstituted N8- GP and the content of several vials may be 
combined into one syringe. The content of several vials may  be combined in one sy
ringe. N8-GP 
may not be added to or mixed with any  other material than Sodium Chloride Solution. 
…
Novo Nordisk will not supply  any Non Investig ational Medical Products (NI MPs). 0.9% Sodium 
Chloride Solution for reconstitution of the N8-GP trial product will be supplied by Novo Nordisk .
…
9.3 Storage
….
The trial product N8 -GP powder and Sodium Chloride Solution must be stored in a secure place at 
trial site. For N8- GP under refrigeration at 2 -8°C, and for Sodium Chloride Solvent at 2 -30°C, both 
protected against light and are hereb y stable until the expiry  date given. It is recommended to use 
the reconstituted N8 -GP immediately  following reconst itution. I f not used immediately , the 
reconstituted product can be stored in the vial for up to 4 hours below 30°C. Exposure to direct 
sunlight as well as freezing must be avoided after reconstitution. As for other parenteral 
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 34 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 35of 41
preparations, the product shou ld be inspected visually  for particulate matter and discoloration prior 
to administration and discarded if either is present. In use time starts from completion of the 
reconstitution see the handling instruction for further details.
….
9.4 Drug accountability and destruction
…
Drug accountability  is not required for Sodium Chloride Solution used for reconstitutions, but it is 
the responsibility of the investigator or delegate to follow Sodium Chloride Solution expiry and 
prevent patient use after expiry.
9.5 Auxiliary supply
Auxiliary  supplies are equipment such as needles, sy ringes, butterflies, sterile swabs, vial adaptor 
etc. These will be provided by  Novo Nordisk , if applicable .
11 Adverse events and technical complaints 
11.1 Definitions
……
Definition of an acute, evolving, or recent myocardial infarction:
1.Pathologic findings of an acute m yocardial infarction (i.e., pathologic findings of an acute 
myocardial infarction will be defined when criteria a ) and b )below are fulfilled):
a)Increase in troponin T above the "diagnostic" limit: i.e. > 0.03 µg/L
b)Patients with:
ST-segment elevation: New ST- segment elevation at the J point in two or more contiguous 
leads with the cut -off points >= 0.2mV in leads V1, V2 or V3 and 0,1 mV in other lea ds 
(contiguit y in the frontal plane is defined b y the lead sequence aVL, I inverted aVR, II, 
aVF, III)
……
Clinical criteria for diagnosing anaphylaxis (infants and children only) (Sampson et al. 
200624): 
…
3. Reduced BP after exposure to known allergen for that patient (minutes to several hours):
a.Infants and children: low sy stolic BP (age specific) or greater than 30% decrease in s ystolic 
BPfrom that patient’s baseline * 
b. Adults: sy stolic BP of less than 90 mm Hg or greater than 
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 35 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 36of 41
* 30% decrease from that person’s baseline Low systolic blood pressure for children is defined as 
less than 70 mm Hg from 1 month to 1 year, less than (70 mm Hg + [2x age ]) from 1 to 10 years.
….
11.5 Precautions and/or overdose
As with any  protein injected i.v. hy persensitivity  reactions may  occur. The possible events include 
rash, pruritus, fever, nausea, headache, vomiting and changes in blood pressure. If an y of these 
events are suspected, further N8 -GP administration should be stopped and the patient should receive 
treatment as appropriate according to the hospital practice and guidelines prior to further treatment 
with N8 -GP.
….
11.6.2 Rules for putting the enrolment on hold
A safet y anal ysis will be performed to evaluate the development of inhibitor at the following 
predefined time point:
• after the first 25 patients have reached been to visit 6 ( 20 - 25 exposure day s )
….
12 Case report forms 
….
In addition paper AE forms, safet y information forms and Technical Complaint forms will be 
provided. These must be used when access to the eCRF is revoked or if the eCRF is unavailable .
….
12.2 Case report form flow 
The investigator must ensure that data is recorded in the eCRF as soon as possible, preferabl y 
within 35days after the visit. Once data have been entered, it will be available to Novo Nordisk for 
data verification and validation purposes. 
….
12.3 Electronic diary
Novo Nordisk will provide the patient’s parent(s)/LAR(s) with an eDiary  for electronic recording of 
details of their child’s prophy laxis administration, bleeding episodes, surgery and treatment hereof, 
see Sections 8.1.12.1 and 8.6. The eDiary  and related support services will be supplied by  a vendor 
working under the direction and supervision of Novo Nordisk. 
…..
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 36 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 37of 41
It is the responsibility  of the I nvestigator or delegate to review and thereb y ensure the eDiary data 
quality . Following must be checked as minim um that the eDiary  data is complete, consistent and 
according to the requirements defined in this protocol. Upon review the Investigator or delegated 
staff must document that the review has taken place and an y actions required e.g. retraining of 
patients.
…
13 Monitoring procedures 
During the course of the trial, the monitor will visit the trial site to ensure that the protocol is 
adhered to, that all issues have been recorded, to perform source data verification and to monitor 
drug accountability . 
The firstAmonitoring visit must be performed as soon as possible after FPFV and no longer than 4 
weeks after. The monitoring intervals will depend on the outcome of the remote monitoring of the 
eCRFs, the trial site's recruitment rate and the compliance of t he trial site to the protocol and GCP. 
The intervals between monitoring visits must not exceed 12 weeks whilst patients are in the trial at 
site between V0 and V14. If all patients at site are in the period after V14 ,intervals between 
monitoring visits must not exceed 26 weeks, provided on site contact at least every 12 weeks. .  
….
16 Statistical considerations
Novo Nordisk will be responsible for the statistical analy sis.
If necessary, a statistical analysis plan (SAP) may be written in addition to the protocol, including a 
more technical and detailed elaboration of the statistical analyses. The SAP will be finalised before 
database lock.
The main statistical reporting of the trial will be performed when 50 patients have completed main 
phase (minimum 25 weeks) with at least 50 EDs and completed visit 9. EDs during ITI treatment 
will notcount in the determination of when a patient has reached 50 EDs.
….
16.2 Definition of analysis sets
Descriptions and analy sis of efficacy  data will be based on the Full A nalysis Set (FAS), as defined 
in ICH E9 guidelines.26The FAS includes all patients exposed to N8 -GP. The safet y analysis and 
descrip tions will be based on the Safet y Anal ysis Set (SAS). The SAS will consist of all patients 
exposed to N8-GP.
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 37 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 38of 41
The patients or observations to be excluded, and the reasons for their exclusion must be 
documented and signed by those responsible before database lock. The patients and observations 
excluded from analysis sets, and the reason for this, will be described in the clinical trial report.
….
16.4.2.6 Other assessments
…
FVIII trough level is defined as the activity  recorded immediately  before N8 -GP injec tion, and 
reported as ( IU/mL). IR30min is defined as the peak activity  recorded 30 minutes after the end of N8 -
GP injection, and reported as [ IU/mL ]/[IU/Kg]. I t is calculated by  subtracting the FVIII trough level 
from the FVIII activity  recorded 30 minutes after ended N8 -GP injection, and dividing the 
difference b y the dose injected at time 0 expressed as U/Kg bw.
…
16.6 Sequential safety analysis and safety monitoring
…
after the first 25 patients have reached been to visit 6 ( 20 - 25 exposure days)
….
17 Ethics
…
17.1 Informed Consent
…
The responsibility  for seeking informed consent must remain with the investigator, but the task may  
be delegated b y the investigator to a medically qualified person, in accordance with local 
requirements. The written informed consent including time must be signed and personall y dated b y 
the person who seeks the informed consent before trial -related activity .
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 38 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 39of 41
The informed consent contains a section explaining that Novo Nordisk is asking to store left over 
blood from blood samples and use it to analyse for further analyses within the trial characterising 
biomarkers within the trial. The accept is voluntary and independent on participation in the trial. 
…
20 Critical documents
…
List of IRB/IEC members and/or constitution (or a general assurance number/statement of 
compliance)
….
For local lab parameters the following will be collected:
….
Laboratory  methods (only non- standard assays) and/or analytic methods
…..
21 Responsibilities
…..
The investigator is accountable for the conduct of the trial at his/her trial site. If an y tasks are 
delegated, the investigator must maintain a list of appropriatel y qualified persons to whom he/she 
has delegated specified significant trial -related duties . The investigator must ensure that there is 
adequate training for all staff participating in the conduct of the trial. It is the investigator’s 
responsibility  to supervise the conduct of the trial and to protect the rights, safet y, and well -being of 
the patients. At least investigator must be trained in the protocol at a Novo Nordisk meeting or by 
web training in the protocol provided by Firecrest. It is recommended that all site staff takes the 
Firecrest protocol training.
….
22 Reports and publications
The information obtained during the conduct of this trial is considered confidential, and may  be 
used by  Novo Nordisk for regulatory  purposes and for the general development of the trial product. 
All information supplied by  Novo Nordisk in connection with this trial shall remain the sole 
propert y of Novo Nordisk and is to be considered confidential information. No confidential 
information shall be disclosed to others without prior written consent from Novo Nordisk. Such 
information shall not be used except in the performance of this trial. The information obtained 
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 39 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 40of 41
during this trial may be made available to other phy sicians who are conducting other clinical trials 
with the trial product, if deemed necessary  by Novo Nordisk. Provided that certain conditions are 
fulfilled, Novo Nordisk may grant access to information obtained during this trial to researchers 
who require access for research projects studying the same disease and/or trial product studies in 
this trial.
Novo Nordisk may publish on its clinical trials website a redacted clinical trial report.
…
23 Retention of clinical trial documentation and human biospecimens
23.1 Retention of clinical trial documentation
…
For Japan: The trial site should retain clinical trial documentation until approval, or 3 y ears after 
the date of premature termination or completion of the clinical trial. The sponsor should retain 
clinical trial documentation for 5 years after the approval (in cas e of drug patient to re -examination, 
until re -examination is completed), or 3 years after the date of premature termination or completion 
of the clinical trial.
23.2 Retention of human biospecimens
Storage and disposition of samples anal ysed at local laboratories will be performed according to 
local laboratory  procedures. 
Blood samples apart from antibody and biospecimen samples will be destroyed after the finalisation 
of the CTR. Antibody  and other biospecimen samples (samples for binding antibodies and 
inhibitors) will be stored until drug approval b y Food and Drug Administration (FDA) and/or 
European Medicines Agency  (EMA). All remaining blood samples will be stored until the trai lhas 
been evalua ted b y appropiate authorities or until the project terminates, but no longer than 15 years 
from end of trial. As new biomarkers related to the disease and/or safet y, efficacy, or mechanism of 
action of N8- GP may  evolve during the conduct of the trial, the analyses of the stored biospecimens 
may also include biomarkers that are unknown at present or have not been included in the scientific 
hypotheses at initiation of the trial. The samples will be stored at Novo Nordisk or a Novo Nordisk 
designated referral bio-repository  with access to the samples. Samples might be transferred to other 
countries, if not prohibited by  local regulations. The patient’s identity  will remain confidential and 
samples will only  be marked and identified b y a unique sample ID. No dir ect identification of the 
patient will be stored together with the samples. The anal yses will not have any medical 
consequences for the patients or their relatives. Only  Novo Nordisk staff and bio- repository  
personnel (if applicable) will have access to th e stored bio specimens. 
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 40 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 20 March 2015 Novo Nordisk
Trial ID: NN7088 -3908 Version: 2.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 41of 41
…..
24 Institutional Review Boards/Independent Ethics Committees and regulatory 
authorities
…..
During the trial, the investigator or sponsor, as applicable, must promptly  report the following to the 
IRB/IEC, in accordance with local requirements: updates to IB, unexpected SAEs where a causal 
relationship cannot be ruled out, protocol amendments acco rding to local requirements, deviations 
to the protocol implemented to eliminate immediate hazards to the patients, new information that 
may affect adversel y the safet y of the patients or the conduct of the trial (including new risk/benefit 
analysis in case it will have an impact on the planned follow -up of the patients), annuall y written 
summaries of the trial status, and other documents as required b y the local IRB/IEC.
The investigator must ensure submission of the clinical trial report synopsis to the I RB/IEC (not 
applicable for Japan).
….
25 Indemnity statement
…..
Only applicable for Poland: Novo Nordisk carries liability  for the Study  exclusively  in the scope 
defined b y the applicable laws and in particular b y the Civil Code and the Pharmaceutical La w 
dated 6 September 2001 (uniform version Journal of Laws of 2008 No. 45 item 271 with 
amendments). In order to support potential claims for liability  attributable to the Study , Novo 
Nordisk and Investigator are covered b y the Insurance Policy issued accor ding to applicable Polish 
law’
Only applicable for Portugal: For venous punctures, pain control measures are allowed according 
to local practice.
  Protocol Amendment  2 glob v 23908 NN7088 0  | VV-TMF-1000733
41  of 41 . -  | 3
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 01 November 2016 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 1of 8
Protocol Amendment
no 3
to Protocol, final version 3.0
dated 17April 2015
Trial ID: NN7088 -3908
Safety and Efficacy of turoctocog alfa pegol (N8- GP) in 
Previous Untreated Patients with Haemophilia A
Trial phase: 3a
Applicable to all countries
Amendment originator:
, International Trial Manager
Department: Biopharm, Trial Operations 2
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
  Protocol Amendment  glob v 33908 NN7088 0  | VV-TMF-842582
8  of 1 . -  | 1
 |
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.

Protocol Amendment
CONFIDENTIALDate: 01 November 2016 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 2of 8
Table of Contents   
Page
Table of Contents ..............................................................................................................................................2
Table of Figures ................................................................................................................................................2
Table of Tables ..................................................................................................................................................2
1Introduction including rationale for the protocol amendment .............................................................3
2Changes ......................................................................................................................................................4
4.2.2 Secondary Endpoint .......................................................................................................................4
5.3.6.1 ITI therapy with N8- GP.................................................................................................................4
8.4 Laboratory assessments .................................................................................................................5
8.4.2.2. Antibody assessments ....................................................................................................................5
8.6.1. Assessments of bleeding episodes and treatment responses .............................................................7
13Monitoring procedures ............................................................................................................................7
16 Statistical considerations ........................................................................................................................8
16.4.2.7 Outcome of ITI ..............................................................................................................................8
Table of Figur es   
Page
No table of figures entries found.
Table of Tables   
Page
No table of figures entries found.
  Protocol Amendment  glob v 33908 NN7088 0  | VV-TMF-842582
8  of 2 . -  | 1
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 01 November 2016 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 3of 8
1 Intr oduction including rationale for  the protocol amendment
This protocol amendment has been prepared to include the following changes to the protocol:
Addition of ITI treatment secondary  endpoint in order to assess the outcome of ITI.ITI 
treatment outcome assessment updated and description of the ITI treatment secondary 
endpoint added to the statistical section of the protocol in relation to this. No new blood 
samples will be required as the samples collected for checking criteria for succes sful ITI 
treatment will be used .
Added clarification that the dose of 60 U/kg of N8-GP to be used before taking the samples 
to assess the outcome of ITI is recommended. This provides more flexibility to investigator
if he/she wants to keep the pati ent on a constant dose.
Half life of FVIII changed from 9 h to 6 h after assessment of available data on FV III 
activity  from paediatric trial NN 7088 -3885 using the time points for half life activit y 
calculation provided in the pathfinderTM6 protocol. 
72 h time post -dose sample is equally important to other samples in half -life evaluation, 
therefore, the word optional has been deleted.
Added clarification about categorisation of clinical significance for lab parameters which are 
out of range due to underly ing condition.
Monitor ing of antibody  development against Host Cell Protein (HCP) has been 
added . No 
new blood samples will be required asthe samples collected for the N8- GP binding antibod y 
analysis will be used. The rational efor implementing the HCP an tibody  analysis is based on 
a recommendation from the U.S. Food and Drug Administration (FDA) .
Assessment of severity  of the bleeding episode added into the list of information to be 
collected on the bleeding episode in order to align with all the trials i n NN7088 program. 
Blood sampling for N8-GP binding antibodies at ITI
-visits has been added in order to have 
an overview of inhibitor dynamics in relation to the whole N8-GP binding antibody  
dynamics forITI patient s.
Allowed collection of additional PEG antibodies samples at a scheduled or unscheduled visit 
per investigator’s discretion. The rational is to provide flexibility  to investigator if he/she 
suspects the development of PEG antibodies at any given stage of the trial.
Addition of several data points to be source data verified for screening failures in order to 
comply  with the CDISC format.
In this protocol amendment:
Any new text is written in italics.
Any text deleted from the protocol is written using strike through .
  Protocol Amendment  glob v 33908 NN7088 0  | VV-TMF-842582
8  of 3 . -  | 1
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 01 November 2016 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 4of 8
2Changes
Table 2 –2 Flow chart explanatory descriptions 
9 Blood samples must be collected prior to dosing at dosing visits. Please check that the required washout period has been met 
for inhibitor testing, see section 8.1.1.3 Before any surgeries are performed an inhibitor t est must be taken if this test is more 
than 30 days. HCP antibodies will be analysed using samples taken for the N8 -GP binding antibodies at the time points 
described in section8.4.2.2.
4.2.2 Secondary Endpoint
Frequency  of Adverse events (AEs) including serious AEs and Medical Events of Special Interest 
(MESI).* 
Incidence of confirmed high titre inhibitors (defined as inhibitor titre > 5BU)*
Number of breakthrough bleeding episodes during prophy laxis with N8-GP(annualised bleeding 
rate).*
Haemostatic effect of N8-GP in treatment of bleeding episodes, assessed by a predefined 4-point 
haemostatic response scale (“excellent”, “good”, “moderate” and “none”).*
Consumption of N8 -GP for proph ylaxis (number of injectio ns and U/Kg per month and per year)
Consumption of N8 -GP for treatment of bleeding episodes (number of injections and U/Kg required 
per bleeding episode)
Total consumption of N8 -GP per patient (prevention and treatment of bleeding episodes) per month 
and annualised value
Outcome of ITI,  assessed by a predefined 4-point ITI outcome scale (“success”, “partial success”, 
“failure” , “other” )
5.3.6.1 ITI therapy with N8 -GP
…
Criteria for successful assessing the outcome of ITI therap y with N8 -GP: 
Success: in line with international consensus13, and based on the mean N8-GP half-life observed in 
adults (18.5h) and children < 6 years of age (15h), successful N8-GP ITI outcome is based on the 
achievement of three stringent efficacy  criteria
Undetectable inhibitor titre < 0.6 BU 
Normalized FVIII in vivo recovery , defined as ≥ 66% of expected incremental recovery  
N8-GP half- life ≥ 96hours after a 72 h treatment -free washout period
Partial success: 
Reduction in inhibitor titre to ≤ 5 BU 
Clinical effect of N8-GP therapy as judged by the investigator
  Protocol Amendment  glob v 33908 NN7088 0  | VV-TMF-842582
8  of 4 . -  | 1
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 01 November 2016 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 5of 8
Failure: 
Failure to attain defined success or partial success within 24 months of uninterrupted ITI 
with N8 -GP
Inhibitor decrease <20% after one year of ITI treatment
Other:
Not fulfilling above criteria, e.g. early withdrawal from ITI treatment etc.
Once the inhibitor is confirmed to be negative, FVIII recovery  should be measured after an injection 
of recommended 60 U/kg of N8-GP without washout period. When FVIII recovery  is shown to be 
≥66% of the expected incremental recovery , based on PK data obtained in paediatric PTPs, a FVIII 
half-life study  needs to be conducted after administration of recommended 60 U/kg of N8-GP after 
a 72 hours treatment- free washout period. This half -life study  should be repeated, i f necessary  based 
on investigators discretion, until the half -life is confirmed to be ≥ 6hours. Blood samples for FVIII 
half-life evaluation should be taken pre-dose and 1h, 6h, 24 h, 48 h, and optional 72 h post-dose 
(see Sec tion 8.4.2.2). If half -life is < 96hours the ITI therapy should continue.
…
8.4 Laboratory assessments
…
Laboratory  results being out of normal range must be categorised as “out of normal range, not 
clinically  significant” or “out of normal range, clinically  significant”. A laboratory  result evaluated 
as “out of normal range, clinically  significant” must be recorded as an AE, or if present at V0 it 
should be recorded as concomitant illness. Categorisation of clinical significance for out of range 
results may not be required for the following laboratory parameters (parts of the underlying 
disorder) and the investigator is therefore not required to perform a categorisation even though 
these parameters are listed in the laboratory report: e.g. FVIII activity, FVIII inhibitors, binding 
FVIII antibodies, PEG antibodies, HCP antibodies and genotype testing including HLA. 
The central laboratories provide results to the trial site in the units preferred by the trial sites while 
the results that are transferred to the trial database will alway s be in SI units.
…
8.4.2.2. Antibody assessments  
The analysis will be performed at a laboratory  selected by Novo Nordisk or at a Novo Nordisk 
laboratory . The procedures for analyses will follow the recommendations provided by Novo 
Nordisk. A description of the method will be included in the final report of this trial.
  Protocol Amendment  glob v 33908 NN7088 0  | VV-TMF-842582
8  of 5 . -  | 1
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 01 November 2016 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 6of 8
Plasma sa mples will be collected for assessment of:
N8-GP/FVIII binding antibodies
Host Cell Protein (HCP) antibodies 
PEG antibodies
FVIII inhibitor 
Antibody  assessment should be measured according to Table 2–1 5-1. Antibody  samples taken 
within ±1 week from the visit (for EOT only – 1 week) and send to central lab can be used for the 
visit assessment if the requirements for 72 hours wash out.
…
HCP antibodies
A selection of the samples collected for the N8 -GP/FVIII binding antibody analysis will be analysed 
for HCP antibodies. HCP are small pieces of protein remaining from the synthesis of recombinant 
FVIII in CHO cells. These proteins are removed during the purification, however very small 
amounts may be present in the drug product and could potentially cause an immune response. This 
analysis will be performed depending on the amount of sample available. 
The analysis of HCP antibodies is planned to include samples taken at the following time points: 
pre-dose prior to first N8- GP exposure and hereafter approximately every 6 months until the visit 9, 
hereafter every 12 months. 
If deemed necessary more samples may be analysed to fully characterise the individual patient’s 
HCP antibody profile.
PEG antibodies
Screening for PEG antibodies is based on assays that are validated according to international 
recognised guidelines.19-21Samples measured above the assay  cut-point will be subject to a 
confirmation test.
PEG antibodies should be measured according to Table 2–1 
and if required, investigator may take 
additional PEG -antibodies samples at other visits. Samples will be analy sed for PEG binding 
antibodies at the end of trial or whenever considered relevant.  
  Protocol Amendment  glob v 33908 NN7088 0  | VV-TMF-842582
8  of 6 . -  | 1
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 01 November 2016 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 7of 8
8.6.1 . Assessments of bleeding episodes and treatment responses
…
Bleeding Episode – information to be collected
Information about bleeding episodes prior to the 2 ED (V2) should always be recorded in eCRF . In 
case the patient is treated outside the trial site the trial site should be informed in case of a bleeding 
episode and the details hereof. After 2 EDs bleeding episodes must be recorded either in the eDiary  
(if treated at home) or in the eCRF (if trea ted at the trial site), see Section 12.3.
Date and time the bleeding episode started
Date and time the bleeding episode stopped
Cause of the bleeding episode
i.e. spontaneous, traumatic or due to surgery
Anatomical location of bleeding episodes
Severity of the ble eding episode, assessed by the i nvestigator as defined in 8.6.1
Amount, and time of each dose of N8 -GP
Haemostatic response assessed b y the 4 -point scale defined in Table 8 –1
…
13 Monitoring procedures 
…
A monitoring visit must be performed as soon as possible after FPFV and no longer than 4 weeks 
after. The monitoring intervals will depend on the outcome of the remote monitoring of the eCRFs, 
the trial site's recruitment rate and the compliance of the trial site to the protocol and GCP. The 
intervals between monitoring visits must not exceed 12 weeks whilst patients are in the trial at site 
between V0 and V14. If all patients at site are in the period after V14, intervals between monitoring 
visits must not exceed 26 weeks, provided on site contact at least every  12 weeks.
…
For screening failures: Data for the screening visit must be entered in the eCRF within preferabl y 3 
days after data are available and the Screening Failure Form must be completed. Sourc e data 
verification is not required except for informed consent, date of visit, demographics (sex, date of 
  Protocol Amendment  glob v 33908 NN7088 0  | VV-TMF-842582
8  of 7 . -  | 1
 |
CONFIDENTIAL
Protocol Amendment
CONFIDENTIALDate: 01 November 2016 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148 -1897 Status: Final
EudraCT No.: 2013 -004025 -88 Page: 8of 8
birth and race), violated inclusion/exclusion criteria, screening failure form reason for screening 
failure and fordata relating to any AEs if applicable. All data entered in the eCRF will be 
transferred into the trial database.
…
16 Statistical considerations
……
Patients initiating I TI treatment will for the statistical anal yses be considered like withdrawals and 
data collected during ITI treatment p eriod will be summarised and reported separately . Evaluation 
of these data will be considered exploratory  only. 
If necessary , a statistical anal ysis plan (SAP) may  be written in addition to the protocol, including a 
more technical and detailed elaboration of the statistical anal yses. If created, the SAP will be 
finalised 
16.4.2.7 Outcome of ITI
Outcome of ITI,  assessed by a predefined 4 -point ITI outcome scale (“success”, “partial success”, 
“failure”, “other”), for patient(s) who undergo ITI treatment during the trial, will be summarised.
  Protocol Amendment  glob v 33908 NN7088 0  | VV-TMF-842582
8  of 8 . -  | 1
 |
CONFIDENTIAL
Protocol Amendment no 4  
CONFIDENTIAL  Date:  14 June 2018Novo Nordisk  
Trial ID: NN7088 -3908  Version:  1.0
UTN: U1111 -1148 -1897  Status:  Final  
EudraCT No.: 2013 -004025 -88 Page:  1 of 5 
Protocol Amendment  
no 4 
to Protocol, version 4 
dated 01-November -2016  
Trial ID:  NN7088 -3908  
Safety and Efficacy of turoctocog alfa pegol (N8 -GP) in  
Previously Untreated Patients with Haemophilia A  
Trial phase: 3a 
Applicable to Israel  
Amendment originator: 
, Clinical Trial s Manager  
Department: Haemophilia, Clinical Operations NN IL  
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.  
IL  Protocol Amendment  4 local il3908 NN7088 0  | VV-TMF-906955
5  of 1 . -  | 1
 |
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.

Protocol Amendment no 4  
CONFIDENTIAL  Date:  14 June 2018  Novo Nordisk  
Trial ID: NN7088 -3908  Version:  1.0 
UTN: U1111 -1148 -1897  Status:  Final  
EudraCT No.: 2013 -004025 -88 Page:  2 of 5 
 
  
 
Table of Contents     
  
 
Table of  Contents............................................................................................................................................2 
1 Introduction including rationale for the protocol amendment ............................................................. 3 
2 Chan
ges ...................................................................................................................................................... 3 
Table of
 contents ............................................................................................................................................... 3 
Table 2–2  Flow chart explanatory descriptions ........................................................................ 3 
 
 
IL  Protocol Amendment  4 local il3908 NN7088 0  | VV-TMF-906955
5  of 2 . -  | 1
 |
CONFIDENTIAL
Protocol Amendment no 4  
CONFIDENTIAL  Date:  14 June 2018  Novo Nordisk  
Trial ID: NN7088 -3908  Version:  1.0 
UTN: U1111 -1148 -1897  Status:  Final  
EudraCT No.: 2013 -004025 -88 Page:  3 of 5 
 
 1 Introduction including rationale for the protocol amendment  
Patients with congenital haemophilia A have a mutation in coagulation Factor 8 (F8) gene. The 
different types of mutations in the F8 gene are associated with different probabilities for 
development of inhibitors. Inhibitors are antibodies that neutralises the factor VIII activity thereby 
rendering treatment with replacement factor products, such as N8-GP, difficult.    
 
Israel was excluded from F8 and HLA genotype testing however, since the incidence of FVIII 
inhibitors is
 the primary endpoint of the trial and certain mutations are related to very high inhibitor 
rates, the mutation composition of the trial population is pivotal for the understanding of the 
immunogenicity.  
 
With the current protocol amendment Novo Nordisk is seeking permission to obtain the F8 
genot
ype from the patients in Israel, if already available. If not available or if it needs to be re-
tested, based on the inve
stigators discretion, F8 and HLA genotype testing will be offered. 
 
The results will be part of the clinical data analysis and reporting and used for trial specific 
purposes only. All information will be kept confidential. 
 
 
In this protocol amendment: 
 Any new text is written in italics.  
 Any text deleted from the protocol is written using strike through. 
 
2 Changes  
Table of contents 
8.4.2.6  F8 and HLA genotype testing (not applicable for Israel) ....................64 
 
Table 2–2  Flow chart explanatory descriptions 
Footer 12.  F8 and HLA genotype sample is only allowed upon patient’s parent(s)/LAR(s) signing 
the consent for genotyping and should only be done if not already documented in patient’s medical 
record. The sample can be collected at any visit between V0 and V8, taking the limitation of the 
allowed blood sampling volume into account. Genotype is not applicable for Israel 
  
IL  Protocol Amendment  4 local il3908 NN7088 0  | VV-TMF-906955
5  of 3 . -  | 1
 |
CONFIDENTIAL
Protocol Amendment no 4  
CONFIDENTIAL  Date:  14 June 2018  Novo Nordisk  
Trial ID: NN7088 -3908  Version:  1.0 
UTN: U1111 -1148 -1897  Status:  Final  
EudraCT No.: 2013 -004025 -88 Page:  4 of 5 
 
  
8.1 Visit procedures 
Inform
ed consent procedure 
The patient’s parent(s)/LAR(s) will be provided with full written and verbal information about the 
trial prior to conduct of any trial-related procedures/activities, in accordance with GCP and local 
requirements, see Section 17.1. 
A child assent form will be provided to patients above 3 years of age according to local 
requirements. This can be performed on a separate day. As this is a long term trial the investigator 
should check the progressing maturation of the child and its ability to assent throughout the trial. 
Informed consent for obtaining genotyping must be collected, if applicable. Genotype consent is not 
applicable for Israel. 
 
8.4.2.6  F8 and HLA  genotype testing (not applicable for Israel) 
At Visit 0, aAll patient’s parent(s)/LAR(s) will be asked about documentation of previous Factor 
VIII gene (F8) and Human Leucocyte Antigen (HLA) genotype tests. If not available or if it needs 
to be re-tested, based on the investigators discretion, F8 and HLA genotype testing will be offered if 
allowed a
ccording to local law. The F8 and HLA genotype analysis will be performed at a  
laboratory selected by Novo Nordisk, using DNA isolated from leucocytes from the patient’s blood. 
No analysis will be performed concerning other genes than F8 and HLA. Samples will be disposed 
appropriately after the test and all test results are kept confidential. 
Investigator and/or patient’s parent(s)/LAR(s) have the right to refuse to provide patient’s F8 and 
HLA genotype documentation or to refuse genotyping. This will not prevent the patient from 
participating in the trial. 
F8 and HLA genotype can be measured any time from visit 0 to visit 8 during the trial . 
Applicable for Japan only: If documentation of the patient´s genotype already exists, the patient is 
offere
d to provide his data for the trial. If no previous data exists and genotyping consent is 
obtained, FVIII and HLA genotype analysis is performed at the laboratory in Bonn, Germany, using 
DNA isolated from leucocytes from the patient’s blood. No analysis will be performed concerning 
other genes than F8 and HLA. Samples will be disposed appropriately after the test and all test 
results are kept confidential. 
Applicable for Israel only: No genotype testing or genotype information will be collected. 
 
16.7  Reporting of F8 and HLA genotype 
Information about unde
rlying gene defects of F8 and HLA will be listed in the clinical trial report, 
except for Israel. No statistical analysis will be performed. 
 
IL  Protocol Amendment  4 local il3908 NN7088 0  | VV-TMF-906955
5  of 4 . -  | 1
 |
CONFIDENTIAL
Protocol Amendment no 4  
CONFIDENTIAL  Date:  14 June 2018  Novo Nordisk  
Trial ID: NN7088 -3908  Version:  1.0 
UTN: U1111 -1148 -1897  Status:  Final  
EudraCT No.: 2013 -004025 -88 Page:  5 of 5 
 
 17.1  Informed consent 
F8 and HLA genotype testing/collection of previous genotype documentation (not applicable 
for Israel): 
 
Genotype testing is offered to the patients participating in this trial. If documentation of the 
patients’ genotype already exists, the patient and/or the patient’s parent(s)/LAR(s) must give their 
consent befor
e the data can be collected for trial purpose. Prior to any trial-related activity, the 
investigator must provide the patient’s parent(s)/LAR(s) with the possibility to abstain from the 
genetic testing/collection of previous documentation, but still be able to participate in the trial. 
Only the F8 and HLA genotype will be analysed by the central laboratory selected by Novo Nordisk 
and no other genomic analyses will be carried out. Samples will be appropriately disposed of, after 
the test. All test results are kept strictly confidential in sufficient consideration of individual 
information. 
IL  Protocol Amendment  4 local il3908 NN7088 0  | VV-TMF-906955
5  of 5 . -  | 1
 |
CONFIDENTIAL
Protocol Amendment no 5
CONFIDENTIALDate: 13 June 2019 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
Status: Final
Page: 1of 5
Protocol Amendment
no 5
to Protocol, version 4
dated 01November 2016
Trial ID: NN7088 -3908
Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Previously Untreated Patients with 
Haemophilia A
Trial phase: 3a
Applicable to all countries
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
  Protocol Amendment  5 glob3908 NN7088 0  | VV-TMF-821486
5  of 1 . -  | 1
 |
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol Amendment no 5
CONFIDENTIALDate: 13 June 2019 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
Status: Final
Page: 2of 5
Table of Contents   
1Introduction including rationale for the protocol amendment ...........................................................3
2Changes ................................................................................................................................................4
  Protocol Amendment  5 glob3908 NN7088 0  | VV-TMF-821486
5  of 2 . -  | 1
 |
CONFIDENTIAL
Protocol Amendment no 5
CONFIDENTIALDate: 13 June 2019 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
Status: Final
Page: 3of 5
1Introduction including rationale for the protocol amendment
The tri al has been on -going since 2013 ,and a per protocol interim analysis is planned to eval uate 
safet y and efficacy when 50 pati ents have reached 50 exp osure day saccording to the previous 
versio n of the EMA Guideline on the clinical investigat ion of recombinant and human plasma -
derived factor VIII products (2011) . The target of 50 patients with 50 exposure days with the 
present recruit ment rate isestimated to be 2021.
Recrui tment is extrem ely difficult in Previously  Untreated Pati ents (PUPs) and the risk o f 
developing neutralising ant ibodies is high . The concurrent development of many therapeutic 
products for hemophilia treatment decreases the availabilit y of previ ously untreated patients for 
clinical trial s, suggesting that informative studies performed in a meaningful number of PUPs will 
not be feasible in a timely  manner. Therefore, formal PUP studies are not required according to the 
updated EMA guideline (2018). 
However, this trial was established prior to the new stance from EMA, which now does not stipulate 
the need for PUP trials. Given that th e original  target will delay retri eval of data, i t has been decided 
to incorporate an interim data analysis toprovide valuable informat ion within this sub -populati on in 
a more timely  manner as every PUP shoul d be closely monitored with regards to treatmen t 
perform ance and inhibitor development.
The following minor clarificat ions to protocol text have been made :
The weighing intervals and the visit windows of the protocol have been aligned. A weight, 
which ismeasured up to 12 weeks before a visit can be used for tri al product dispending in 
children more than 3 y ears of age as well as for all children after visit 15 (table 2.2 a nd 
section 8.3.1) .
During the clinical development programme it was demonstrated that the specific 
chromogenic assay set -up emplo yed with NHP as calibrator over
-estimated plasma FVIII 
activit y and the one -stage clotting assay in the applied setup under -estimated the activit yof 
N8-GP when using NHP as calibrator due to PEG interference with the aPTT reagent. 
Categorisat ion of clinical significance for out of range lab parameters due to underlying 
condi tionremoved in order to make categorisat ion equal for all laboratory resu lts.
Administrative changes ,including incorporation of previously approved local amendments .
In thi s protocol  amendment:
Any new text is written in italics.
Any text deleted from the protocol is written using strike through.
  Protocol Amendment  5 glob3908 NN7088 0  | VV-TMF-821486
5  of 3 . -  | 1
 |
CONFIDENTIAL
Protocol Amendment no 5
CONFIDENTIALDate: 13 June 2019 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
Status: Final
Page: 4of 5
2Changes
Sections 1, 5.1, and 16: 
Due to the extended time frame of the trial related to slow  recruitment rate from the available PUP 
population, an interim analysis w ill be performed to retrieve safety data.
Table 2 -2:
The frequency of body  weight m easurements sh ould fo llow local pract ice, but should at least be 
measured every 10 weeks in children ≥3 years of age and within a timeframe of 6 weeks in children 
<3 years of age. For practical purposes, when dispensing trial drug after V15, the body w eight from 
an earl ier measurement (or visit) can be used for all age groups if the measurement was performed 
within the previous 12 weeks .Please refer to Section 8.3.1
Section 8.3.1:
Body  weight shoul d be measured in connect ion with regularly visit where trial drug is dispensed. 
For practi cal purposes when dispensing trial drug the weight from an earlier measurement (or visit) 
can be used if the measurement was performed within the pre vious 10 weeks (in children <3 years 
of age, wi thin 6 weeks). If new body  weight is not needed to be measured at a visit, the body  weight 
from last weighing should be used. After visit 15, a body w eight measured within the previous 12 
weeks for all age gro ups can be used.
8.4. Laboratory assessments
…Laboratory  resul ts being out of norm al range m ust be categori sed as “out of normal range, not 
clinically significant” or “out of normal range, clinically significant”. A laboratory  resul t evaluated 
as “out of n ormal  range, clinically  significant” m ust be recorded as an AE, or if present at V0 it 
shoul d be recorded as concomitant illness. Categorisati on of  clinical significance for out of range 
resul ts may not be required for the following laboratory  param eters ( parts of the underlying 
disorder) and the invest igator is therefore not required to perform a categorisation even though these 
param eters are listed in the laboratory  report: e.g. FVIII activit y, FVIII inhibitors, binding FVIII 
antibodies, PEG antibodies, HCP ant ibodies and genotype testing including HLA. …
8.4.1.1 FVIII activity
After the patient has been dosed with N8 -GP, FVIII activit y shoul d be m easured wi th a qualified an
APTT based one-stage cl otting assay or chromogenic assay, w hich means that some a ssays may use
calibrated by  anN8-GP reference standard for calibration . The N8-GPreference standard will be 
provi ded by Novo Nordisk ,together wi th a descri ption of  how to handle, store and use. The site 
must ensure that the reference standard has not expired and request a new one when relevant.
  Protocol Amendment  5 glob3908 NN7088 0  | VV-TMF-821486
5  of 4 . -  | 1
 |
CONFIDENTIAL
Protocol Amendment no 5
CONFIDENTIALDate: 13 June 2019 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
Status: Final
Page: 5of 5
Dependent on the ty pe of aPTT reagent used in the one- stage clotting assay ,by the local lab an 
exempt ion from this requi rement can be made . In such cases Novo Nordisk will need to approve the 
suggested assay on an individual basis. For approval of aPPT based assays please contact Novo 
Nordi sk. 
8.4.2.1 FVIII activity
In each assay both an N8 -GP reference standard and a human plasma standard calibrated against the 
WHO international FVIII standard are used as assay calibrators. 
16.5 Interim reporting
An interim efficacy and safety evaluation is planned w hen approximately 50 patients have reached 
25 exposure days. The data w ill be presented for separately for the main phase and extension as 
well as combined.
  Protocol Amendment  5 glob3908 NN7088 0  | VV-TMF-821486
5  of 5 . -  | 1
 |
CONFIDENTIAL
Protocol Amendment no 6
CONFIDENTIALDate: 21 June 2019 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
Status: Final
Page: 1of 4
Protocol Amendment
no 6
to Protocol, version 5
dated 13June 2019
Trial ID: NN7088 -3908
Safety and Efficacy of turoctocog alfa pegol (N8 -GP) in Previously Untreated Patients with 
Haemophilia A
Trial phase: 3a
Applicable to Israel
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
IL  Protocol Amendment  6 il3908 NN7088 0  | VV-TMF-1123968
4  of 1 . -  | 2
 |
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol Amendment no 6
CONFIDENTIALDate: 21 June 2019 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
Status: Final
Page: 2of 4
Table of Contents   
1Introduction including rationale for the protocol amendment ...........................................................3
2Changes ................................................................................................................................................3
IL  Protocol Amendment  6 il3908 NN7088 0  | VV-TMF-1123968
4  of 2 . -  | 2
 |
CONFIDENTIAL
Protocol Amendment no 6
CONFIDENTIALDate: 21 June 2019 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
Status: Final
Page: 3of 4
1Introduction including rationale for the protocol amendment
Patients wi th congeni tal haemophilia A have a mutati on in coagul ation Factor VIII (F8) gene. The 
different ty pes of  mutations in the F8 gene are associated with different probabilit ies for 
development of inhibitors. Inhibitors are antibodies that reduce or eliminate the activit y of Factor 
VIII proteins thereby rendering treatment with replacement factor products, such as N8 -GP, 
difficult.
Patients fro m Israel were excluded from  the F8 and Human Leucocy te Ant igen (HLA) genotype 
testing in the previ ousversi onsof protocol . However, since the incidence of Factor VIII inhibitors 
is the primary  endpoint of the tri al and certain mutations are related to very  high inhibitor rates, the 
mutati on com position of  the tri al populati on is pivotal  for the understanding of the immunogenicit y.
Protocol  Amendment no 4 version 1.0 dated 14 June 2018 (applicable only  for Israel ), which has 
recent ly been approved by  the Heal th Authorit ies in Israel introduced F8 and HLA genoty pe testing 
for all patients going forward. Protocol Amendment no 4 versio n 1.0 dated 14 June 2018 was 
incorporated in protocol versio n 5 dated 13 June 2019.
With the current protocol amendment Novo Nordisk is seeking permission to obtain the F8 and 
HLA genoty pe testing results from withdrawn pat ients if already available in documentation .
The results will be part of the clinical data analysis and reporting and used for trial specific 
purposes only. All inf ormation will be kept confident ial.
In thi s protocol  amendment:
Any new text is written in italics.
Any text deleted from the protocol is written using strike through.
2Changes
17.1 Informed consent
F8 and HLA genotype testing/collection of previous genotype documentation:
Genoty pe testing is offered to the patients participating in this trial. If documentation of the
patients’ genoty pe al ready exists, the patient and/or the patient’s parent(s)/LAR(s) must give their
consent before the data can be collected for trial purpose. Prior to any  trial-related activit y, the
investigator must provide the patient’s parent(s)/LAR(s) with the possibilit y to abstain from  the
genet ic testing/co llection of previous documentation, but still be able to participate i n the tri al.
Only the F8 and HLA genoty pe will  be analysed by  the central  laboratory  selected by  Novo Nordi sk
IL  Protocol Amendment  6 il3908 NN7088 0  | VV-TMF-1123968
4  of 3 . -  | 2
 |
CONFIDENTIAL
Protocol Amendment no 6
CONFIDENTIALDate: 21 June 2019 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
Status: Final
Page: 4of 4
and no other genomic analyses will be carried out. Samples will be appropriately disposed of, after
the test. All test results are kept strict ly confidential in sufficient consideration of individual
inform ation.
Only applicable for Israel: The parent(s)/LAR(s) of w ithdrawn trial patients w ill be approached for 
consent to obtaining the F8 and HLA genotype testing results if already available in do cumentation .
IL  Protocol Amendment  6 il3908 NN7088 0  | VV-TMF-1123968
4  of 4 . -  | 2
 |
CONFIDENTIAL
Protocol Amendment no 7
CONFIDENTIALDate: 02 July  2019 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148-1897 Status: Final
EudraCT No.: 2013- 004025 -88 Page: 1of 3
Protocol Amendment
no 7
to Protocol, version 4.0
dated 01Nov 2016
Trial ID: NN7088 -3908
Safety and Efficacy of turoctocog alfa pegol (N8 -GP) in
Previously Untreated Patients with Haem ophilia A
Trial phase: 3a
Applicable to Japan
Amendment originator:
, Trial Manager, Clinical Operat ions, CMR, Japan
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
JP  Protocol Amendment  7 jp3908 NN7088 0  | VV-TMF-965747
3  of 1 . -  | 1
 |
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.

Protocol Amendment no 7
CONFIDENTIALDate: 02 July  2019 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148-1897 Status: Final
EudraCT No.: 2013- 004025 -88 Page: 2of 3
Table of Contents   
1Introduction including rationale for the protocol amendment ...........................................................3
2Changes ................................................................................................................................................3
JP  Protocol Amendment  7 jp3908 NN7088 0  | VV-TMF-965747
3  of 2 . -  | 1
 |
CONFIDENTIAL
Protocol Amendment no 7
CONFIDENTIALDate: 02 July  2019 Novo Nordisk
Trial ID: NN7088 -3908 Version: 1.0
UTN: U1111 -1148-1897 Status: Final
EudraCT No.: 2013- 004025 -88 Page: 3of 3
1Introduction including rationale for the protocol amendment
In accordance with Japanese regulat ions, the regulatory  category  of this clinical tri al has been 
updated and the assessment of expectedness clarified.
In thi s protocol  amendment:
Any new text is written in italics.
Any text deleted from the protocol is written using strike through.
2Changes
5.1   Ty pe of tri al
…
The tri al design is based on the guideline on clinical invest igation of recombinant and human 
plasma -derived factor VIII products developed by CHMP in EU.9
For Japan only: The NN7 088-3908 trial w ill be classified as a post- marketing clinical trial if 
obtaining marketing approval in Japan. Therefore, the term ‘chiken’, w hich is a term for a clinical 
trial conducted for getting marketing approval, is replaced in the protocol and other relate d 
materials/documents w ith the term ‘post -marketing clinical trial.’
…
11.2   Reporting of adverse events
…
All AEs, ei ther observed by  the invest igator or reported by the patient, must be reported by the 
investigator and evaluated. Novo Nordisk assessmen t of expectedness is performed according to the 
following reference documents: invest igator’s brochure,7N8-GP, current version and any updates 
thereto.
For Japan only: If obtaining marketing approval in Japan, sponsor’s assessment of expectedness is 
done according to the package insert of the commercial products in Japan.
…
JP  Protocol Amendment  7 jp3908 NN7088 0  | VV-TMF-965747
3  of 3 . -  | 1
 |
CONFIDENTIAL
Protocol Amendment no 8  
CONFIDENTIAL  Date:  15 June 2020  Novo Nordisk  
Trial ID: NN7088 -3908  Version:  1 
UTN: U1111 -1148 -1897  Status:  Final  
EudraCT no.: 2013 -004025 -88 Page:  1 of 10 
Protocol Amendment  
no 8 
to Protocol, version 1.0 
dated 04 November 2013  
Final Protocol version 1.0 (04 -Nov-2013) in cluding : 
Amendment no . 1, version 0.1, Portugal (30 -Jul-2014)  
Amendment no. 2, version 2.0 (20 -Mar-2015 ) 
Amendment no. 3, version 1.0 (01 -Nov-2016 ) 
Amendment no. 4, version 1.0 , Israel (14 -Jun-2018)  
Amendment no. 5, version 1.0 (13 -Jun-2019)  
Amendment no. 6, version 1.0, Israel (21 -Jun-2019)  
Amendment no. 7, version 1.0, Japan (02 -Jul-2019) 
Trial ID:  NN7088 -3908  
Safety and Efficacy of turoctocog alfa pegol (N8 -GP) in Previously Untreated Patients with  
Haemophilia A  
Trial phase: 3a  
Applicable to all countries  
 
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.  
  Protocol Amendment  Global no. 83908 NN7088 0  | VV-TMF-1418665
10  of 1 . -  | 1
 |
CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed w ithout prior w ritten approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol Amendment no 8  
CONFIDENTIAL  Date:  15 June 2020  Novo Nordisk  
Trial ID: NN7088 -3908  Version:  1 
UTN: U1111 -1148 -1897  Status:  Final  
EudraCT no.: 2013 -004025 -88 Page:  2 of 10 
Table of Contents    
1 Introduction including rationale for the protocol amendment ............................................................. 3 
2 Changes ...................................................................................................................................................... 4 
  Protocol Amendment  Global no. 83908 NN7088 0  | VV-TMF-1418665
10  of 2 . -  | 1
 |
CONFIDENTIAL
Protocol Amendment no 8  
CONFIDENTIAL  Date:  15 June 2020  Novo Nordisk  
Trial ID: NN7088 -3908  Version:  1 
UTN: U1111 -1148 -1897  Status:  Final  
EudraCT no.: 2013 -004025 -88 Page:  3 of 10 
 
 1 Introduction including rationale for the protocol amendment  
The foremost purpose of this eight h protocol  amendment is to finalise the NN7088 -3908 trial prior 
to the milestone of 100 patients achieving 100 exposure days (EDs). Novo Nordisk A/S (NN) would 
like to maintain the current protocol defined trial end date of 13 November 2021 (LPLV). However, 
NN has predicted that the trial will not reach the originally targeted 1 00 patients by the protocol 
defined end of recruitment date of 02 October 2020. Based on the number of currently recruited 
patients and th e recruitment rate in the trial, it has been predicted that the trial would need to 
continue at least until Q4 2025  to reach the milestone of 100 patients with 100 EDs . Still, NN 
expects to have completed the main phase with 50 patients with 50 EDs and V9 by Q3 2020. It has 
therefore  been  decided to maintain the planned date of LPLV, but to terminate recruitment of 
patients into NN7088 -3908 with a predicted lower patient number than originally planned. This 
decision ensures that the paediatric investigation  plan (PIP) commitment to EMA is achieved. In 
addition, PUP trials are no longer an EMA requirement in Haemophilia  
(https://www.ema.europa.eu/en/documents/scientific -guideline/guideline -clinical -investigation -
recombinant -human -plasma -derived -factor -viii-products -revision -2_en.pdf), consequently all 
regulatory commitments will be met.   
On 2 9 May 2019, the Safety Committee for N8 -GP validated  a safety signal in the NN7088 -3908 
trial. The safety signal was related to a transient low incremental recovery (IR) following  the initial 
administrations of turoctocog alfa pegol in the absence of detectable inhibitors in a proportion of 
previously untreated patients (PUPs) within the first 5 exposure days.  The observed low IR was 
generally transient, and the majority of  patients returned to baseline levels over time . To ensure 
additional insights into the efficacy and safety of N8 -GP during low IR periods , an intensified  PEG 
antibody  analysis  has been  implemented . The analysis will be done  from  blood samples collected 
for N8 -GP binding antibodies . Therefore, no additional blood samples will need to be collected.  
Other clarifications  to the protocol :  
To align the protocol with the most recent monitoring process , which  has been simplified to allo w 
for more risk -based monitoring , the protocol has been  updated so that monitoring on -site visits can 
be substituted with remote monitoring when  considered  feasible.   
 
In this protocol amendment:  
• Any new text is written in italics.  
• Any text deleted from the protocol is written using strike through.  
 
  Protocol Amendment  Global no. 83908 NN7088 0  | VV-TMF-1418665
10  of 3 . -  | 1
 |
CONFIDENTIAL
Protocol Amendment no 8  
CONFIDENTIAL  Date:  15 June 2020  Novo Nordisk  
Trial ID: NN7088 -3908  Version:  1 
UTN: U1111 -1148 -1897  Status:  Final  
EudraCT no.: 2013 -004025 -88 Page:  4 of 10 
 
 2 Changes  
Following sections in the protocol are affected  by this eighth  protocol amendment : 
 
1     Summary  
[…] 
Time frames for evaluation of Objectives/Endpoints  
All objectives/endpoints  will be evaluated when the first 50 PUP s have reached at least 50 exposure 
days with V9  dates, when  the first 100 PUP have reached 100 exposure dates,  and at end of trial. 
End of trial will be up to 4 years after the first patient has reached 100 exposure dates  days. 
[…] 
Trial design:  
[…] 
The European medical agency requires  required submission of safety and efficacy data from 
minimum 50 exposure days in at least 50 patients for approval of the indication in PUPs , with a 
post-approval commitment to follow - at least 100 patients for a minimum of 100 exposure days . 
When the first 50 patients have reached a minimum of 50 exposure days  and V9 , the analysis and 
evaluation for the main trial report will be performed. All patients  Patients may continue in the 
extension phase for the purpose of collecting data for a minimum of  100 exposure days in at least 
100 patients .  
  Protocol Amendment  Global no. 83908 NN7088 0  | VV-TMF-1418665
10  of 4 . -  | 1
 |
CONFIDENTIAL
Protocol Amendment no 8  
CONFIDENTIAL  Date:  15 June 2020  Novo Nordisk  
Trial ID: NN7088 -3908  Version:  1 
UTN: U1111 -1148 -1897  Status:  Final  
EudraCT no.: 2013 -004025 -88 Page:  5 of 10 
 
 2    Flow chart  
Table 2 -1 Flow chart visits and assessments  
 
[…] 
Table 2 -2 Flow chart explanatory descriptions  
9. Blood samples must be collected prior to dosing at dosing visits. Please check that the required 
washout period has been met for inhibitor testing, see section 8.1.1.3 Before any surgeries are 
performed an inhibitor test must be taken if this test is mo re than 30 days. HCP antibodies and PEG 
antibodies will be analysed using samples taken for the N8 -GP binding antibodies at the time points 
described in section  8.4.2.2 . 
  Protocol Amendment  Global no. 83908 NN7088 0  | VV-TMF-1418665
10  of 5 . -  | 1
 |
CONFIDENTIAL
Protocol Amendment no 8  
CONFIDENTIAL  Date:  15 June 2020  Novo Nordisk  
Trial ID: NN7088 -3908  Version:  1 
UTN: U1111 -1148 -1897  Status:  Final  
EudraCT no.: 2013 -004025 -88 Page:  6 of 10 
 
 3    Background information and rationale for the trial  
[…] 
3.2    Rationale for the trial  
[…] 
The rationale for performing the pathfinder™6 trial is to evaluate the safety (including 
immunogenicity) and efficacy of N8 -GP in the treatment of PUPs with severe haemophilia A in 
accordance with EMA requirements.  For E urope, EMA requires  required  a separate investigation in 
the PUP population as part of the development programme to be initiated before market 
authorisation . The approval of the indication in PUPs  paediatric investigation plan (PIP) will be 
based on a clin ical trial in a minimum of 50 PUPs evaluated for efficacy and safety during at least 
50 EDs connected with a post -approval commitment to follow up at least 100 PUPs for a minimum 
of 100 EDs . The 50 patients will continue  in an extension phase to collect lo ng term safety data.  to 
reach at least 100 EDs , and additional 50 patients will be included also to reach at least 100 EDs.  
[…] 
5    Trial design  
5.1    Type of trial  
[…] 
The number of patients to be investigated in this trial follows  a PIP by EMA which Novo Nordisk 
has committed to.  the minimum EU guideline requirements for approval of the indication in PUPs, 
which  will be  based on a pre -authorisation clinical trial in a minimum of 50 PUPs evaluated for 
efficacy and safety during at least 50 EDs, connect ed with a post -approval commitment to follow -
up at least 100 PUPs for a minimum of 100 EDs.  
According to the previous EMA Guideline treatment with N8 -GP in the pathfinder™6 PUP trial 
was able to start when 20 patients participating in the paediatric PTP tr ial (pathfinder™5) were 
available (including data from a minimum of 10 paediatric patients below 6 years of age), and 
pharmacokinetic investigations in paediatric PTPs were completed.  
[…] 
Patients will be followed in the extension phase until at least 100 patients have reached at least 100 
EDs each  LPLV . EDs during immune tolerance induction therapy (ITI) will count in the 
determination of when  a patient has reached 100 EDs  a patient’s total number of EDs reached at 
his EOT visit.  
  Protocol Amendment  Global no. 83908 NN7088 0  | VV-TMF-1418665
10  of 6 . -  | 1
 |
CONFIDENTIAL
Protocol Amendment no 8  
CONFIDENTIAL  Date:  15 June 2020  Novo Nordisk  
Trial ID: NN7088 -3908  Version:  1 
UTN: U1111 -1148 -1897  Status:  Final  
EudraCT no.: 2013 -004025 -88 Page:  7 of 10 
 
 5.2    Rationale for tria l design  
[…] 
The main phase of the trial will generate safety and efficacy, aiming for a minimum of 50 EDs per 
patient. This number of EDs is was previously  required by the EMA guideline9 for evaluation of 
new FVIII products. The trial does not include a placebo control group, as it is considered unethical 
to administer an ineffective treatment to patients with haemophilia. An active control has not been 
included a s extensive comparative d ata from recently registered rFVIII products are available in 
comparable global populations including patients from EU and US.14, 15 Furthermore, the EMA 
guideline does not require a comparison to neither placebo nor an active comparator.  
[…] 
5.3.6.1    ITI therapy with N8 -GP 
[…] 
Patients who develop inhibitors, within the pathfinder™6 trial, will be offered continued ITI 
treatment with N8 -GP for a maximum of 24 months , also in case this extends past LPLV of the 
trial. ITI therapy with FVIII concentrates ot her than N8 -GP is not allowed within the trial. It may 
also be decided by the Investigator and/or parent/legal representative to withdraw the patients 
developing FVIII inhibitors.  
[…] 
6    Trial population  
6.1    Number of patients  
Number of patients planned to be screened: 150  
Number of patients planned to be started on trial product: 125  
Number of patients expected to complete the trial: 100  
Due to slow recruitment rate from the available PUP  population , these patient numbers may not be 
met in time f or LPLV.   
6.5    Patient replacement  
Withdrawn patients may be replaced to ensure that 100 patients complete the trial with at least 100 
EDs. Assuming a drop -out rate of 20%, it is estimated that 125 patients must be started on N8 -GP to 
  Protocol Amendment  Global no. 83908 NN7088 0  | VV-TMF-1418665
10  of 7 . -  | 1
 |
CONFIDENTIAL
Protocol Amendment no 8  
CONFIDENTIAL  Date:  15 June 2020  Novo Nordisk  
Trial ID: NN7088 -3908  Version:  1 
UTN: U1111 -1148 -1897  Status:  Final  
EudraCT no.: 2013 -004025 -88 Page:  8 of 10 
 
 obtain the 100 co mpleted patients. This may, however, be adjusted during the trial based on the 
actual drop -out rate . 
[…] 
7    Milestones  
[…] 
Patients with inhibitor s will be allowed to receive continued ITI treatment for up to 24 months , also 
in case this extends after LPLV.  
[…] 
8    Methods and assessments  
[…] 
8.1.9 End of trial visit  
The EOT visit can take place at any time after completion of 100  EDs and V14 or if the patient is 
withdrawn from the trial.  
[…] 
8.4.2.2    Antibody assessments  
[…] 
PEG antibodies  
PEG  IgM/IgG  antibodies should be measured according to Table 2 –1 and if required, investigator 
may take additional PEG -antibodies samples at other visits . Samples will be analysed regularly for 
PEG binding antibodies at the end of trial or whenever considered relevant  and results will be 
reported to investigators at the end of trial, or whenever considered relevant, and will be included 
in the CTR.  
[…] 
13    Monitoring procedures  
[…] 
A monitoring visit must  be performed as soon as possible after FPFV and no longer than 4 weeks 
after. The monitoring intervals will depend on the outcome of the remote monitoring of the eCRFs, 
  Protocol Amendment  Global no. 83908 NN7088 0  | VV-TMF-1418665
10  of 8 . -  | 1
 |
CONFIDENTIAL
Protocol Amendment no 8  
CONFIDENTIAL  Date:  15 June 2020  Novo Nordisk  
Trial ID: NN7088 -3908  Version:  1 
UTN: U1111 -1148 -1897  Status:  Final  
EudraCT no.: 2013 -004025 -88 Page:  9 of 10 
 
 the trial site's recruitment rate and the compliance of the trial site to the protocol  and GCP. The 
intervals between monitoring visits  must not exceed 12 weeks whilst patients are in the trial . at site 
between V0 and V14. If all patients at site are in the period after V14, intervals between monitoring 
visits must not exceed 26 weeks, prov ided site contact at least every 12 weeks.   
[…] 
16    Statistical considerations  
[…] 
An updated reporting of the trial with supportive data will be performed when 100 patients have had 
at least 100 EDs. Data from all patients will be included up to latest  visit prior this cut -off date. The 
data will be presented for the main + extension phase and the extended prophylaxis period (beyond 
100 EDs) separately as well as combined.   
A final report of the trial will be made after the LPLV cut -off on 13 November 2021. In case some 
ITI patients haven’t finished their treatment at the time of LPLV, an addendum to the final report 
will be made once the last ITI patient has completed the trial.  
All data will be reported separately in a final report when the trial is c ompleted.  
  Protocol Amendment  Global no. 83908 NN7088 0  | VV-TMF-1418665
10  of 9 . -  | 1
 |
CONFIDENTIAL
Protocol Amendment no 8  
CONFIDENTIAL  Date:  15 June 2020  Novo Nordisk  
Trial ID: NN7088 -3908  Version:  1 
UTN: U1111 -1148 -1897  Status:  Final  
EudraCT no.: 2013 -004025 -88 Page:  10 of 10 
 
  
Figure 16 -1    Individual patient flow a nd time periods for trial reporting  
[…] 
16.1    Sample size calculation  
No formal sample size calculations have been performed. The sample size of  100 completers  is was 
based on previous EMA guideline9. 
[…] 
16.5    Interim reporting  
[…] 
An updated report will be made when the first 100 patients have had at least 100 EDs. A final report 
with supportive data will be made when all patients have completed both parts of the trial  
[…] 
A final report of the tri al will be made after the LPLV cut -off on 13 November 2021. In case some 
ITI patients have  not finished their treatment at the time of LPLV, an addendum to the final report 
will be made once the last ITI patient has completed the trial.  
 
 
  Protocol Amendment  Global no. 83908 NN7088 0  | VV-TMF-1418665
10  of 10 . -  | 1
 |
CONFIDENTIAL